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The mammalian target of rapamycin (mTOR) signalling pathway takes part in both 
extracellular and intracellular signals. It is a major regulator of cell metabolism, growth, 
proliferation and survival. mTOR also regulates critical processes such as cytoskeletal 
organization, ribosomal biogenesis, transcription and protein synthesis. The mTOR 
pathway has been implicated in many diseases such as cancer, neurodegeneration and 
diabetes, which impact homeostasis and cellular functions. Moreover, mTOR has also 
been shown to play a critical role in immune cell regulation of T and B cells together with 
neutrophils and antigen presenting cells, as it integrates signals between them extending 
to the entire immune microenvironment.         
The aim of my study was to investigate the role of a component of the mTOR complex 1, 
Raptor, in myeloid cells. My	findings	show	that	the	absence	of	Raptor	knock	out	(KO)	
does	 not	 affect	 bone	 marrow	 derived	 macrophage	 (BMDM)	 differentiation	 and	
maturation.	However,	the	absence	of	Raptor	influences	BMDM	polarisation	towards	
an	 inflammatory	 phenotype,	 at	 least	 at	 the	 level	 of	 transcription	 as	 observed	 by	
increases	in	mRNA	expression	of	inflammatory	cytokines	such	as	TNFα,	IL-12β,	and	
IL-6.	 This	 finding	was	 consolidated	 by	 an	 increase	 in	 NFκΒ	 pathway	 signalling	 in	
Raptor	KO	BMDMs.		
Downstream	 intracellular	 signalling	 in	 myeloid	 cells	 was	 affected	 by	 deletion	 of	
Raptor	as	I	found	reduced	S6K	phosphorylation	in	Raptor	KO	BMDMs	compared	to	
wild	 type	 (WT)	 BMDMs.	 As	 a	 consequence	 of	 Raptor	 absence	 in	 BMDMs,	 STAT3	
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Over the millennia organisms have evolved mechanisms allowing them to utilise cues 
from their environment for growth and survival. Living organisms rely on continuous 
biochemical reactions that need constant nutrient and energy availability. This is to permit 
synthesis of new cellular components such as nucleic acids, proteins and lipids leading to 
an increase in cell size and number. However, these organisms must also cope with times 
of reduced nutrient and energy accessibility and this necessitates their adaptation to stress 
signals accordingly, in order to balance anabolic and catabolic processes. In times of 
stress, organisms begin to gradually slow down proliferation and start recycling 
organelles and aged proteins that will provide them with new metabolites to remain alive. 
The mechanistic target of rapamycin, previously known as the mammalian target of 
rapamycin (mTOR), is a major component of a signalling pathway that enables 
multicellular organisms to sense environmental cues that promote growth and survival 1. 
As this pathway supports cell growth, it also provides homeostasis by balancing growth 
and starvation signals. Deregulation of mTOR has been implicated in many diseases in 
which homeostasis becomes compromised, such as cancer, neurodegeneration, and 
diabetes. mTOR increases longevity by controlling rates of cellular maturation 1. 
Furthermore, mTOR is capable of integrating signals occurring within the immune 
microenvironment and plays a major role in regulating immune cells, particularly T cells, 
B cells, neutrophils and antigen presenting cells (APCs) 2 3 4. mTOR acts as a central link 
between cellular metabolism and immune cell function, as it regulates many aspects of 
immune cell differentiation, growth and development 5.   
Given the significance of this pathway in controlling major facets of cell survival and 
disease states, targeting mTOR as a therapeutic approach has been a focus for many years 
in regards to cancer, ageing, metabolic and neurodegenerative diseases. 
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1.1 mTOR  
mTOR is an evolutionary conserved serine/threonine protein kinase that has a molecular 
weight of 289 kDa. It is constitutively expressed and usually regulated post-
translationally 6.  It is part of the phosphoinositide 3-kinase family (PIKK) 1 7. mTOR was 
discovered as the target of the immunosuppressive drug rapamycin, thereby it was given 
the name of ‘mechanistic target of rapamycin’. Rapamycin was discovered in a search for 
new antibiotics; it is produced from streptomyces hygroscopicus extracted from soil 
samples taken in Easter Island (the island is named Rapa Nui in native Polynesian, hence 
the name rapamycin) 8. Scientists found rapamycin to possess growth retardation 
properties as it has inhibitory effects on the cell cycle. It also has immunosuppressive and 
anti-tumour activities 9. Rapamycin inhibits mTOR function by binding to the FK binding 
protein 12 (FKBP12), which in turn binds mTOR through the FKBP12-rapamycin-
binding (FRB) domain. Rapamycin induces a conformational change in the mTOR-
RAPTOR complex by binding to the kinase domain found on mTOR in a mechanism that 
is still not thoroughly understood. This conformational change potentially destabilizes 
mTOR-RAPTOR complex leading to an impairment of the coupling between mTORC1 
and its substrates. Hence this prevents the recruitment of key substrates such as S6 kinase 
1 (S6K) and eukaryotic translation initiation factor 4E eIF4E-binding protein 1 (4E-BP1), 
thereby inhibiting the phosphorylation of these substrates. Hindering the phosphorylation 
of these substrates impedes mRNA translation and subsequent protein synthesis 10 11. 
From the time rapamycin was discovered, many other drugs have been developed, known 
as rapalogs, which also block mTOR 12. 
1.1.1 mTOR structure 
Structurally mTOR has 2 terminals that take on different roles. The N terminus is 
composed of cluster of HEAT repeats, containing binding domains of Huntingtin, 
elongation factor 3 (EF3), protein phosphatase 2A (PP2A), and the yeast kinase TOR1. 
HEAT repeats are needed for protein-protein interactions. mTOR also has a FAT domain 
that contains portions of FK506- binding protein 12-rapamycin associated protein 1 
(FRAP), ataxia telangiectasia mutated (ATM), and transcription factor co-activator 
(TRRAP). Adjacent to the FAT domain is an FRB domain, constituted of the FKBP 12-
rapamycin binding domain, which is next to the kinase domain. This kinase domain is 
necessary for the kinase activity of mTOR. The C terminus is required for mTOR 
 
23 
structural integrity and is composed of portions of FRAP, TRRAP, and ATM C-terminal 
(FATC) domain 13 (Figure 1.1).  
mTOR is a 289 kDa protein composed of HEAT repeats, FAT and FRB domain, which are important for 
protein to protein interactions. The kinase domain is needed for mTOR’s kinase activity. FATC domain is 
important for the structure integrity. 
 
1.1.2 mTOR complexes 
mTOR is the catalytic subunit of two complexes known as mTORC1 and mTORC2. 
Unique proteins distinguish the two complexes. mTORC1 is composed of regulatory 
associated protein of mTOR (RAPTOR) a scaffolding protein vital for assembly of the 
complex, proline-rich Akt substrate 40 kDa (PRAS40), mammalian lethal with Sec13 
protein 8 (mLST8), and DEP domain-containing mTOR- interacting protein (DEPTOR). 
The presence of RAPTOR and PRAS40 distinguish mTORC1. RAPTOR and mLST8 are 
adaptor proteins needed for protein-protein interactions, while PRAS40 and DEPTOR 
constrain mTORC1 activity. PRAS40 has been shown to inhibit mTORC1 as it binds to 
RAPTOR through what is known as a TOR signalling motif (TOS) that is found on 
mTORC1 substrates (4E-BP1 and S6K). PRAS40 is said to compete with these substrates 
for binding and phosphorylation of mTORC1 thereby constraining its activation 14. As 
mTORC1 activity decreases DEPTOR is recruited to the complex along with PRAS40 
where they promote inhibition of the complex 15. mTORC2 comprises the adaptor protein 
rapamycin insensitive companion of mTOR or RAPTOR independent companion of TOR 
(RICTOR), also a scaffolding protein needed for complex assembly. mTORC2 also 
contains the mammalian stress-activated protein kinase interacting protein 1 (mSIN1), 
which is essential for targeting mTORC2 to the plasma membrane, allowing interaction 
with Akt. Another adaptor protein is the protein observed with RICTOR (PROTOR). 
mTORC2 also includes both mLST8 and DEPTOR. Therefore, mTORC2 is defined by 
N-Terminus C-Terminus
HEAT repeats
FAT FRB FATCKinase Domain
289 kDa
mTOR
Figure 1.1 Structure of mTOR  
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the presence of RICTOR, mSIN1 and PROTOR. mTORC1 and mTORC2 complexes are 
needed for intracellular signalling abilities, each having specific substrates 13.  
Activation of mTORC1 strictly depends on the interaction of mTOR and RAPTOR. As 
mentioned previously, rapamycin and the rapalogs destabilise the mTOR-RAPTOR 
interaction and therefore deactivate this complex, halting the downstream signalling 
pathway 16. Rapamycin does so by binding to FKBP12, which in turn binds to the mTOR 
FRB domain, leading to a conformational change weakening the connection between 
mTOR and RAPTOR, perturbing recruitment and access to substrates, diminishing 
further complex activation 17. This rapamycin sensitivity is seen in mTORC1 and to a 
lesser extent mTORC2. mTORC2 sensitivity to rapamycin is observed in prolonged 
usage of rapamycin, this may be due to a sequestration of mTOR making it less 
accessible for mTORC2 assembly 18 (Figure 1.2). 
mTOR can form two complexes, mTORC1 and mTORC2. Each complex has different functions and 
downstream signalling substrates. mTORC1 is composed of a scaffolding protein RAPTOR, the protein 
mLST8, also an adaptor protein, PRAS40 and DEPTOR, other constituents of the complex needed to 
constrain the activity of the complex by competing with substrates for binding and phosphorylation sites, 
thereby inhibiting mTORC1 and substrate interactions. mTORC2 comprises RICTOR, a scaffolding 
protein, the adaptor protein PROTOR and mSIN1, essential for translocating the complex to the membrane, 
where it interacts with Akt. This complex also contains DEPTOR and mLST8, which serve the same 
purposes as in mTORC1.  
1.1.3 Regulation of mTOR activity 
mTOR is capable of integrating signals from the surrounding environment in the form of 
nutrients or growth factors thereby regulating cell growth and survival. There are many 
positive and negative regulators to this signalling pathway that will either activate or 
suppress mTORC1, respectively 19. Ras homolog enriched in brain (RHEB) lies directly 
upstream of mTORC1 and positively regulates signalling through the complex 20. This 











Figure 1.2 mTOR complexes 
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bound to GDP. Additionally, tuberous sclerosis complex 1 and 2 (TSC1 and TSC2) 
negatively regulates RHEB 19. TSC2 is a tumour suppressor forming a heterodimeric 
complex with TSC1. Mutations in either TSC1 or TSC2 give rise to TSC hamartoma 
syndrome and a lung disorder known as lymphangioleiomyomatosis. TSC2 contains a 
GTPase activating protein (GAP) domain that activates the GTPase activity of RHEB, 
thereby inactivating it and consequently, the TSC complex is a negative regulator of 
mTORC1 activity21. 
The upstream signalling cascade leading to mTORC1 activation relies on recruitment of 
PI3K by growth factors, which in turn phosphorylates phosphatidylinositol 4,5-
bisphosphate (PIP2), forming phosphatidylinositol 3,4,5-trisphosphate (PIP3). Formation 
of PIP3 recruits Akt to the membrane, where it is phosphorylated by 3-phosphoinositide 
dependent protein kinase-1 (PDK1) at position T308. Active Akt will phosphorylate 
TSC1, disrupting the TSC1/TSC2 complex, inhibiting its GAP function, therefore 
allowing stabilization of GTP-RHEB and consequently activation of mTORC1 22 20. 
Extracellular signal-regulated kinases (ERK1/2), part of the mitogen-activated protein 
kinases (MAPK) pathway, also has an inhibitory role on the TSC1/TSC2 complex 23. By 
phosphorylating TSC2, it causes a similar disruption of the complex, promoting 
mTORC1 activation. 
Apart from growth factors, amino acids are essential for mTORC1 activation 24. Amino 
acids promote RHEB and mTORC1 interaction and therefore are necessary for its 
activation 25. Amino acids, mainly leucine, exert their function by activating Rag 
GTPases. These proteins are constituted of a heterodimer of RagA or RagB and RagC or 
RagD. In their inactive form, RagA (or RagB) are loaded with GDP and RagC (or RagD) 
are bound to GTP. Once amino acids are present, a switch to an active conformation takes 
place and RagA (or RagB) is loaded with GTP and RagC (or RagD) with GDP. The Rag 
heterodimer interacts with RAPTOR, thereby promoting RHEB-mTORC1 contact by 
allowing mTORC1 to reach surfaces of late endosomes and lysosomes where Rag 
GTPases are found 26. Other molecules related to the immune system may also play a role 
in mTORC1 activation. CD28, a costimulatory molecule on T cells needed for their 
activation and survival, is a strong activator of mTORC1 27 28. Interleukin 2 and 4 (IL-2 
and IL-4) activate PI3K, which in turn activates mTORC1 in T cells. On the other hand, 
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programmed death ligand 1 (PDL1) binds to PD1 on T cells, leading to mTORC1 
inhibition 17 29. 
At times of nutrient deprivation, low energy and oxygen levels, stress signals activate the 
TSC1/TSC2 complex, leading to mTORC1 deactivation. When energy levels are low, the 
adenosine triphosphate:adenosine monophosphate (ATP:AMP) ratio is lower, AMP-
activated protein kinase (AMPK) is activated by higher levels of AMP and in turn 
phosphorylates TSC1/TSC2, enhancing its GAP activity, which deactivates mTORC1 30 
31. This will in turn halt cellular growth and proliferation. The Wnt pathway also activates 
mTORC1, but in stressful conditions glycogen synthase kinase 3β (GSK3β) 
phosphorylates TSC1/TSC2, inducing inhibition of mTORC1 32. During times of low 
oxygen levels the hypoxia-induced factor protein regulated in the development of DNA 
damage response 1 (REDD1) is upregulated, REDD1 supports TSC1/TSC2 assembly and 
heightens its inhibitory role on mTORC1 33. REDD1 does so by liberating TSC2 from its 
interaction with 14-3-3 proteins (proteins that bind to various signalling proteins) during 
scarce oxygen conditions 34. Less is known about regulation of mTORC2 activation and 
inhibition. Upon receiving growth signals, PI3K activation leads to Akt phosphorylation 
at T308, however, full activation of Akt happens after, phosphorylation at position S473, 
which is mediated by mTORC2 35 it has also been suggested that mSIN1 promotes 
translocation of mTORC2 to the membrane where it phosphorylates Akt at S473 that may 
lead to mTORC2 activation by Akt itself which might occur through a positive loop 
mechanism, though this model needs to be supported by more work 36 (Figure 1.3).  
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mTORC1 is activated by growth factor signalling and in the presence of nutrient abundance, especially 
amino acids. PI3K phosphorylates PIP2 making PIP3, which recruits Akt to the membrane and thereupon is 
phosphorylated by PDK1. Activated Akt inactivates GSK3β and phosphorylates the negative regulator of 
RHEB, the TSC1/2 complex, leading RHEB to change from an inactive GDP state to an active GTP state. 
RHEB positively regulates mTORC1 when it is in a GTP state. Amino acid presence leads to activation of 
Rag complexes by switching them to an active conformation loaded with GTP and therefore activates 
mTORC1. The MAPK pathway also leads to mTORC1 activation since Erk1/2 phosphorylates TSC1/2, 
thereupon activating RHEB.  In times of amino acid depletion, Rag complexes are loaded with GDP and 
exist as inactive heterodimers. During oxygen deprivation REDD1 activates TSC1/2 complex, keeping 
RHEB and therefore inactive. When the ratio of ATP:AMP is low, AMPK also activates the TSC1/2 
complex, diminishing mTORC1 activity. The Wnt pathway activates mTORC1 but in times of nutrient 
scarcity GSK3β, which is downstream of Wnt, activates TSC1/2 and therefore inactivates RHEB. 
Rapamycin inhibits mTORC1 activation by binding to FKBP12, which causes a conformational change in 
the complex, preventing mTOR-RAPTOR interaction. PTEN also inhibits mTORC1 activation by 
dephosphorylating PIP3. mTORC2 regulation is less understood, it activates Akt leading to many 
downstream effects such as its regulation of the cell cytoskeleton through stimulation of F-actin stress fibres 






































Figure 1.3 mTOR regulation 
 
28 
1.1.4 Downstream mTOR signalling 
Actions of mTORC1 and mTORC2 are dictated by their substrate specificities. mTORC1 
activation leads to increased protein synthesis and is involved in upregulation of genes 
needed for glucose metabolism, lipid metabolism and mitochondrial biosynthesis 38. 
Furthermore, it results in inhibition of catabolic pathways such as autophagy 39 40. 
mTORC1 has two known substrates, S6K1 and 4E-BP1 41. These two substrates associate 
with mRNAs in order to control protein synthesis by regulating mRNA initiation, 
transcription and progression. 4E-BP1 in its unphosphorylated form suppresses cap 
dependent mRNA translation. Once it becomes phosphorylated by mTORC1, 4E-BP1 
separates from eukaryotic translation initiation factor 4E (eIF4E). eIF4E recruits eIF4G, a 
translation initiation factor, to the 5’ end of mRNAs, promoting translation of mRNAs 
that contain 5’ untranslated regions (UTRs) 42. S6K1 phosphorylates eIF4B leading to its 
activation; this allows eIF4A to unwind 5’ UTRs of most mRNAs, enhancing protein 
synthesis. S6K1 assists eIF4A in degrading programmed cell death 4 (PDCD4), which 
inhibits the interaction of eIF4A with the translation pre-initiation complex, allowing 
protein synthesis 43. In terms of its regulation of autophagy, mTORC1 suppresses it by 
inhibiting the production of autophagosomes, achieved through phosphorylation of 
autophagy related 13 (Atg13). This phosphorylation event interrupts the formation of the 
complex composed of Atg1-Atg13-Atg17, which is needed for the generation of 
autophagosome 40 44.   
mTORC2 activation leads to cellular polarization and actin cytoskeletal reorganization 45 
46. It also plays a role in cell growth and survival 47. mTORC2 phosphorylates Akt at 
S473 35. Once Akt is phosphorylated it is able to regulate forkhead box protein O1 
(FOXO1) and FOXO3 transcription factors by phosphorylating them, thereby inhibiting 
their release and recruitment to the nucleus, where they are able to activate genes needed 
for apoptosis. In their phosphorylated state, they are sequestered in the cytoplasm 48. 
Another mTORC2 target is serum glucocorticoid-regulated kinase 1 (SGK1), which is a 
cAMP- and cGMP-dependent protein. Downstream of SGK1 is the transcription factor 
FOXO1. As SGK1 is activated it phosphorylates FOXO1 thereby inhibiting it through its 
relocation from the nucleus to the cytoplasm where it is ubiquitinated and degraded. 
FOXO1 degradation leads to cell survival and growth 49. Protein kinase C kinase (AGC) 
is also an mTORC2 target that phosphorylates and inhibits FOXO transcription factors 50 
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51. Furthermore, mTORC2 is known to phosphorylate protein kinase C alpha (PKCα), 
which leads to reorganization of the actin cytoskeleton 52 (Figure 1.4). 
mTORC1 phosphorylates a number of substrates, which leads to an increase in protein synthesis, glucose 
and lipid metabolism and mitochondrial biogenesis. It phosphorylates 4E-BP1which is needed to negatively 
regulate transcription and therefore once it is phosphorylated protein synthesis and cellular growth is 
increased. mTORC1 also phosphorylates a substrate inhibiting autophagy in times of excess nutrients. 
mTORC1 phosphorylates S6K also leading to an increase in mRNA translational and subsequent protein 
synthesis. mTORC2 phosphorylates both Akt and SGK1 which in turn phosphorylate FOXO1 inhibiting 
apoptosis thereby initiating cell survival and growth. PKC is phosphorylated by mTORC2 initiating 
cytoskeletal organisation through f-actin polymerisation.  
1.1.5 mTOR inhibitors and their applications 
The mTOR pathway plays a central role in key cellular processes such as growth, survival 
and proliferation and is hyper-activated in many human malignancies such as melanoma 
and ovarian cancer 53. Aberrant mTOR signalling in tumours may be due to either loss of 
function of tumour suppressor proteins for example TSC1/2 or PTEN, or activation of 
oncogenes such as PI3K, Akt, and Ras, which activate the mTOR complexes 54. 
Therefore, in recent years the mTOR pathway has become an attractive target for anti-





















Figure 1.4 mTOR downstream signalling pathways 
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Rapamycin, also known as sirolimus, is a naturally occurring macrolide, as described 
earlier. It has diverse usage as an antifungal, immunosuppressive and anti-proliferative 
drug 8. Rapamycin and derivatives known as rapalogs, temsirolimus (CCI-779), AP23573 
and everolimus (RAD001), inhibit tumour cell proliferation 10. These rapalogs were 
developed since rapamycin was less bioavailable in vivo with poor solubility 55.  
Rapamycin, as well as the rapalogs, halts B cell chronic lymphocytic leukemia (B-CLL) 
proliferation by inhibiting cells in the G1 phase 56, which would likely induce apoptosis. 
Evaluation of this mechanism was carried out on different tumour cell lines. Luo et al 
showed that the antiproliferative ability of rapamycin was due to the inhibitory affect it 
has on cell cycle progression. Rapamycin prevents the downregulation of cyclin-
dependent kinase inhibitor p27kip1 and regulation of p27kip1 levels seem to be important in 
determining rapamycin antiproliferative activity  57.  
In addition to rapamycin’s anti-proliferative effects in vitro, it also affected tumour 
growth and angiogenesis in vivo. Guba et al treated CT-26 cells derived from colon 
adenocarcinomas and B16-B10 melanoma cells with rapamycin intraperitoneally on day 
0 or day 7 after tumour implantation, and showed a decrease in tumour growth and 
neovascularization of the tumours 58.  
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1.2 mTOR and immune cell regulation 
1.2.1 Introduction to inflammation 
During times of infection and tissue injury, inflammatory responses enable maintenance 
of homeostasis and survival of the host. Inflammation has been known for many centuries 
and scientific contributions over the years have led to milestones in understanding this 
important aspect of immunity 59. Inflammation comes in many forms leading to different 
pathways being activated that in turn, determine the type of response produced by the 
host. The level of severity of inflammation can either be acute, for example during 
infections, or chronic, as observed in neurodegenerative diseases and cancer 60. Acute 
inflammation is the initial response to the foreign stimuli and involves many cells such as 
neutrophils and macrophages along with mediators as cytokines, working together to 
eliminate the foreign body and consequently reduce inflammation. Chronic inflammation 
on the other hand occurs as these cells and mediators are unable to resolve inflammation 
leading to adverse effects on the host. Inflammation is considered a generic response and 
associates with innate immunity as opposed to adaptive immunity that responds in a 
specific manner to a particular target 59. 
The inflammatory response comprises several constituents; inducers, sensors, mediators 
and target tissues. These components form different combinations, depending on 
pathways triggered by the inducers 61. Bacterial pathogens are recognized by Toll like 
receptors (TLRs), which are part of the innate immune response 62. These receptors are 
found on macrophages, which in turn induce cytokine production e.g. tumor necrosis 
factor alpha (TNFα), IL-1β, IL-6, as well as mediators such as nitric oxide (NO) and 
chemokines such as CCL2. Leukocytes are able to move and migrate actively through 
blood vessels and into surrounding tissues as they receive cues from their surroundings.  
Cytokine release results in vasodilation and extravasation of neutrophils to the site of 
inflammation and both extravasated and resident macrophages help destroy the pathogen 
63. Macrophages also produce IL-12 and IL-23 to assist TH1 and TH17 T cell 
differentiation to promote the inflammatory response even further 64. Resolution of this 
inflammatory response occurs as the trigger subsides and clearing of the infection ensues, 
accompanied by tissue repair and regaining of active homeostatic functions. If the 
pathological trigger is not eliminated and the response proceeds, this usually leads to 
chronic inflammatory responses that could be detrimental to the host 65.  
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Chronic inflammation can be detrimental to the host, as tissue damage is caused by 
excessive reactive oxygen and nitrogen species along with TH1 and TH17 bi-products, 
thereby increasing pathogenic and disease progression. Macrophages are able to halt the 
inflammatory response by upregulating apoptotic signals or suppress the inflammatory 
cascade by dampening the response by producing pro-resolving (resolvins) factors, aiding 
tissue repair 66. This scenario differs during viral infections, in which interferons alpha 
(IFNα) and beta (IFNβ) are produced from the infected cells, inducing expansion of 
cytotoxic T cells that are able to destroy the virally infected cells 67.  
Additional cells that play an important role in immunity and inflammation are mast cells 
and basophils, which regulate allergy responses and clearing of parasitic infections as 
they release histamine, along with IL-4 and IL-13 68 69.  
1.2.2 Interactions between macrophages and T and B cells 
Macrophages are known as antigen presenting cells; they interact with T cells by 
presenting processed proteins to the cell surface and along with MHC class II, they bind 
to the T cell receptor (TCR) thereby activating T cells. Macrophages have also been 
shown to produce cytokines that are needed for T and B cell development and maturation 
70 71 72.  
How mTOR takes part in this inflammatory process will be described below according to 
different cell types.   
1.2.3 mTOR and macrophages 
As macrophages are a major topic of this thesis, this section will focus on the role of the 
mTOR pathway in regulating macrophage polarization in different metabolic statuses, 
and disease 73. 
Macrophages are multifaceted cells that play major roles in the immune system. They are 
professional phagocytes and they also take part in homeostasis, development and tissue 
repair. Macrophages are found in all tissues. They display versatility in their functions 
according to the specific tissue they reside in. They acquire specialized characteristics 
based on the tissue of residence, for example in the brain they are microglia cells and 
specify a function of microglia (i.e. aid neuronal function); in the liver they are Kupffer 
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cells and specialize in breaking down blood cells by their phagocytic actions 74. 
Ontologically macrophages arise from the yolk sac during early embryogenesis, as the 
embryo develops hematopoiesis takes place in the fetal liver, in which macrophages are 
formed. Postnatal bone formation leads to a reduction in fetal liver hematopoiesis, 
replaced by bone marrow hematopoiesis 75 76. Macrophages can also differentiate from 
monocytes, which develop from bone marrow progenitors. Monocytes circulate in the 
periphery until they receive activation signals leading to extravasation and differentiation 
into macrophages 73. Regardless of their origin, most macrophages have a major lineage 
regulator known as colony stimulating factor 1 receptor (CSF1R). It is a transmembrane 
tyrosine kinase receptor, necessary for macrophage differentiation 77. Macrophages also 
participate in adaptive immune responses and can act as APCs 78.   
Macrophages are able to keep the balance between inflammatory responses and 
immunomodulatory functions, depending on the environmental signals they receive. In 
terms of their phenotype, many publications have described how macrophages can 
assume two opposing phenotypes, one more inflammatory and aimed at eradication of 
microbes, called  M1 (classical) and one that aids tissue repair and restoration of 
homeostasis, called M2 (alternative) 78 79 80 81 (Figure 1.5). Since macrophages are 
heterogeneous in nature, this classification is very general and it should be noted that 
macrophages lie within a spectrum of subtypes. However, for simplification in this thesis 
I will describe macrophages as M1 or M2 64. M1 macrophages can be activated by 
lipopolysaccharides (LPS) alone or in the presence of IFNγ and exert proinflammatory 
functions by secreting cytokines and enabling tissue inflammation. The M1 or classical 
macrophages are known for their cytotoxic abilities and are the first line of defence 
observed in innate immunity. They have a proinflammatory role, being able to engulf 
foreign entities and through a respiratory burst (releasing of reactive oxygen species) will 
destroy them spreading products of inflammation into their surroundings. A specific 
marker that is expressed by the M1 phenotype is nitric oxide synthase (iNOS) which is 
needed to metabolize arginine into nitric oxide (NO). Cytokines that are produced are IL-
6, IL-12 and TNF-α 82. M2 macrophages are activated through IL-4 and IL-13 78 83, these 
activate signal transducer and activator of transcription 6 (STAT6) a transcription factor 
along with nuclear receptors peroxisome proliferator-activated receptor gamma (PPARγ 
and PPARδ), which are all needed for full M2 activation and immunomodulation 84. A 
specific marker pertaining to this phenotype is mannose receptor C type 1 MRC1, and the 
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usual cytokines produced are IL-10 and transforming growth factor beta (TGF-β) 83. In 
relation to M2 polarization there is an increase in arginase 1 expression and activity that 
promotes tissue repair through conversion of L-arginine to L-ornithine and subsequent 
polyamine synthesis 85.  
Macrophages need to maintain specific metabolic programs to support energy utilization. 
M1 macrophages use the glycolytic metabolic pathway supported by hypoxia inducible 
factor 1 alpha (HIF-1α), whereas M2 macrophages use fatty acid oxidation mediated by 
the transcriptional activator peroxisome proliferator-activated receptor gamma coactivator 
1-beta (PGC-1β) and PPARγ 86. These data suggest a link between both macrophage 





In vivo bone marrow myeloid progenitors are released into the periphery where monocytes continuously 
circulate, once an activation signal is intercepted these monocytes extravasate into the peripheral tissue, 
where they become macrophages in the presence of monocyte colony stimulating factor (MCSF). 
Depending on the signals received, macrophages carry on different functions. Macrophages receiving 
signals through LPS/IFNγ for instance become what are known as the classical or M1 macrophages and 
release inflammatory cytokines such as TNFα and IL-12 which help fight against foreign bodies. If they 
receive signals through IL-4/IL-13 they become alternative or M2 macrophages and are needed for tissue 
repair and immunomodulation restoring balance and homeostasis.   




Previous publications have shown that constitutive mTORC1 activation in macrophages 
through deletion of the negative regulator of mTOR TSC1 leads to an increase in 
proinflammatory cytokine production while IL-10 is decreased. M2 polarization in these 
macrophages was defective, as M2 markers had reduced expression. Akt activation was 
reduced at both phosphorylation sites T308 and S473, which contributed to impaired M2 
polarization, highlighting the importance of the mTOR pathway in macrophage 
polarization and regulation 87. 
Another group published that TSC1/2 is a regulator of macrophage polarization through 
different signalling pathways independent from mTOR 88. Mice that had specific myeloid 
cell TSC1 deficiency were used to assess the role of mTOR in macrophage polarization. 
Mice were highly sensitive to LPS shock; macrophages from these mice produced 
increased amounts of proinflammatory cytokines such as TNFα, IL-12 and NO. This 
suggests that these macrophages have an increased ability to differentiate into M1 
macrophages88. Macrophages from TSC1 knockout (KO) mice had reduced Akt 
activation but higher MEK/ERK activity. Upon mTOR inhibition with rapamycin, 
macrophages deficient in TSC1 or mTOR showed a slight increase in inflammatory 
cytokine production 88 accompanied by enhanced macrophage activation of NFκB and 
decreased STAT3 activation 88. After an addition of LPS to either TSC1 KO or mTOR 
KO macrophages, there was a continuous increase in their inflammatory response, 
suggesting the existence of mTOR independent pathways, consistent with data obtained 
with rapamycin 88.  
This group also showed a decrease in M2 response and few immune cell infiltrates, when 
TSC1 KO mice were challenged with OVA-induced allergic asthma. It was confirmed by 
the decrease of M2 expression markers Arg1, Ym1, Fizz1 after IL-4 treatment. This was 
an important observation, since IL-4 drives M2 polarization and plays a major role in 
allergic asthma pathogenesis. But after mTOR inhibition with rapamycin, the M2 defects 
were almost completely rescued by increase in Arg1, Ym1 and Fizz1. This in itself 




Weichhart et al also demonstrated that inhibiting mTOR in macrophages leads to an 
increase in proinflammatory cytokines by activation of NFκB with a decrease in IL-10 
due to reduction of the transcription factor STAT3. In contrast to previous results, 
Weichhart et al showed that deleting the negative regulator of mTOR TSC1/2 reverses 
the proinflammatory cytokine shift, which is in direct contrast to data reported by Byles et 
al and Zhu et al 89 87. In an attempt to understand more on how mTOR regulates innate 
immunity, Weichhart et al challenged BALB/c mice with Listeria monocytogenes (L.m), 
an infection they normally succumb to due to low IL-12, IL-6 and IFNγ secretion 89. In 
another experiment, mice were treated with rapamycin 3 days prior to the bacterial 
challenge with a lethal dose (LD50 OR LD100) of Listeria monocytogenes (L.m), these 
mice demonstrated improved survival which was shown by less bacterial burden in liver 
and spleen, with an increased production of NO. In order to prove innate cell dependency 
for this survival pattern, macrophages and dendritic cells were depleted using clodronate 
this abolished resistance to infection the mice had shown and emphasized that myeloid 
cells are important for the in vivo effects that were observed 89. 
Festuccia et al investigated the role mTORC2 has on inflammation and macrophage 
stimulation. The PI3K/Akt axis is central to reducing inflammation as macrophages are 
stimulated by TLR ligands. It is well known that the PI3K pathway and Akt activation 
dampens TLR activation and therein decreases the inflammatory response via mTORC2 
in order to restore balance after TLR activation and inflammation 90. 
mTORC2 activates Akt and indirectly the PI3K signalling pathway therefore it was 
important to know how mTORC2 may regulate inflammation. Macrophages isolated from 
mice with a specific myeloid deletion of Rictor, demonstrated high expression of M1 
genes as compared to M2 genes once stimulated with TLR ligands. In vivo experiments 
were also performed to mimic an acute or chronic inflammatory state as mice were fed a 
high fat diet (chronic inflammation) or were injected with LPS (acute inflammation). In 
the absence of Rictor mice with the high fat diet were observed to have a gradual increase 
in inflammation but was not as high as those mice receiving LPS injections that showed a 
higher sensitivity. This led to a heightened TLR signalling upon infection, with 
macrophages skewed to a M1 phenotype with excessive inflammatory responses. An 
increase in TNFα production was observed, and that a reduction of inflammation was 
seen with deletion of PTEN which is a negative regulator of the PI3K pathway. In general 
 
38 
these findings reiterate the point that mTOR regulates macrophage polarization as 
mTORC2 negatively regulates TLR signaling 91.  
Others have shown that PI3K promotes an inflammatory response in LPS stimulated 
THP-1 derived macrophages by increasing proinflammatory cytokines as IL-1β, IL-6, IL-
8, and TNFα, consequently as PI3K is inhibited by LY (pan-PI3K inhibitor) secretion of 
these cytokines was reduced, therefore giving PI3K an important role in macrophage 
regulation 92. Usage of PI3K inhibitors LY294002 (LY) and Wortmannin or mTOR 
inhibitors AZD8055 (AZD) and rapamycin, to test the mechanisms of cytokine secretion 
in Jurkat cells (that have constitutively active Akt phosphorylation), was investigated. 
Phosphorylation of Akt, GSK-3β and p70S6K were assessed. The PI3K and mTOR 
inhibitors reduced phosphorylation of Akt and p70S6K while no reduction was observed 
in phosphorylation of GSK-3β (only slightly with mTOR inhibitors) 92. In THP-1 derived 
macrophages phosphorylation of p70S6K was also reduced thus restricting 
proinflammatory cytokine production 92 . 
To identify the role of PI3K in macrophage motility, THP-1 derived macrophages were 
stimulated with LPS and placed on transwells treated with or without PI3K inhibitor 
(LY); different proinflammatory cytokines were added as chemoattractants. Migration of 
macrophages treated with PI3K inhibitor (LY) was reduced, highlighting PI3K 
involvement in macrophage motility and subsequently mTOR involvement in 
macrophage regulation 92. 
mTOR plays a major role in differentiating macrophages into tumour-associated 
macrophages (TAMs) promoting tumour development and progression mainly by 
encouraging tumour angiogenesis. Published data showed that human monocytes 
stimulated with LPS either lacking mTORC1 activity by its inhibition through rapamycin 
or activated using RNAi mediated knockdown of TSC2, regulated monocyte 
differentiation. Rapamycin instigated differentiation of macrophages to an M1 phenotype 
where IL-12 production was increased and IL-10 was reduced. Knockdown of TSC2 
caused macrophages to develop into M2 macrophages and had the opposite cytokine 
readout more IL-10 production and reduced IL-12 93.  
Ai et al, have also shown that by inhibiting mTORC1 in macrophages by rapamycin 
decreases chemokine expression and atherosclerosis, this result may be used as a 
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treatment for atherosclerotic plaques 94. They used bone marrow from mice with myeloid 
specific RAPTOR KO (Mac-RapKO) and transplanted it into mice deficient of low-
density lipoprotein receptor (Ldlr -/-). These mice were fed a western type diet and 
atherosclerotic lesions were assessed. The (Mac-RapKO) mice had less macrophage 
infiltration within the lesions, smaller lesion size, and decreased macrophage chemokine 
expression (CCL2 and CXCL2). Treatment of macrophages with minimally modified 
low-density lipoprotein resulted in an increase in chemokine expression levels and 
STAT3 phosphorylation for WT mice as compared to Mac-RapKO, which showed 
reductions in both chemokine expression and STAT3 phosphorylation, suggesting an 
antiatherogenic role of mTORC1 inhibition 94. 
These overall findings outline the importance of mTOR in macrophage differentiation, 
regulation and polarization (Figure 1.6). These results also propose a potential role in 
targeting mTORC1 in macrophages for various treatment approaches. 
 
mTOR plays a vital role in macrophage differentiation, regulation and metabolism by receiving signals 
through nutrients and / or growth factors and through TLR signalling leading to macrophage activation and 
subsequently downstream effects on their differentiation, maturation, activation and polarization. 
1.2.4 mTOR and T cells 
Immunosuppressive effects of rapamycin were thought to originate from its ability to halt 
T cell proliferation as mTOR activity degrades the cell cycle inhibitor p27 while 











activating cyclin D3. Rapamycin’s inhibition was hypothesized to lead to T cell anergy (T 
cell inactivation after antigen encounter) 28. However further studies showed that there 
was a difference between rapamycin’s ability to inhibit cell cycle progression and its 
ability to promote T cell anergy. Blocking the cell cycle at G1 without addition of 
rapamycin did not promote T cell anergy 95. Furthermore, inducing T cell proliferation in 
the presence of rapamycin did not prevent T cell anergy. These findings demonstrate that 
rapamycin does not promote anergy by reducing T cell proliferation but by inhibiting the 
mTOR pathway, thereby highlighting the capability of mTOR to regulate T cells 96.  
Unlike other differentiated cells, which utilize mitochondrial respiration and the TCA 
cycle in presence of oxygen for energy generation in the form of adenosine triphosphate 
(ATP), T cells employ oxidative glycolysis in their clonal expansion. This is when 
quiescence naïve T cells are interrupted by engagement of their TCR by specific antigen 
and MHCII, activating T cells to become effector T cells 97. The use of oxidative 
glycolysis is known as the Warburg effect 98. Once T cells are activated, biosynthesis of 
nucleotides, proteins and lipids commences. Since mTOR actively plays a role in 
metabolism it also promotes immune metabolic functions 99. Activated T cells upregulate 
metabolic functions that in turn prompts the PI3K signalling pathway, thereby increasing 
Akt phosphorylation and subsequently mTORC1 activation. mTORC1 activation 
promotes expression of proteins needed for glycolysis through HIF-1α 100. Inhibiting 
mTORC1 through activation of AMPK, inhibits IL-12 production and leads to T cell 
anergy 101. Depleting amino acids as another form of mTORC1 inhibition has also been 
investigated and was shown to impede T cell functions 102. Therefore, mTOR has been 
shown to play a major role in T cell regulation through metabolism and activation of the 
PI3K/Akt pathway, as inhibition of mTORC1 has led to T cell deregulation.  
1.2.5 mTOR and B cells 
There is less information on mTOR regulation of B cells. Early stages of B cell 
development were impaired when an mTOR hypomorph (a mutation causing partial loss 
of gene function) mouse was used as a model 103. Furthermore these B cells were unable 
to proliferate properly in response to B cell antigen receptor (BCR) and CD40 stimulation 
104. In order to assess maturational regulation of mTOR on B cells, a conditional deletion 
of TSC1 (TSC1 KO) on murine B cells was achieved. This lead to increased mTOR 
activation, herein B cell maturation was impaired as the amount of marginal zone B cells 
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was reduced. In a follow up to the previous experiment an in vivo experiment in which 
rapamycin was administered intraperitoneally to mice every other day for 16 days to 
inhibit mTOR signalling was performed. B cell marginal zones were partially increased 
and thereby part of the maturational axis was restored. Surprisingly, both hyper-activation 
of mTOR and mTOR inhibition reduced antibody production 104.  
To evaluate the role of mTOR on B cell survival and function, the PI3K-mTOR axis was 
investigated using inhibitors to the mTOR pathway. B cell activation through the BCR 
enhances mTOR activation leading to B cell clonal proliferation and survival depending 
on antigen exposure 105. B cell stimulation with TLR and CD40 also activates the PI3K-
mTOR pathway. Rapamycin inhibits CD40-dependent proliferation and induces apoptosis 
that otherwise would be inhibited by CD40 activation 106. Rapamycin also has been 
shown to inhibit LPS mediated B cell proliferation 107. Little is known about B cell 
metabolism, like T   B cells upregulate the glycolysis pathway and increase glucose 
uptake, depending on the PI3K pathway. Metabolism of B cells depends also on the 
pentose phosphate shunt and HIF-1α, which implies a role of mTOR in B cell metabolism 
108. 
From the findings above it is possible to speculate an important role of mTOR in 
macrophage, T cell, and B cell differentiation and maturation. This central role joins two 
aspects of cell survival and growth, metabolism and immune cell function. However, it 
should be pointed out that there are many parts in regards to the mTOR pathway and the 
role it plays in these cell types that have not yet been elucidated. Further extending our 
knowledge of mTOR regulation, is a key step required to clarify these unanswered 
questions, which will enable us to understand effectively mechanisms of the cell types 
within the scope of mTOR.  
1.3 Pancreatic cancer 
The pancreas is a glandular organ that is composed of the head of the pancreas, neck, 
body and tail. The pancreas is responsible for both endocrine and exocrine functions in 
the body. It functions as an endocrine gland as it secretes hormones such as insulin, 
glucagon, and somatostatin. This secretion occurs through clusters of cells known as 
pancreatic islets or more precisely the islets of Langerhans. The main role of the pancreas 
as an endocrine gland is to control blood sugar levels. However, the pancreas also 
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assumes a vital role in the digestive system, as it is also an exocrine gland maintaining 
balance of metabolic levels. This occurs within cells known as the acini, where they 
secrete pancreatic juice that contain digestive enzymes feeding into the duodenum 109 110 
Pancreatic cancer has one of the worst survival rates. It is the 9th most common cancer 
found in the United Kingdom with a 5% average survival rate of 5 years 111. There are 
some risk factors that have been assessed in pancreatic cancer including smoking, chronic 
pancreatitis, diabetes, and family history. The likely reason for such a low survival rate 
may relate to the poor early stage detection this cancer receives. Patients typically present 
with symptoms when the disease has already become too advanced for surgical 
intervention 112 113. 
More than 95% of pancreatic cancers are exocrine tumours since they originate from 
exocrine pancreatic cells, and about 90% of these are pancreatic ductal adenocarcinomas 
(PDACs). The most common precursor lesions of the PDACs are non-invasive epithelial 
neoplasms known as pancreatic intraepithelial neoplasias (PanINs). These are divided 
into 4 grades according to the increasing degree of architectural and cytological atypia 
observed 114; PanIN-1A, PanIN-1B, PanIN-2 and PanIN-3 115. These early stage 
alterations may open a window of opportunity for early diagnosis, before a full-blown 
transformation to invasive PDACs occurs. PDAC development is a result of accumulation 
of mutations in tumour suppressor genes and/or oncogenes. Activating point mutations in 
the KRAS gene occurs in the early stages of the precursor lesions, PanIN-1. Inactivating 
mutations in INK2A (p16/CDKN2A) arise in the intermediate stages of PanIN-2, while 
inactivating mutations of TP53, SMAD4 and BRCA1 have been found in late lesions of 
PanIN-3 116 (Figure 1.7).   
The malignant pancreatic cells do not develop in isolation and a complex desmoplastic 
stroma has been described 117. The tumour microenvironment contains cellular and 
acellular components such as immune cells, pancreatic stellate cells, fibroblasts, blood 
vessels, extracellular matrix proteins, cytokines and growth factors. The stroma itself 
differs in composition as the cancer advances, and may occupy a larger fraction of the 
tumour than cancer cells. This microenvironment plays a deleterious role by suppressing 
immune responses that may be attempting to eradicate tumour cells 118 119. 
 
43 
Pancreatic cancer may develop from acinar, endocrine, centroacinar or ductal cells. Pancreatic cancer 
gradually gains more desmoplasia as it develops and mainly originates from ductal cells. There are many 
precursor lesions known as pancreatic intraepithelial neoplasias (PanINs) that are divided into 4 grades 
(PanIN-1A, PanIN-1B, PanIN-2 and PanIN-3). Each grade is known to gain specific mutations such as 
KRAS, INK4A (p16/CDKN2A), TP53, and SMAD4. As these lesions gain mutations, progression to 
pancreatic ductal adenocarcinomas ensues. (Figure taken from Morris et al, 2010 117) 
1.4 Pancreatic cancer and the surrounding tumour microenvironment 
As mentioned above, pancreatic cancers usually begin as precursor lesions and develop 
into PDACs. In recent years it has been established that inflammation can have cancer-
promoting activity 120.The inflammatory components not only promote cancer but also 
increase incidence of metastasis and contribute to the high mortality rate 121. The presence 
of inflammatory cells accompanied by secretion of pro-inflammatory cytokines (for 
example TNF-α), chemokines, growth and angiogenic factors (for example VEFG and 
insulin-like growth factor) support the switch to a pro-tumourigenic environment 122 123. 
This microenvironment leads tumour cells to become refractory to immune surveillance. 
It contains cytokines such as TNF-α and IFN-γ, as well as reactive oxygen species, 
generated by tumour-associated macrophages and neutrophils, which all cause cellular 
damage. Consequently, tumour cells respond with an increase in signals that support 
wound healing and restoration of normal cellular function. These heightened signals for 
wound healing and cell proliferation leads to the development of tumour cells 124 125. It 
has been shown that the main immunosuppressive cells found within the pancreatic 
tumour microenvironments are T regulatory cells (T regs), myeloid derived suppressor 
cells (MDSCs), tumour associated macrophages (TAMs), and cancer associated 
fibroblasts (CAFs). They account for about 50% of the tumour stromal population 126 
(Figure 1.8) .  
Figure 1.7 Development of pancreatic ductal adenocarcinomas 
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1.4.1 T regulatory cells (T regs) 
T regs are known for their immunosuppressive features as they suppress T cytotoxic cells. 
It has been shown that in pancreatic cancers there are more T regs found in the stroma as 
compared to T cytotoxic cells, thereby enhancing tumour progression 127. 
1.4.2 Myeloid derived suppressor cells (MDSCs)  
MDSCs are a heterogeneous group of myeloid cells.  They have been attributed with high 
expression levels of CD11b and Gr1 and are considered monocytic and granulocytic, 
making it difficult to distinguish them from other myeloid cells (neutrophils, 
macrophages and dendritic cells) 80. Moreover as MDSCs are believed to populate the 
tumour stroma at different stages of myeloid cell differentiation there is no general 
consensus on how to identify these cells with specific cell markers 128. Their main role is 
immunosuppression, and this has been observed in their suppression of T and NK cell 
activity and proliferation 129. Tumour cells release specific cytokines (G-CSF and/ GM-
CSF) into the tumour microenvironment recruiting MDSCs to the site, where they expand 
in quantity 130. These MDSCs release additional cytokines and chemokines into the 
tumour microenvironment promoting angiogenesis that is needed to support tumour 
progression, which in time may lead to metastasis 131.  
1.4.3 Tumour associated macrophages (TAMs) 
Macrophages constitute a large component of the tumour microenvironment 132 and these 
are referred to as tumour associated macrophages (TAMs) 133. TAMs are considered 
‘double-edged swords’ for their involvement either in tumour progression or tumour 
inhibition. This depends on the type of signals they receive from either the tumour cells 
or their surroundings. These signals may skew these TAMs into a particular phenotype 
that may be pro or anti-tumour progressive 134 135. 
Nevertheless, most TAMs express a predominantly M2 tumour-promoting phenotype136. 
TAMs produce cytokines and chemokines that play a major role in tumour development 
by increasing angiogenesis, upregulating VEGF leading to an angiogenic switch. Novel 
angiogenic markers made by granulocytes have also been observed to cause refractoriness 
to immune surveillance 137. At the first stages of pancreatic tumour formation, these 
tumour cells need oxygen and nutrients to help them grow. In order for these cells to 
 
45 
continue to survive and proliferate while gaining more mutations, they send out signals to 
recruit macrophages and neutrophils to the tumour surroundings 138. This inflammatory 
tumour microenvironment with infiltrating immune cells promotes tumour formation and 
extends the survival and proliferation tumour cells 139. Cancer cells are able to circumvent 
immune surveillance as they release signals and interact with myeloid cells leading to an 
upregulation of IL-10 secretion while down regulating TNF-α and IFN-γ secretions 140. 
Tumour cells release chemotactic factors that increase influx of macrophages, forming 
niches within the tumour microenvironment 141. TAMs take part in remodelling the 
tumour microenvironment by increasing expression of matrix metalloproteinases (MMPs) 
and other matrix remodelling enzymes 142. This remodelling supports tumour motility and 
therefore leads to tumour invasion and metastasis 143. The amount of TAM infiltration is 
often inversely proportional to overall survival, meaning TAM infiltration is a sign of 
poor prognosis 134.  
1.4.4 Cancer-associated fibroblasts (CAFS) 
Fibroblasts are major components of the cancer stroma and are known as cancer 
associated fibroblasts. In a tumour setting CAFs are said to be constantly activated and do 
not revert back to an inactivated state, nor do they go through apoptosis like normal 
fibroblasts 144. Resident fibroblasts are an important source of cancer-associated 
fibroblasts (CAFs) and contribute to tumour progression in many ways. They become 
activated as they receive signals from cancer cells and the surrounding stroma where they 
organise the extracellular matrix and help cancer cells proliferate and migrate by 
increasing β-catenin expression and decreasing E-cadherin on cancer cells, thereby 
increasing invasiveness of cancer cells 145. Reactive oxygen species also promote 
conversion of resident fibroblasts into CAFs by accumulation of chemokine CXCL12 and 
HIF1α 146. CAFs also originate from bone marrow derived mesenchymal stem cells, 
hematopoietic stem cells, epithelial and endothelial cells 147. CAFs originating from bone 
marrow mesenchymal stem cells were shown to convert resident fibroblasts into CAFs by 
secretion of TGFβ 148. CAFs are a source of IL-6 which in turn leads to an increase in 
angiogenesis and tumour progression 149.      
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The pancreatic tumour microenvironment is made up of many components, apart from the malignant cells; 
they are made up of macrophages infiltrating the niche known as TAMs which release cytokines promoting 
immunomodulation. CAFs also play an important role where they are needed for subsequent metastasis by 
changing the extracellular matrix. They activate VEGF by their secretion of IL-6 leading to blood vessel 
formation and therefore a supply of oxygen to the cancer cells. Classical macrophages and neutrophils only 
add on to the inflammatory state observed in tumour microenvironments. T cells are found but many are of 
the regulatory type known as T regs, which promote tumour progression. Stem cells are present and effect 
the tumour environment by continuously replenishing the surrounding with new cancer cells. 
Cancer cell
Stem cell
Cancer associated fibroblast (CAF)






Figure 1.8 The tumour microenvironment 
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1.5 The mTOR pathway and pancreatic cancer 
One of the early genetic alterations observed in PDAC development is a mutation in the 
KRAS oncogene 150. This mutation is observed in the earliest stages of PanIN 
progression, being present in approximately 20% of lesions of the PanIN-1A stage 151 152. 
This KRAS oncogene plays a major role in signalling as it activates the PI3K/Akt 
pathway in 60% of PDACs 153. As mentioned previously PI3K/Akt signalling is also 
involved in mTOR activation and further signalling and activation of its substrates. 
mTOR is activated in 75% of PDACs 154. Emphasis must be placed on developing more 
inhibitors against the mTOR-signalling pathway as this pathway reduces apoptosis 
occurrence in cells and may be used as a survival advantage by tumour cells. Many 
inhibitors to this pathway have been developed showing promising results. These results 
are further amplified once gemcitabine is used in combinatorial therapy 155 156. 
A research group highlighted the need of selective targeted therapies based on individual 
pancreatic cancer phenotypes. They found that PDACs that had both KRAS and PTEN 
mutations were highly dependent on mTOR signalling. Inhibition of the mTOR pathway 
yielded better outcome by observing a halt in tumour cell proliferation leading to tumour 
regression 157. 
These results emphasise the importance of having selective patient therapies in order to 
promote effective treatment against pancreatic tumours.  
1.6 Hypothesis 
Given the current literature on mTOR, I hypothesize that targeting mTORC1 pathways 
via deletion of Raptor in myeloid cells will polarize macrophages to a more inflammatory 
phenotype and this will have an impact on pancreatic tumour progression and the tumour 
microenvironment. 
In order to test my hypothesis, I aim to: 
1.7 Aims 
1. Characterise the role of Raptor of the mTORC1 complex in macrophage 
maturation, differentiation, and function. 
 
48 
2. Explore the effect of Raptor KO on macrophage polarisation.  
3. Explore the effect of Raptor KO on macrophage signalling. 




2 Materials and Methods 
2.1 Mice 
All procedures performed on animals were carried out in accordance with the U.K. Home 
Office Animal and Scientific Procedures Act 1986, under the project licence 70/7411. 
The licence holder is Professor Frances Balkwill. Original breeding pairs were a generous 
gift from Professor Markus Rüegg. The mouse lines were generated and kept at the 
Biological support unit (BSU) within Charterhouse Square (at a given time they were also 
transferred to the BSU at St. Georges Hospital). They are C57BL/6 mice, genetically 
modified to delete Raptor within myeloid compartments using a Cre/LoxP recombination 
system (Raptor f/f; Csf1r Cre-ERT (KO)). It is an inducible model that requires 
administration of tamoxifen (Sigma Aldrich, cat- T5648-1G lot- WXBB5732V), via an 
intraperitoneal (I.P) injection on 3 consecutive days. As controls C57BL/6 mice 
containing Cre without LoxP bind to the Csf1r promoter region were used for 
comparisons (Raptor WT/WT; Csf1r Cre-ERT (WT)). In order to be certain of the 
genotypes, mice ear clips were given to Transnetyx, Inc, USA. 
Experiments were performed on Raptor WT/WT; Csf1r Cre-ERT (WT) and Raptor f/f; 
Csf1r Cre-ERT (KO) mice, I.P injections were given once every 3 consecutive days. On 
the 4th day mice were culled and collection of bone, spleen and blood was made (unless 
otherwise specified).  
*I.P injections, oral gavages, and tissue collection were performed with help from ATS 
staff members (Mrs. Julie Cleaver, Mrs. Tracey Chaplin Perkins, and Mr. Hagen 
Schmidt) and Mr. Colin Pegrum (an animal technician working in the Centre for Cancer 
and Inflammation.  
2.1.1 Subcutaneous tumour experiments  
Mice from Raptor WT/WT; Csf1r Cre-ERT (WT) and Raptor f/f; Csf1r Cre-ERT (KO) 
mice, were given I.P injections once for 3 consecutive days. On the 4th day a KPC 
pancreatic tumour cell line (TB32048) (derived from a PDAC tumour in a 
female/C57BL/6 mouse) was injected into one flank of the shaven mice. This cell line 
was generated from a female C57BL/6 KPC mouse and was given to the lab as a 
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generous gift from Professor David Tuveson. Injections with the pancreatic cell line 
TB32048 were used to induce tumour formation (precautions were taken to make sure the 
cell line was mycoplasma free). These cells were cultured in a T175 flask (Corning, 
175cm2 cell culture flask, ref- 431080) using Dulbecco’s Modified Eagle Media (DMEM) 
(Sigma Aldrich, cat- D5796 lot- RNBF3517) with 10% heat inactivated Hyclone Fetal 
Bovine Serum (FBS) (Sigma Aldrich, cat- SV30160.03 lot- RXL35906), 100units/ml 
penicillin and 100µg/ml streptomycin (Sigma Aldrich, cat- P4333, lot- 115M4795V). The 
cells were placed in a 5% CO2 incubator (Galaxy 170S New Brunswick eppendorf 
company) at 37°C. Cells were used at passage number 2 and were dissociated from the 
flask using 2X trypsin-EDTA solution (10X Sigma Aldrich, cat- SLBP3635 lot- 59418C) 
diluted in phosphate buffer saline (PBS) (Sigma Life Sciences cat- D8537, lot- 
RNBF3793). Media and trypsin were kept at 37°C for optimal conditions using a water 
bath. Cells were centrifuged at 211 rcf for 5 min at 4°C. Cells were counted using 
Beckman Coulter vi-cell XR (cell viability analyser, AH06019). 100,000 cells were 
injected per mouse. Mice wellbeing was monitored twice per week, observing any 
changes in weight, tumour growth, visible ulcerations, piloerection, loss of appetite or 
difficulty in movement. Oral gavages of tamoxifen followed every week for 3 
consecutive days to sustain Raptor knockout status until tumours were palpable and have 
reached 1.2cm in diameter. Once tumours had grown to 1.2cm in diameter all mice were 
culled, spleen, blood, and tumour were collected. FACS staining and analysis was 
performed. 
2.1.2 Orthotopic tumour experiments  
Mice from Raptor WT/WT; Csf1r Cre-ERT (WT) and Raptor f/f; Csf1r Cre-ERT (KO) 
mice, were given I.P injections once a day for 3 consecutive days. Mice were shaved and 
injected with Vetergesic (Buprenorphine) (0.3 mg/ml stock concentration that was diluted 
1:10 with sterile H20) subcutaneously (s.c). This was given two hrs before the start of the 
operation. On the day of the surgery a KPC pancreatic tumour cell line (TB32048) was 
injected orthotopically into the pancreas of each mouse. This cell line was generated from 
a female C57BL/6 KPC mouse and was given to the lab as a generous gift from Professor 
David Tuveson. Injections with the pancreatic cell line TB32048 was used to induce 
tumour formation (precautions were taken to make sure the cell line was mycoplasma 
free). These cells were cultured in a T175 flask (Corning, 175cm2 cell culture flask, ref- 
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431080) using Dulbecco’s Modified Eagle Media (DMEM) (Sigma Aldrich, cat- D5796 
lot- RNBF3517) with 10% heat inactivated Hyclone Fetal Bovine Serum (FBS) (Sigma 
Aldrich, cat- SV30160.03 lot- RXL35906), 100units/ml penicillin and 100µg/ml 
streptomycin (Sigma Aldrich, cat- P4333, lot- 115M4795V). They were placed in a 5% 
CO2 incubator (Galaxy 170S New Brunswick eppendorf company) at 37°C. Cells were 
used at passage number 2 and were dissociated from the flask using 2X trypsin-EDTA 
solution (10X Sigma Aldrich, cat- SLBP3635 lot- 59418C) diluted in phosphate buffer 
saline (PBS) (Sigma Life Sciences cat- D8537, lot- RNBF3793). Media and trypsin were 
kept at 37°C for optimal conditions using a water bath. Cells were centrifuged at 211 rcf 
for 5 min at 4°C. Cells were counted using Beckman Coulter vi-cell XR (cell viability 
analyser, AH06019). Following this step cells were resuspended in BD Matrigel 
Basement Membrane Matrix High Concentration (BD Biosciences, ref- 354248). The 
matrigel was left to thaw overnight and was made up on the day of the surgery from 
300µl PBS and 500µl of matrigel (concentrate), which was then resuspended slowly 30-
40 times to make sure no clumps or bubbles were formed. Pancreatic tumour cells were 
suspended at a concentration of 1,000 cells in 5µl and from this mix 5µl was injected per 
mouse. Dr. Sarah Spear, a postdoc working in the Centre for Cancer and Inflammation 
performed the surgery. Mice were sprayed with iodine solution to attain maximum sterile 
conditions; thereafter with a scalpel (Swann-Morton, ref- 0501) an incision was made 
above the pancreas. The pancreas and spleen were removed gently from the interior 
cavity and as it was out of the body, cells were injected into the pancreas. Injections into 
the pancreas were made using a Hamilton syringe 700 series, disposable needles of 25µl 
volume and 22s gauge (bevel tip) (Fisher Scientific, ref-10100332) were used. Pancreas 
was not touched until signs of matrigel solidification were observed. Following 
solidification both pancreas and spleen were placed back into the interior cavity. One or 
two interrupted sutures using a 6/0 gauge coated vicryl sutures (Ethicon, ref- W9500T) 
were made on the peritoneal wall. Then two 9mm Clay Adams Clips (VetTech solutions, 
ref- IN015A) with an Autoclip applier (VetTech solutions, ref- IN015B) were used to 
shut the wound. Mice were again injected with 30µl of Vetergesic s.c. Mice went through 
a recovery period of approximately 45 min, on heat boxes at 37°C. Surgical clips were 
removed one week after surgery. Mice wellbeing was monitored twice per week, 
observing any changes in weight, tumour growth (by palpating pancreas area), visible 
ulcerations, piloerection, loss of appetite or difficulty in movement. Oral gavages of 
tamoxifen followed every week for 3 consecutive days to sustain Raptor knockout status 
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until tumours were palpable and have reached 1.2cm in diameter. Mr. Colin Pegrum and 
Dr. Sarah Spear were needed for their experience in approximating tumour size by 
palpation. Once tumours have grown to 1.2cm in diameter all mice were culled, spleen, 
blood, and tumour were collected. FACS staining and analysis was performed. 
2.1.3 Tamoxifen preparation 
1.0G tamoxifen vial was mixed with 25ml corn oil (Sigma Aldrich, ref- C8267) 
(40mg/ml-1) and left shaking at 55°C. Aliquots were made and placed into eppendorf 
tubes stored at -20°C. 
2.2 Tissue collection and processing 
2.2.1 Bones 
To isolate bone marrow derived macrophages (BMDMs), mice were sacrificed and both 
femur and tibia were collected in PBS on ice. The muscle and skin were removed using a 
disposable scalpel (Swann-Morton, ref- 0501 lot- 6521603). A syringe (1ml soft-ject 
syringe, lot- 16B29C8) (BD, microlance 3 27G ¾ 0.4x19mm ref- 302200 lot- 1507 16) 
filled with DMEM with 10% heat inactivated FBS, penicillin and streptomycin was used 
to flush bone marrow cells from the bones through a cell strainer (Falcon, sterile cell 
strainer 70µm nylon mesh ref- 352350) and collected in a 50ml falcon tube. After 
centrifugation at 211 rcf for 5 min at 4°C the cell pellet was resuspended in fresh DMEM 
and plated in non-treated petri dishes (Falcon, untreated cat- 351058 lot- 4210803). 
Addition of 20ng/ml of Macrophage Colony Stimulating Factor (MCSF) (eBioscience, 
cat- 34-8983-85) was used to assist in BMDM differentiation. The bone marrow cells 
isolated from bones were allowed to differentiate for 7 days and then were harvested. To 
harvest the cells, Cell Dissociation buffer (Life Technologies, enzyme free PBS based 
cat- 13151-014 lot- 1736823) was added and cell scrapers (Falcon, 18cm handle/1.8cm 





Murine bone of femur and tibia are flushed (STEP 1), and myeloid progenitors along with other cells are 
placed into a petri dish (day 0). MCSF is added (STEP 2) in order to skew development and maturation of 
macrophages only from myeloid progenitors while other cells die off. On day 7 (STEP 3) M0 macrophages 
have matured, they are replated and stimulated with either LPS/IFNγ becoming what is known as classical 
or M1 macrophages. These release proinflammatory cytokines, for example TNFα and IL-12 and help fight 
against foreign bodies. They may also be stimulated with IL-4/IL-13 and become alternative or M2 
macrophages. These macrophages are needed for tissue repair and immunomodulation leading to balance 
and homeostasis. Macrophages stimulated with either LPS/IFNγ or IL-4/IL-13 are then used for 
experiments accordingly.    




Spleen was removed from mice and placed in ice cold PBS. Spleen was meshed up using 
a 3ml plunger and kept wet by addition of cold FACS buffer (PBS, 1% FBS and (2mM) 
EDTA (Ambion, 0.5M pH 8.0 lot- 1512003 P/N: AM9262)). Cells were passed through a 
70µm cell strainer and collected using a 50ml falcon tube. The tube was centrifuged at 
211 rcf for 5 min at 4°C. Cell pellet was resuspended in 10ml of RBC lysis buffer (cat- 
555899, BD Biosciences) diluted in water (1:10) and tube was inverted 5 times. It was 
incubated at room temp (RT) for 10 min. Addition of 10ml cold FACS buffer to stop the 
lysis process and a further centrifugation was performed. The cell pellet was resuspended 
in cold FACS buffer and further passed into a 70µm cell strainer. The mixture was 
centrifuged and supernatant was removed. Cells were resuspended in cold FACS buffer. 
Cell count was performed and cells were resuspended in an appropriate volume of cold 
FACS buffer for FACS staining. 
2.2.3 Blood 
Mice were placed in a tank containing 3% isofluorane / O2 for anaesthesia. During 
anaesthesia mice were kept warm by placing tissues underneath their bodies. Using a 1ml 
syringe (27 gauge needle) a cardiac puncture was performed into the heart.  About 1.0ml 
fresh blood was obtained and placed immediately into EDTA-coated eppendorf tubes and 
placed on ice. To collect plasma, the blood was centrifuged at 0.2 rcf for 10 min. 
Supernatant was removed and centrifuged two more times at 2.3 rcf for 5 min and then 
again at 16.1 rcf for 3 min. Plasma was obtained from the final centrifugation, and stored 
at -80°C. The whole blood found on the bottom of the tube was resuspended in 5ml of 
RBC lysis buffer diluted in water (1:10) for 10 min at RT, tube was inverted 5 times. An 
addition of 10ml cold FACS buffer was used to stop the lysis process. The mixture was 
centrifuged at 211 rcf for 5 min at 4°C and supernatant was removed. Cells were washed 
by resuspending in cold FACS buffer then were centrifuged. This procedure was 
performed twice. Cell count was performed and cells were resuspended in an appropriate 





The subcutaneous tumour was removed from the mice and was cut in half longitudinally 
using a scalpel. One half was placed immediately in dry ice and stored at -80°C. The 
other half was placed in cold PBS. The tumour was cut into tiny pieces and was placed in 
a 50ml falcon with Dnase I (50mg/ml) (Roche, cat- 10104159001) and collagenase D 
(1mg/ml) (Sigma Aldrich, cat- 11088858001) for digestion. The falcon tube was placed 
in a shaker at 200 rcf for 20 min at 37°C.  To stop the digestion process EDTA (5mM) 
was added. After digestion, tumour cells were passed through a 70µm cell strainer with 
further meshing using a 3ml syringe plunger. To keep cells from drying cold FACS buffer 
was added. Cell suspension was centrifuged at 211 rcf for 5 min at 4°C. The cell pellet 
was resuspended in cold FACS buffer and further passed into a 70µm cell strainer. The 
mixture was centrifuged and supernatant was removed. Cell count was performed and 
cells were resuspended in an appropriate volume of cold FACS buffer for FACS staining. 
2.2.4.2 Orthotopic	tumour	
The orthotopic pancreatic tumour was removed from the mice and was cut in half 
longitudinally using a scalpel. One half was placed immediately in dry ice and stored at -
80°C. The other half was place in cold PBS. The tumour was cut into tiny pieces and was 
placed in a 50ml falcon with a 5ml mix of Dnase I (10mg/ml) (Sigma Aldrich, cat- 
D4513) and collagenase (2mg/ml) (Sigma Aldrich, cat- C9263) for digestion. The falcon 
tube was placed in a shaker at 200 rcf for 20 min at 37°C.  To stop the digestion process 
50µl of EDTA (5mM) was added. After digestion, tumour cells were passed through a 
70µm cell strainer with further meshing using a 3ml syringe plunger. To keep cells from 
drying cold FACS buffer was added. Cell suspension was centrifuged at 211 rcf for 5 min 
at 4°C. The cell pellet was resuspended in cold FACS buffer and further passed into a 
70µm cell strainer. The mixture was centrifuged and supernatant was removed. Cell count 
was performed and cells were resuspended in an appropriate volume of cold FACS buffer 
for FACS staining. 
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2.3 Flow cytometric analysis  
Harvested cells (refer to 2.2.1: 2.2.2: 2.2.3: 2.2.4) were stained at 1.0x106 cells/well for 
FACS analysis. They were plated onto a 96 well v-bottom microtiter plate (lot- 2774065). 
The plate was centrifuged at 244 rcf for 5 min at 4°C in a Thermo Scientific centrifuge 
(Sorvall, -ST16R). Supernatant was removed and the pellet found on bottom of the well 
was resuspended in 50µl of anti CD16/32, Fc block (BD Biosciences, -553142,) diluted 
with cold FACS buffer (1:200). Cells and Fc block were incubated for 15 min at 4°C. 
Another 50µl of antibody master mix (2X) (Table. 2.1 and 2.2) was added to the well. 
Cells and antibodies were incubated for 30 min at 4°C in the dark. The plate was 
centrifuged at 244 rcf for 5 min at 4°C, supernatant was removed and well was washed 
with cold FACS buffer, followed by another centrifugation at 244 rcf for 5 min at 4°C. 
Fixable viability dye was also added at a volume of 50µl to differentiate between live and 
dead cells. It was diluted in FACS buffer (1:200), kept at 4°C for 20 min in the dark. Plate 
was centrifuged at 244 rcf for 5 min at 4°C. Cells were washed twice in FACS buffers 
with centrifugation in between each wash. A 1:1 dilution of PBS and 4% PFA was added 
to the cells in a volume of 100µl for 30 min at RT to fix the cells. Cells were washed 
twice with FACS buffer and centrifugation was performed between each wash at 244 rcf 
for 5 min at 4°C.  Cells were resuspended into 200µl of FACS buffer and kept at 4°C in 
darkness until time of acquisition.        
Compensation was performed using 1 drop of Ultracomp ebeads (full spectrum cell 
analysis) (eBioscience, cat- 01-2222-42) in FACS buffer. Single cell suspensions were 
analysed using flow cytometry by the BD LSR FORTESSA machine. The machine uses 
FACS DIVA software (BD Biosciences), analysis and interpretation was done by FlowJo 
software (Tree Star 9.4.7). Experimental data was analysed using Excel for Mac. Graphs 









CD45 BV785 Biolegend 145-2C11 100320 B207976 
CD3 PE-Cy7 Biolegend 30-F11 103149 B208623 
CD4 BV605 Biolegend RM4-5 100548 B209228 
CD8 APC eBioscience 53-6.7 17-0081-82 E07056-1635 
CD11b BV650 Biolegend M1/70 101239 B197319 
F4/80 PE eBioscience BM8 12-4801-80 E01704-1642 
MHCII APC/Cy7 Biolegend M5/114.15.2 107628 B198298 
Ly6G Alexafluor700 eBioscience RB6-8C5 56-5931-82 E09029-1632 
Ly6C E450 eBioscience HK1.4 485932-82 E14323-103 
CD19 Percp5.5 Biolegend 6D5 115534 B183173 
CD11C FITC eBioscience N418 11-0114-82 F001541630 
Table 2.1 List of antibodies used for subcutaneous and orthotopic staining of blood, 









Flt3/CD135 PE eBioscience A2F10 12-1351-81 E01493-1634 
CD34 FITC eBioscience RAM34 11-0341-82 E00264-1631 
CD127 APC/efluor 780 eBioscience A7R34 47-1271-80 E10810-1636 
c-Kit/CD117 APC eBioscience 2B8 17-1171-82 E07203-1634 
Lin efluor 450 eBioscience 17A2 88-7772-72 E10650-1632 
Sca1 PerCP/Cy5.5 eBioscience D7 45-5981-82 E08412-1633 
CD16/32 PE/Cy7 eBioscience 93 25-0161-82 - 
CD45 BV785 Biolegend 30-F11 103149 B208623 
CD45 APC eBioscience 30-F11 17-0451-82 E07148-1631 
CD11b BV650 Biolegend M1/70 101239 B214270 
CD11b PE/Cy7 eBioscience M1/70 25-0112-81 - 
F4/80 PE eBioscience BM8 12-4801-82 E01705-1638 
CD3 PE/Cy7 Biolegend 145-2C11 100320 B207976 
CD4 BV605 Biolegend RM4-5 100548 B195962 
CD8 APC eBioscience 53-6.7 17-0081-82 E07056-1633 
MHCII APC/Cy7 Biolegend M5/114.15.2 107628 B198298 
CD19 PerCP/Cy5.5 Biolegend 6D5 115534 B183173 
Ly6G Alexafluor 700 eBioscience RB6-8C5 56-5931-82 E09029-1632 
Ly6C efluor 450 eBioscience HK1.4 48-5932-82 E14323-103 
CD11C FITC Biolegend N418 117306 B191236 
FVD efluor 506 eBioscience - 65-0866-14 E15162-128 
Table 2.2 List of antibodies used for macrophage lineage and maturation staining 
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2.4 BMDM gene expression analysis 
2.4.1 BMDM stimulation 
BMDMs that have been harvested (refer to section 2.2.1) were replated in a 6 well plate 
(CoStar, Cell culture plate ref- 3506), at 1x106 cells/well and were left approximately 16 
hrs for cells to settle. BMDMs were stimulated either with 100 ng/ml of LPS (Sigma 
Aldrich, cat- L2630) and 20 ng/ml of IFNγ (Peprotech, cat- 315-05) or were stimulated 
with 10ng/ml of IL-4 (Peprotech, cat- 214-14) and 10ng/ml of IL-13 (Peprotech, cat- 210-
13) (Table 2.3). Stimulation was performed at differing time points 2, 4, 6, 12, 22, and 30 
hrs. Plate was placed in a 5% CO2 incubator at 37° C. 





LPS Sigma Aldrich L2630 100ng/ml 1mg/ml 
IFNγ Peprotech 315-05 20ng/ml 100µg/ml 
IL-4 Peprotech 214-14 10ng/ml 100µg/ml 
IL-13 Peprotech 210-13 10ng/ml 50µg/ml 
Table 2.3 List of ligands used for BMDM stimulation 
2.4.2 RNA extraction 
Media was removed from cells in petri dishes and washed twice in PBS. Cell lysates were 
obtained by adding 350µl of RLT buffer (Qiagen, cat- 79216). Cells were scraped using 
cell scrapers and lysates were placed in eppendorf tubes. These tubes were snap-frozen 
immediately in dry ice and were stored at -80° C. 
2.4.3 RNA isolation 
Cell lysates were thawed on ice. The Qiagen RNeasy mini kit (250) (Qiagen, cat- 74106) 
was used for RNA isolation and purification.  Extreme caution was taken to clean area 
before following RNA isolation procedure. RNAZap (Ambion, cat- AM9780) was 
sprayed onto surfaces, pipettes, vortex, and centrifuge.  Addition of 350µl of 70% ethanol 
was used (Sigma, cat- E7023). Cell lysate and ethanol were mixed gently by pipetting a 
few times. The mixture was added onto RNeasy spin columns. The columns were 
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centrifuged for 20 sec at 9.3 rcf. To the columns 350µl of RW1 buffer was added. Again a 
centrifugation of 9.3 rcf for 20 sec was done. A master mix of DNase solution was 
prepared by making up 70µl of RDD buffer plus 10µl of DNase stock (Qiagen, Rnase free 
Dnase set (50) cat- 79254), 80µl of this master mix was added onto each column, and was 
left to incubate for 10 min, then spun for 20 sec at 9.3 rcf. 500µl of RPE buffer was added 
onto the column then spun for 20 sec at 9.3 rcf. An addition of 500µl of 80% ethanol was 
added to the column, and then centrifuged for 2 min at 9.3 rcf. To make sure no ethanol 
was left on the column, a new 2ml tube was used with a centrifugation step for 5 min at 
maximum speed. The column was transferred to a new 1.5ml tube and an elution process 
to isolate RNA was performed by adding 15µl of nuclease free H2O (Ambion, P/N: 
AM9938 lot- 1311047). The tubes were centrifuged for 1 min at 16.1 rcf. Apart from the 
elution step, discarding the filtrate followed all centrifugation steps. Tubes were stored in 
-20°C. Measurement of RNA concentration was achieved using the nanodrop (ND-1000 
Spectophotometer). 
2.4.4 cDNA synthesis 
The high capacity cDNA reverse transcription kit (Applied Biosystems, cat- 4368813) 
was used for cDNA synthesis. A 2X Reverse Transcription master mix (MM) was 
prepared for one reaction (Table 2.4). 
Reagent Volume (µl) / reaction 
10X RT Buffer 2 
25X dNTP Mix (100mM) 0.8 
10X RT Random Primers 2 
MultiScribe Reverse Transcriptase 1 
Nuclease Free H2O 4.2 
Total per Reaction 10 





To prepare the cDNA reverse transcription reaction, 10µl of the 2X Reverse Transcription 
master mix was added onto PCR strip tubes (Axygen, cat- PCR-0208-C) on ice. 10µl of 
RNA was added (after normalization) onto the tubes and mixed by pipetting. The tubes 
were sealed and a vortex was used to ensure proper mixing. A brief centrifugation was 
performed to make sure all contents were on the bottom of the tube. The tubes were kept 
on ice until they were ready to load on the thermal cycler (Bio-Rad, T100) (Table 2.5). 
cDNA was placed in -20°C until ready for qPCR. 
 Step 1 Step 2 Step 3 Step 4 
Temperature 25°C 37°C 85°C 4°C 
Time 10 min 120 min 5 min ∞ 
Table 2.5 Cycling conditions for cDNA synthesis / reaction 
2.4.5 qPCR 
Using the cDNA produced in section 2.4.4, a dilution of the cDNA in nuclease free water 
was achieved (1:10) and a qPCR MM was made using iTaq universal probe system (Bio-
Rad, Universal probe supermix cat- 172-5131) (Table 2.6). Expression levels of different 
genes were analysed (Table 2.8).  




Nuclease free water - 
Table 2.6 Master mix using iTaq universal probe system 
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The qPCR was performed using the step one plus real time PCR system (Applied 
biosystems). Mixture was added onto a 96 well plate (Applied biosystems, microAmpfast 
optical 96-well reaction plate, 0.1ml PCR compatible, DNA/RNA/ Rnase free ref- 
4346906). Plates were sealed with adhesive film (Applied biosystems, microAmp optical 
adhesive film, PCR compatible, DNA/RNA/ Rnase free lot- 201310207 P/N: 4311971) 
and centrifuged for approximately 1 min at maximum speed. Cycling Conditions are 
found in (Table 2.7).   
 
Cycles Time Temperature (°C) 
1 2 min 50 
1 10 min 95 
40 15 sec 95 
 1 min 60 
Table 2.7 Cycling conditions for qPCR 
 
2.4.5.1 Gene	Expression	Analysis	
Analysis was performed subsequently by exporting the raw CT values of the 40 cycles 
produced for each gene. In order to calculate the ΔCT, the CT value of the housekeeping 
gene B2M was subtracted from the CT value of the gene of interest.    
ΔCT = CT (gene of interest) - CT (housekeeping gene) 
To obtain the final result 2 ^ (-ΔCT) was used to achieve relative expression against the 
house keeping gene. Experimental data was analysed using Excel for Mac. Graphs were 




Gene Primer code Company Lot number 
RAPTOR Mm00712698_m1 Applied Biosciences P150703-005 102 
TNFα Mm00443258_m1 Applied Biosciences 1457792 
IL-12b Mm00434174_m1 Applied Biosciences 1406055 
IL-6 Mm00446190_m1 Applied Biosciences 1453207 
iNOS Mm01309898_m1 Applied Biosciences 1081296 
IL-10 Mm00439614_m1 Applied Biosciences 1415579 
MRC1 Mm00485148_m1 Applied Biosciences 1423400 
B2M Mm00437762_m1 Applied Biosciences 1464053 
Table 2.8 List of genes used for TaqMan gene expression 
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2.5 Protein analysis 
2.5.1 BMDM stimulation 
BMDMs that had been harvested (refer to section 2.2.1) were replated in a 6 well plate. 
Replating was at 1x106 cells/well and was left approximately 16 hrs for cells to settle. 
BMDMs were stimulated with 100 ng/ml of LPS and 20 ng/ml of IFNγ (refer to Table 
2.2). Stimulation was performed at differing time points 15, 30, 60, 120, and 180 min. 
Plate was placed in a 5% CO2 incubator at 37°C. 
2.5.2 Protein lysis 
Radio Immunoprecipitation Assay Buffer (RIPA) (Sigma Aldrich, cat- R0278 
SLBD5707) in combination with a protease inhibitor cocktail I (one tablet/ 10ml RIPA 
buffer) (Roche, cat- 11836153001 lot- 14015000) was made prior BMDM protein lysis. 
BMDMs were lysed by first washing wells twice in cold PBS, making sure that no PBS is 
left on the well after suctioning. 80µl of RIPA buffer with phosphatase inhibitor cocktail 
II (Sigma Aldrich, cat- P5726) and phosphatase inhibitor cocktail III (Sigma Aldrich, cat- 
P0044) in a 1:100 dilution was added for 30 min on ice. BMDM lysates were harvested 
using cell scrapers and placed in individual eppendorf tubes that have been centrifuged 
for 15 min at 15.7 rcf at 4°C. Lysates were kept at -20°C. 
2.5.3 Protein quantification 
Bicinchoninic Acid Assay (BCA Assay) 
BMDM protein concentration was measured using 200µl of 4% w/v copper II sulphate 
solution (Sigma Aldrich, cat- C2284) that was diluted 1:50 in bicinchoninic acid (Sigma 
Aldrich, cat - B9643). This BCA reagent was added to 10µl of either BMDM samples or 
10µl of Bovine Serum Albumin (BSA) standards (Sigma Aldrich, cat- A4503) which 
were diluted in PBS in a 96 well plate (CoStar, Cell culture plate ref- 3599). The plate 
was incubated for 30 min at 37°C, then the optical density was measured using a plate 
reader spectrophotometer at 595 nm (OpSys MR Dynex technologies). BMDM protein 
concentrations were then calculated using the standard curve. 
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2.5.4 Western blot 
Prior to loading on gel, samples were prepared by adding 5µl (4X) of NuPAGE LDS 
sample buffer (Life Sciences Solutions, cat- NP0008) along with 2µl (10X) of NuPAGE 
sample reducing agent (Life Sciences Solutions, cat- NP0009) into eppendorf tubes.  To 
this mix 13µl of protein was added making sure equal amounts of protein is placed into 
each well within the gel (may add H2O if necessary). This mixture was vortexed and 
placed on a heat block for 10 min at 70°C.   
2.5.4.1 Gel	Eectrophoresis	
Preparation of running buffer: 
25ml of NuPAGE tris-acetate (TA) SDS running buffer (20X) (Life Sciences Solutions, 
cat- LA0041) was added to 475ml of deionized H20. 
Running buffer was added into a chamber that had a gel already placed into it. Samples 
were loaded onto NuPAGE Novex 3-8% tris-acetate protein gel (Life Sciences Solutions, 
cat- EA03785BOX). A HiMArk pre-stained protein standard ladder (Life Sciences 
Solutions, cat- LC5699) was also loaded onto the gel well. 500µl of NuPAGE antioxidant 
(Life Sciences Solutions, cat- NP0005) was added on to cover the gel area. The gel was 
run at 150V for approximately 90 min, separating the protein based on its molecular 
weight. 
25ml of NuPAGE transfer buffer (20X) (Life Sciences Solutions, cat- NP0006) was 
added to 425ml of deionized H2O. 50ml of methanol (Fisher Scientific, cat- 11976961) 
was added including 500µl of NuPAGE antioxidant. 
Polyvinylidene fluoride (PVDF) (Novex Life Technologies, cat- LC2005) Invitrolon filter 
paper sandwich 0.45µm pore size was used. Transfer was at 30V for approximately 1h 15 
min. 
2.5.4.2 Immunoblotting	
Preparing TBS (10X) 
10X TBS buffer was prepared from 1.5M NaCl (Sigma Aldrich, cat- 71380) and 200mM 
of Trizma base (Sigma Aldrich, cat- T1503) in deionized H2O (bringing pH to 7.6 using 
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HCL and a pH meter).  A 1:10 dilution of 10X TBS in deionized H2O was prepared to 
make 1X TBS.  The addition of 0.1% v/v Tween20 (Sigma Aldrich, cat- P7949) was done 
to make TBST. Blocking Buffer was prepared by adding 1X TBST to dissolve 5% w/v of 
dried skimmed milk powder (Marvel), membrane was blocked for 1 hr at room 
temperature on a rocker. 
Primary antibody for staining the membrane was used at a 1:1000 dilution with blocking 
buffer (Table 2.9). It was kept overnight at 4°C on a rocker. Membrane was washed 3 
times in 1X TBST for 5 min each on a rocker. Then was stained with HRP-linked 
secondary donkey anti-rabbit IgG (GE Healthcare, cat- NA9340) at a 1:2000 dilution 
using blocking buffer for 1 hr at room temperature on a rocker. Membrane was washed 3 
times in 1X TBST for 5 min each on a rocker. Addition of 750µl of Amersham ECL 
western blot detection reagent (GE Healthcare, cat- RPN2106) was used on the 
membrane and incubated for 1 min. Developing of the membrane was done using Super 
Rx X-ray film (Fujifilm, cat- 4741019236). The machine was a medical film processor 
(Konica Minolta, Model- SRX-101A). Developing of membrane was also done using the 
Amersham Imager 600 (Chemidoc system ref-R188609). 
Reblotting the membrane was achieved by adding Reblot plus strong (10X) (Millipore, 
cat- 2504) at a dilution of 1:10 in deionized H20 and applied onto the membrane for 5 min 
at room temperature on a rocker. 
Housekeeping protein detection was done by using β- actin, (a mouse anti-β-actin) used at 
a dilution of 1:5000 (Sigma Aldrich, cat- A1978 clone-AC15) and the secondary to that 










RAPTOR Cell Signalling 24C12 Jan-16 11 2280S 
p-AKT Cell Signalling S473 Sep-15 14 9271L 
AKT (Pan) Cell Signalling 1.10E+08 Feb-16 3 4685S 
p-S6 Ribosomal 
protein S23S/236 Cell Signalling D57.2.2E Apr-15 11 4858S 
S6 Cell Signalling 5G10 2217 5 
p-P44/42 MAPK Cell Signalling T202/Y206 Dec-14 28 91015 
P44/42 MAPK Cell Signalling ERK1/2 Aug-15 26 9102S 
p-IKBα (S32) Cell Signalling 14D4 Oct-15 14 2859S 
IKBα Cell Signalling - Jul-11 9 9242S 
p-STAT3 (Y705) Cell Signalling D3A7 Mar-16 26 9145S 
STAT3 Cell Signalling 79D7 Jul-12 3 4904S 




2.6 Detection and quantification of secreted cytokines by enzyme 
linked immunosorbent assay (ELISA)  
Media was collected from plated BMDMs that were harvested and used for gene 
expression assays (refer to section 2.4). BMDMs were stimulated with 100 ng/ml of LPS 
and 20 ng/ml of IFNγ or stimulated with 10ng/ml of IL-4 and 10ng/ml of IL-13 (refer to 
Table 2.2). The stimulation was performed at differing time points 2, 4, 6, 12, 22, and 30 
hrs. Plate was placed in a 5% CO2 incubator at 37°C (refer to section 2.4). The media was 
collected in a 5ml falcon tube and was centrifuged at 211 rcf for 5 min at 4°C. 
Supernatant was carefully removed and placed in eppendorf tubes at -80°C. ELISA kits 
(Table 2.10) were used to detect secretion of cytokines in BMDM media.  
Previous day 96 well plate (CoStar, EIA/RIA half area flat bottom lot- 16213005) was 
coated with 50µl of capture antibody (refer to Table 2.10) diluted in PBS (1:250), covered 
and kept at 4°C. 
The following day the plate was washed 3 times with wash buffer (PBS + 0.05% tween). 
100µl of assay diluent (PBS + 10% FBS) was added as a blocking solution for 1 hr at 
room temperature. After blocking, the plate was washed a further 3 times with washing 
buffer. An addition of 50µl of either standard (serial dilution) or sample (1:250) diluted in 
assay diluent was added to each well (in triplicates). Plate was incubated at room 
temperature for 2 hrs. Next the plate was washed 5 more times with wash buffer. 50µl of 
HRP and 50µl of working detection were added to the plate for 1 hr (1:250) in assay 
diluent. Plate was washed 7 times in wash buffer with 1 min soaks each. 50µl of substrate 
solution TMB-peroxidase (KBL Insight biotechnology, P/C 50-76-00 [TMB peroxidase 
substrate 130522 P/C 50-76-01; peroxidase substrate solution B 130611 P/C 50-65-00]) 
was added for approximately 30 min in the dark (until wells turned blue). 25µl of stop 
solution (1M phosphoric acid) was then added to stop the reaction (wells turned yellow). 
Plate was read within 30 min using plate reader at 570nm. Experimental data was 
analysed using Excel for Mac. Graphs were prepared using GraphPad Prism 5 Mac OS X 






   
Cytokine Company Catalogue Number Lot Number 
TNFα BD optEIA 558534 5204766 
IL12b (p40) BD optEIA 555165 3135570 
IL-6 BD optEIA 555240 4357560 
IL-10 BD optEIA 555252 5323643 




2.7 Migration assay 
2.7.1 Migration towards fibroblasts 
BMDMs that have been harvested (refer to section 2.2.1) were replated in a 24 well plate 
(CoStar, Cell culture plate ref- 3527) on transwells (permeable supports 6.5mm inserts 
5.0µm polycarbonate membrane tissue culture treated lot- 29915004). Replating was done 
at 1x105 cells/transwell and were left approximately 4 hrs for cells to settle. BMDMs 
were stimulated either with 100 ng/ml of LPS and 20 ng/ml of IFNγ or were stimulated 
with 10ng/ml of IL-4 and 10ng/ml of IL-13 (refer to Table 2.3).  Stimulation was 
performed for 4 hrs. Plate was placed in a 5% CO2 incubator at 37°C. At the same time 
on separate wells mouse embryonic fibroblasts (MEFs) were also replated at 1x105 
cells/well. Once the BMDMs were stimulated DMEM was removed and replaced with 
fresh media and transwells were moved on top of wells with fibroblasts (making the ratio 
of BMDMs to Fibroblasts 1:1). Plate was placed in a 5% CO2 incubator at 37°C for 24 
hrs. Onto a new 24 well plate 500µl of crystal violet (0.2% in 0.5% ethanol) was added, 
DMEM was removed from the transwells then inserts were placed into the crystal violet 
for 10 min. The inserts were removed from the crystal violet and washed in water. The 
inserts were left to dry approximately 30 min. 300µl of acetic acid (10%) was added into 
fresh wells, dry inserts were placed into the acetic acid. 100µl of acetic acid were placed 
into 96 well plates (in triplicates) and read using a plate reader at 595nm. Experimental 
data was analysed using Excel for Mac. Graphs were prepared using GraphPad Prism 5 
Mac OS X version 5.0b (121908).  
2.7.2 Migration towards pancreatic cancer cells (TB32047) 
BMDMs that have been harvested (refer to section 2.2.1) were replated in a 24 well plate 
(CoStar, Cell culture plate ref- 3527) on transwells (permeable supports 6.5mm inserts 
5.0µm polycarbonate membrane tissue culture treated lot- 29915004). Replating was done 
at 1x105 cells/transwell and were left approximately 4 hrs for cells to settle. BMDMs 
were stimulated either with 100 ng/ml of LPS and 20 ng/ml of IFNγ or were stimulated 
with 10ng/ml of IL-4 and 10ng/ml of IL-13 (refer to Table 2.3).  Stimulation was 
performed for 4 hrs. Plate was placed in a 5% CO2 incubator at 37°C. At the same time 
on separate wells a KPC pancreatic tumour cell line pancreatic cancer cells (TB32047) 
(derived from a PDAC tumour in a male/C57BL/6 mouse) were also replated at 1x105 
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cells/well. Once the BMDMs were stimulated DMEM was removed and replaced with 
fresh media and transwells were moved on top of wells with cancer cells (making the 
ratio of BMDMs to cancer cells 1:1). Plate was placed in a 5% CO2 incubator at 37°C for 
24 hrs. Onto a new 24 well plate 500µl of crystal violet (0.2% in 0.5% ethanol) was 
added, DMEM was removed from the transwells then inserts were placed into the crystal 
violet for 10 min. The inserts were removed from the crystal violet and washed in water. 
The inserts were left to dry approximately 30 min. 300µl of acetic acid (10%) was added 
into fresh wells dry inserts were placed into the acetic acid. 100µl of acetic acid were 
placed into 96 well plates (in triplicates) and read using a plate reader at 595nm. 
Experimental data was analysed using Excel for Mac. Graphs were prepared using 
GraphPad Prism 5 Mac OS X version 5.0b (121908).  
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2.8 Phagocytosis assay 
2.8.1 Phagocytosis with fluorescent beads 
BMDMs that have been harvested (refer to section 2.2.1) were resuspended in 1% FBS 
DMEM media. BMDMs were replated in a 6 well plate for 5 conditions (Media only, 15, 
30, 60, and 90 min). Another 6 well plate was used to replate BMDMs for one condition 
(ice control). Re-plating was at 1x106 cells/well and was left approximately 4 hrs for cells 
to settle in a 5% CO2 incubator at 37°C. Media was removed and replaced with serum 
free DMEM media for 1 hr in the incubator. BMDMs were stimulated with 100ng/ml 
LPS overnight in 10% FBS DMEM media. The following day 1ml of the fluorescence 
beads were added (Life technologies, Fluospheres Carboxylate modified microspheres 
1.0µm yellow/green fluorescent 505/515 cat- F-8823) at a concentration of 60 x 10^/well 
(stock concentration 3.6 x 1010) to the wells according to the time point. The ice control 
was always on ice. Beads were diluted in FACS buffer. After the last time point was 
reached wells were washed in cold FACS buffer and then 1ml FACS buffer. Cells were 
scraped using a cell scraper. Cells were pooled in a separate tube labelled as minus DAPI. 
Cells were centrifuged at 211 rcf for 5 min at 4°C. They were resuspended in 200µl of 
FACS buffer. Before cells were acquired on the BD LSR FORTESSA machine DAPI 
was added to each sample at a 1:5000 dilution. Analysis and interpretation was done by 
FlowJo software (Tree Star 9.4.7). Experimental data was analysed using Excel for Mac. 
Graphs were prepared using GraphPad Prism 5 Mac OS X version 5.0b (121908). 
2.8.2 Phagocytosis with pancreatic cancer cells (TB32048) 
BMDMs were harvested on day 6, they were scraped with cell dissociation buffer. 
BMDMs were labelled with an orange-red cell tracker (Thermo fisher scientific, ref- 
V22885 Dil) at a concentration of 5µl / 2x106 cells/ 1ml for 30 min at 37°C in serum free 
media (DMEM without FBS). During the 30 min incubation, cancer cells (TB32048) 
were stained with far red cell tracker (Thermo fisher scientific, ref- V22887 Vibrant DiD 
cell labelling solution) at a concentration of 5µl / 2x106 cells/ 1ml for 30 min at 37°C in 
serum free media. After the 30 min incubation, cells were washed twice in normal media 
(DMEM with FBS). BMDMs were replated in a 6 well plate for 6 conditions (Media 
only, 2, 4, 6, 8, and 16 hrs). Another 6 well plate was used to replate BMDMs for one 
condition (ice control at 16 hrs). Replating was at 5x105 cells/well. MCSF was added 
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onto the BMDMs since they were replated at day 6. Cancer cells were plated in regular 
petri dish plates (Falcon, 100 x15mm ref- 351008) at 8 x106 / plate. On day 7 BMDMs 
were stimulated with 100ng/ml of LPS overnight in a 5% CO2 incubator at 37°C. Cancer 
cells were treated with 100µM gemcitabine (Hospira, Onco-tain, PL 04515/0224 ; PA 
437/6311) overnight in a 5% CO2 incubator at 37°C. On day 8, cancer cells were scraped 
and washed in normal media, they were then placed on top of the BMDMs in descending 
order starting from the 8 hr time point. After the last time point was reached wells were 
washed in cold FACS buffer and then 1ml FACS buffer. Cells were scraped using a cell 
scraper. Cells were pooled in a separate tube labelled as minus DAPI. Cells were 
centrifuged at 211 rcf for 5 min at 4°C. They were resuspended in 200µl of FACS buffer. 
Before cells were acquired for all the time points on the BD LSR FORTESSA machine, 
DAPI was added to each sample at a 1:5000 dilution. Cancer cells were added onto the 16 
hr plate and left overnight in a 5% CO2 incubator at 37°C an ice control well was kept 
overnight at 4°C in the dark. The following day the cells from the 16 hr time point and ice 
control were scraped in the same way as for the other time points. Cells were centrifuged 
at 211 rcf for 5 min at 4°C. They were resuspended in 200µl of FACS buffer. Prior to 
acquisition on the BD LSR FORTESSA machine, DAPI was added to each sample at a 
1:5000 dilution. Analysis and interpretation was done by FlowJo software (Tree Star 
9.4.7). Experimental data was analysed using Excel for Mac. Graphs were prepared using 
GraphPad Prism 5 Mac OS X version 5.0b (121908). 
2.9 Fc receptor quantification 
Harvested cells (refer to 2.2.1) were stained at 1.0x106 cells/well for FACS analysis. They 
were plated onto a 96 well v-bottom microtiter plate (lot- 2774065). The plate was 
centrifuged at 244 rcf for 5 min at 4°C in a Thermo Scientific centrifuge (Sorvall, -
ST16R). Supernatant was removed and the pellet found on bottom of well was 
resuspended in 100µl of antibody master mix (Table. 2.11). Cells and antibodies were 
incubated for 30 min at 4°C in the dark. The plate was centrifuged at 244 rcf for 5 min at 
4°C, supernatant was removed and well was washed with cold FACS buffer, followed by 
another centrifugation at 244 rcf for 5 min at 4°C. Fixable viability dye was also added at 
a volume of 50µl to differentiate between live and dead cells. It was diluted in FACS 
buffer (1:200), kept at 4°C for 20 min in the dark. Plate was centrifuged at 244 rcf for 5 
min at 4°C. Cells were washed twice in FACS buffers with centrifugation in between 
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each wash. A 1:1 dilution of PBS and 4% PFA was added to the cells in a volume of 
100µl for 30 min at RT to fix the cells. Cells were washed twice with FACS buffer and 
centrifugation was performed between each wash at 244 rcf for 5 min at 4°C.  Cells were 
resuspended into 200µl of FACS buffer and kept at 4°C in darkness until time of 
acquisition.        
Compensation was performed by using 1 drop in FACS buffer of Ultracomp ebeads (full 
spectrum cell analysis) (eBioscience, cat- 01-2222-42). Single cell suspensions were 
analysed using flow cytometry by the BD LSR FORTESSA machine.  The machine uses 
FACS DIVA software (BD Biosciences), analysis and interpretation was done by FlowJo 
software (Tree Star 9.4.7). Experimental data was analysed using Excel for Mac. Graphs 
were prepared using GraphPad Prism 5 Mac OS X version 5.0b (121908).  




CD64 (FcγR1) PE (1:200) Biolegend X54-5/7.1 139303 B191539 
CD16/32 FITC (1:200) eBioscience 93 11-0161-81 E00172-1632 
CD206 
(MMR) 
APC (1:400) eBioscience MR6F3 17-0261-80 - 
CD86 BV605 (1:200) Biolegend GL-1 105037 B202374 
Table 2.11 List of antibodies used for Fc receptor staining 
2.10 iNOS quantification 
2.10.1 Intracellular staining 
Harvested cells (refer to 2.2.1) were stained at 1.0x106 cells/well for FACS analysis. They 
were plated onto a 96 well v-bottom microtiter plate (lot- 2774065). The plate was 
centrifuged at 244 rcf for 5 min at 4°C in a Thermo Scientific centrifuge (Sorvall, -
ST16R). Supernatant was removed and the pellet found on the bottom of the well was 
resuspended in fixable viability dye at a volume of 50µl to differentiate between live and 
dead cells. It was diluted in FACS buffer (1:200), kept at 4°C for 20 min in the dark. Plate 
was centrifuged at 244 rcf for 5 min at 4°C. Cells were washed twice in FACS buffers 
with centrifugation in between each wash. Supernatant was removed and the pellet found 
on bottom of the well was resuspended in 50µl of anti CD16/32,Fc block (BD 
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Biosciences, -553142,) diluted with cold PBS (1:200). Cells and Fc block were incubated 
for 15 min at 4°C. The plate was centrifuged at 244 rcf for 5 min at 4°C, supernatant was 
removed and well was washed with cold PBS (twice), followed by another centrifugation 
at 244 rcf for 5 min at 4°C. Supernatant was removed, and plate was pulse vortexed to 
completely dissociate the pellet. To the plate 100µl of fixation/permeabilization working 
solution (Fixation/permeabilzation diluent: eBioscience, ref- 00-5222-56; 
Fixation/permeabilzation concentrate: eBioscience, ref- 00-5123-43) was added in 1:3 
dilution, then pulse vortexed once more. The plate was incubated at 4°C for 1 hr in the 
dark. 1X Permeabilization buffer (eBioscience, ref- 00-8333-56) was added to the plate 
after incubation in 1:10 dilution using distilled water. The plate was centrifuged at 244 rcf 
for 5 min at 4°C, supernatant was removed and well was washed with 1X 
permeabilization buffer. Centrifugation was repeated at same conditions. Supernatant was 
removed and pellet was reuspended in 100µl of 1X permeabilization buffer. iNOS 
(eBioscience, PE, clone: CXNFT ref- 12-5520-82 lot-E17914-103 ; 1:400) antibody was 
added (isotype was also used : rat IgG2aκ). The plate was incubated at 4°C for a 
minimum of 30 min in the dark. Plate was washed with permeabilization buffer twice 
with centrifugation at 244 rcf for 5 min at 4°C, each wash. Cells were resuspended into 
200µl of FACS buffer and kept at 4°C in darkness until time of acquisition. Single cell 
suspensions were analysed using flow cytometry by the BD LSR FORTESSA machine.  
The machine uses FACS DIVA software (BD Biosciences), analysis and interpretation 
was done by FlowJo software (Tree Star 9.4.7). Experimental data was analysed using 
Excel for Mac. Graphs were prepared using GraphPad Prism 5 Mac OS X version 5.0b 
(121908).  
2.11 BMDM cytoskeleton analysis (Immunofluorescence staining)  
BMDMs that have been harvested (refer to section 2.2.1) were replated in a 24 well plate 
on coverslips. Replating was at 5x105 cells/well and were left approximately 16 hrs for 
cells to settle. BMDMs were stimulated either with 100ng/ml of LPS and 20ng/ml IFNγ 
or were stimulated with 10ng/ml of IL-4 and 10ng/ml of IL-13 (refer to Table 2.3). 
Stimulation was performed for 4 hrs. The plate was placed in 5% CO2 incubator at 37°C. 
Coverslips were washed twice in PBS and were fixed using 4% PFA for 15 min at room 
temperature. Two more washing steps followed fixation with PBS. Permeablization of 
cells with 0.1% Triton-X100 (Sigma Aldrich, 066K0089) for 5 min at room temperature 
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was achieved. Cells were washed once in PBS and blocked in 2.5% BSA (Sigma Life 
Science, A4503-500G), + 5% goat serum (Sigma Life Science, SLBK7718V) for 1 hr at 
room temperature in the dark. Cells were stained with phalloidin stain (Life technologies, 
ref- A22287 lot-1731699 ; Alexa fluor 647) (diluted in blocking solution ; 2.5% BSA plus 
1% goat serum in PBS) for 1 hr at room temperature. Cells were washed after staining 
twice in PBS. Then washed once in water. Coverslips were removed gently from the 
wells and were mounted on slides using prolong gold antifade reagent with DAPI (Life 
technologies, ref- P36931 lot-1681269). Slides were kept in the dark up to time of 
reading. Slides were read using the LSM 710 Confocal microscope (Zeiss Laser Scanning 
Microscope LSM710). 4-5 fields were captured; analysis was performed using ImageJ 
software.   
2.12 F / G actin ratio assay 
BMDMs that have been harvested (refer to section 2.2.1) were resuspended in 1% FBS 
DMEM media. BMDMs were replated in a 6 well plate for 6 conditions (Media only, 5, 
20, 30, 60, and 90 min). Another 6 well plate was used to replate BMDMs for one 
condition (ice control). Replating was at 1x106 cells/well and was left approximately 4 
hrs for cells to settle in a 5% CO2 incubator at 37°C. Media was removed and replaced 
with serum free DMEM media for 1 hr in the incubator. BMDMs were stimulated with 
100ng/ml LPS overnight. The following day 1ml of the fluorescence beads were added 
(Life technologies, Fluospheres Carboxylate modified microspheres 1.0µm yellow/green 
fluorescent 505/515 cat- F-8823) at a concentration of 60 x 10^/well (stock concentration 
3.6 x 1010) to the wells according to the time point. The ice control was always on ice. 
Beads were diluted in FACS buffer. After the last time point was reached wells were 
washed in cold FACS buffer and then 1ml FACS buffer. Cells were scraped using a cell 
scraper. Cells were centrifuged at 211 rcf for 5 min at 4°C. They were resuspended in 
100µl of FACS buffer. Cells were plated onto a 96 well v-bottom microtiter plate (lot- 
2774065). The plate was centrifuged at 244 rcf for 5 min at 4°C in a Thermo Scientific 
centrifuge (Sorvall, -ST16R). Supernatant was removed and the pellet found on bottom of 
well was resuspended in fixable viability dye at a volume of 50µl to differentiate between 
live and dead cells. It was diluted in FACS buffer (1:200), kept at 4°C for 20 min in the 
dark. Plate was centrifuged at 244 rcf for 5 min at 4°C. Cells were washed twice in FACS 
buffers with centrifugation in between each wash. A 1:1 dilution of PBS and 4% PFA 
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was added to the cells in a volume of 100µl for 30 min at RT to fix the cells. Cells were 
washed twice with FACS buffer and centrifugation was performed between each wash at 
244 rcf for 5 min at 4°C.  Cells were permeablized with 0.1% triton-X100 (Sigma 
Aldrich, 066K0089) for 10 min at RT. Plate was centrifuged at 244 rcf for 5 min at 4°C. 
Supernatant was removed and cells were resuspended in FACS buffer, followed by 
another spin at 244 rcf for 5 min at 4°C. Cells were stained with F-actin (1:400) and G-
actin (1:550) stain (Table 2.12) at a volume of 100µl. Plate was kept at 4°C, for 1 hr. The 
plate was centrifuged at 244 rcf for 5 min at 4°C. Cells were washed twice with FACS 
buffer and centrifugation was performed between each wash at 244 rcf for 5 min at 4°C. 
Cells were resuspended into 200µl of FACS buffer and kept at 4°C in darkness until time 
of acquisition.        
Compensation was performed by using 1 drop in FACS buffer of Ultracomp ebeads (full 
spectrum cell analysis) (eBioscience, cat- 01-2222-42). Single cell suspensions were 
analysed using flow cytometry by the BD LSR FORTESSA machine. The machine uses 
FACS DIVA software (BD Biosciences), analysis and interpretation was done by FlowJo 
software (Tree Star 9.4.7). Experimental data was analysed using Excel for Mac. Graphs 
were prepared using GraphPad Prism 5 Mac OS X version 5.0b (121908).  
Stain/dye Fluorochrome Company Reference/ Catalogue Number 
F-actin APC Thermofisher A22284 
G-actin PE Thermofisher D12372 






3 Characterisation of Macrophages Lacking Raptor Protein 
3.1  Introduction 
Macrophages are highly plastic cells that respond to different environmental cues and are 
considered to participate in frontline host defence in times of infection and disease. As 
they are plastic cells they have diverse phenotypes allowing them to adopt different 
effector states. Macrophages needed for innate and adaptive immune responses are 
known to assume a classical phenotype and are usually placed in the M1 macrophage 
category 158 76. Those needed for physiological homeostasis, maintenance, and tissue 
repair are of the alternative phenotype, and are categorized as M2 macrophages 158. 
Nevertheless it should be noted that this description of two extreme phenotypes is an 
oversimplification of macrophage phenotypes in situ where a spectrum of phenotypes is 
observed 142. Stimulating with either LPS/IFNg 159 63 160 161, or IL-4/IL-13 162 163 64 is a 
commonly used method of polarizing these macrophages into either of the two extremes. 
Addition of LPS along with IFNg generates classical macrophages whereas addition of 
IL-4/IL-13 leads to alternative macrophages.  
Since macrophages are important cells of the immune system and contribute to host 
survival and homeostasis 164, it is important to try and understand how the mTOR 
pathway affects macrophage differentiation, maturation and activation. There are many 
groups who have perturbed the pathway by inhibiting upstream negative (TSC1/2 
complex) or positive regulators (RHEB) 89 87 88 165 but little research has been done on 
specific proteins of the mTOR complexes in macrophages. It would be interesting to 
observe how mTORC1 regulates macrophages and how this regulation may affect their 
surroundings in regards to their polarisation. The main focus of the experiments in this 
chapter was to inhibit the mTOR pathway by removing the Raptor protein, part of 
mTORC1, which is known to assemble the complex together and promote downstream 
signalling required for cell growth and persistence, and observe effects on macrophage 




3.2  Model 
In order to understand mTORC1 and the influence of Raptor protein on differentiation, 
growth, and maturation of macrophages, an inducible Cre/LoxP mouse model was used 
under the Csf1r promoter on the C57Bl/6 genetic background. This allowed conditional 
knockout of the Raptor gene within myeloid compartments (Figure 3.1). LoxP sites 
flanked either side of exon 6 of the Raptor gene. Once tamoxifen was injected into the 
mice via the intraperitoneal route (I.P), Cre, under the control of the Csf1r promoter 
region, removed exon 6 from cells in the myeloid compartment. Components of the 
mTOR pathway are essential for embryonic survival therefore, constitutive Raptor KO 
mice are not viable and could not have been used 166. 
An inducible model using the Cre/LoxP system that is under the control of the Csf1r promotor region. As 
tamoxifen is added exon 6 is removed within myeloid cell compartments.   




3.3  Confirming Raptor KO in macrophages 
It was essential to confirm that knockout, KO, of Raptor expression was achieved in 
myeloid cells before beginning any experiments. To test this inducible model I decided to 
assay for Raptor mRNA by qPCR. BMDMs from Raptor WT/WT; Csf1r Cre-ERT (WT) 
and Raptor f/f; Csf1r Cre-ERT (KO) were either left unstimulated (NS) or stimulated by 
either LPS/IFNg or IL-4/IL-13 for 4 hrs (Figure 3.2A). Expression of Raptor from the 
KOs was markedly reduced in comparison to the WTs in all of the conditions. This shows 
that the inducible model accomplished a decrease in Raptor transcription and therefore 
lowers RNA levels of Raptor in the KOs. Results were taken as relative expression to the 
housekeeping gene B2m, a constitutive gene expressed in myeloid cells during normal or 
pathophysiological conditions (Figure 3.2A).  
In order to validate this result, it was important to look at Raptor protein levels. I used 
WT and KO BMDMs; they were either left unstimulated (NS) or stimulated with 
LPS/IFNg for 15, 30, 60, 120, and 180 minutes.  Protein lysates were prepared, and 
immunoblotting was performed. A reduction in intensity of the bands appeared in the KO 
protein lysates signifying a decrease in expression of Raptor protein levels as compared to 
WT lysates, which showed stronger band intensities. Protein levels were compared to the 
loading control β-actin that had equal band intensities associated with equal protein 












qPCR was performed on BMDMs that were left unstimulated (NS) or stimulated either with LPS/IFNg or 
IL-4/IL-13 for 4 hrs. Expression levels of Raptor were low in the KO as compared to WT (n=6), β2m was 
used as a house keeping gene (A). Western blot performed on BMDM lysates (NS, or LPS/IFNg stimulated 
either for 15, 30, 60, 120 and 180 minutes). Immunoblot stained for Raptor showing diminished bands on 
BMDMs from KO, as compared to WT controls. Blot was also stained for β-actin a house keeping protein, 
showing protein level and loading on to gel was equal. This immunoblot in the Figure is representative of 3 
independent experiments (BMDM lysates from 3 different mice) (B). 
3.4  Does the absence of Raptor affect the common myeloid progenitor 
population? 
The way macrophages develop is very important for their function. In order to answer the 
question of whether Raptor is important for macrophage differentiation and development 
I investigated the levels of common myeloid progenitors in the Raptor KO BMDMs. 
Hematopoietic stem cells (HSC) are self-renewing, multipotent progenitor cells from 
which differentiated cells in the bone marrow arise.  Common progenitors are bone 
marrow stem cells that continually populate the niche with cells that give rise to either 
myeloid or lymphoid lineages 167 168 169. Within the two lineages they separate into 
diverse cell types. Macrophages are produced from the myeloid lineage. HSCs and their 
differentiated progeny may be distinguished from one another through their expression of 
various cell surface lineage markers. To be able to distinguish between stem cells and 
differentiated cells I performed experiments using fluorescence activated cell sorting 
(FACS), on bone marrow cells (BM) at day 0 (cells taken directly after bone flushing) 
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Figure 3.2 Confirmation of Raptor KO 
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and BMDMs from day 3 and day 7 maturation in vitro of WT and Raptor KOs (cultured 
in DMEM media). I incorporated a cell specific lineage marker cocktail of antibodies to 
identify the two populations. This cocktail (LIN; lineage), includes markers that are 
expressed on stem cells and will not be expressed on differentiated cells. Stem cells that 
express these surface markers were labelled LIN+ while differentiated cells that do not 
express these markers were labelled LIN-. Cells were gated on live cells and from that 
gate all the LIN- cells were gated. From the LIN- cell gate, it was important to focus on 
markers that were specific to the common myeloid progenitors hence combinations of 
these markers were used to gate on the referred cell types. These markers were: stem cells 
antigen 1 (Sca1) a common biological marker used to identify hematopoietic stem cells; 
CD117 (c-Kit), a cell surface marker used to identify hematopoietic cells in bone marrow; 
hematopoietic progenitor cell antigen (CD34), an adhesion molecule needed for 
progenitor cell migration, and Fc receptor (CD16/32) found on myeloid cells.  (LIN- Kit+ 
Sca- CD34+ CD16/32mid). The results show no significant differences within the common 
myeloid progenitor population in absence of Raptor either when harvested or during 




No difference observed in common myeloid progenitor populations of KOs on day 0 (BM), day 3 and day 7 
BMDMs as compared to WTs (n=3). Student’s t-test was used to check for statistical significance: NS= 
non- significant. 
3.5  Does the absence of Raptor affect macrophage phenotype? 
Macrophages from bone marrow (BM) day 0, and BMDMs from day 3 and day 7 culture 
of Raptor WT and Raptor KO, were quantified using FACS to look for any differences in 
their survival and maturation 170 171 172. There was no significant difference between the 
KO and WT macrophages. The markers used were: CD45+CD11b+ F480+ (Figure 3.4). 
CD45 is a cell surface marker expressed on all lymphoid and myeloid cells, while CD11b 
is expressed on cell surfaces of myeloid cells and F480 is a specific marker for 
macrophages.  
It was reassuring to observe that as the quantity of the common myeloid progenitors 
decreased with time (as shown in Figure 3.4), the amount of macrophages (F480+) 
increased. This means that as these myeloid progenitors are maturing with time; they are 









































































There is no significant difference between the macrophage populations in Raptor KO as compared to 
Raptor WT controls in BM or on day 3 and day 7 of BMDM maturation (n=3). Student’s t-test was used to 
check for statistical significance: NS= non-significant. 
3.6  Does the absence of Raptor generate a more proinflammatory 
macrophage phenotype?    
It is reported that a disruption or loss of mTORC1 signalling leads to an overall increase 
in inflammation 89. In order to study this with RAPTOR KO in myeloid cells, the levels 
of mRNA expression of genes associated with inflammation were studied by qPCR. I 
stimulated WT and KO BMDMs with either LPS/IFNg or IL-4/IL-13 and assessed at six 
time points (2, 4, 6, 12, 22, and 30 hrs). Time points I chose for these experiments were 
based on different optimization trials that I tried in order to obtain a full scope of gene 
transcription patterns. The genes that were chosen to represent inflammatory or 
immunomodulatory genes have all been well established in literature. They are used when 
investigating inflammation and cellular homeostasis and are usually categorized as being 
either M1 or M2 genes. The M1 genes used were TNFα, Il-12b, NOS2, Il-6 173. The M2 
genes were Il-10 and Mrc1 174 175.  
As well as mRNA assays I used ELISAs to measure protein levels for most of the 
cytokines, TNFα, IL-12b, IL-6, IL-10, and FACS for iNOS, and Mrc1 (CD206), to 
quantify protein levels of inflammatory modulators.  
Figure 3.4 Macrophage populations in BM and harvested BMDMs 
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3.6.1  TNFa 
Relative expression of TNFα for KO BMDMs was significantly higher than WT BMDMs 
at 2, 12 and 30 hrs of stimulation with LPS/IFNg. For the rest of the time points (4, 6, and 
22 hrs) TNFα expression showed no difference. B2m was used as a house keeping gene 
(Figure 3.5). Moreover, levels of secreted protein showed a similar trend, there was no 
difference in secretion apart from 30 hrs of LPS/IFNg stimulation where it was more in 
the KOs as compared to the WTs. Unstimulated BMDMs were used to assess basal levels 
and showed no expression. (Figure 3.6).  
Figure 3.5 Relative expression of TNFα   
qPCR analysis of TNFα mRNA levels from WT and Raptor KO BMDMs stimulated with 100ng/ml of LPS 
and 20ng/ml of IFNg, showing a significantly higher expression in KO BMDMs stimulated with LPS/IFNg  
for 2, 12 and 30 hrs. BMDMs were also stimulated with 10ng/ml of both IL-4 and IL-13 but no TNFα was 
induced in this group or the NS group. Relative expression was taken as expression against b2m (a house 
keeping gene). Time points 2, 6, 12, 22, and 30 hrs (n=3) ; time point 4hrs (n=6). Student’s t-test was used 
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** 0.0039
* 0.0166 ** 0.0052
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Protein level analysis was performed on supernatant of BMDMs from WT and Raptor KO BMDMs 
stimulated with 100ng/ml of LPS and 20ng/ml of IFNg, showing a significant increase in secretion of TNFα 
in KOs stimulated with LPS/IFNg at 30 hrs compared to WT. LPS/IFNg stimulation at other time points 
shows no difference in TNFα protein secretion for either WT or KOs. BMDMs were also stimulated with 
10ng/ml of both IL-4 and IL-13 but minimal levels of TNFα were induced. All time points n=3. Student’s t-
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There was a significantly higher relative expression of Il-12b mRNA in Raptor KO 
BMDMs compared with WT BMDMs after 4, 12 and 30 hrs stimulation with LPS/IFNg. 
While at 2 and 6 hrs there was no difference in expression of Il-12b mRNA in Raptor KO 
BMDMs stimulated with LPS/IFNg compared with WT BMDMs (Figure 3.7). However, 
protein levels show different results than those seen on mRNA levels. During 4 and 12 
hrs stimulation with LPS/IFNg there is a significant increase in IL-12 (p40) secretion in 
WT BMDMs as compared to the Raptor KOs. The rest of the time points show no 
difference once BMDMs were stimulated with LPS/IFNg between WT BMDMs 








qPCR analysis of mRNA levels for IL-12b from WT or Raptor KO BMDMs stimulated with 100ng/ml 
of LPS and 20ng/ml of IFNg, showing a significantly higher expression of IL-12b in KOs stimulated 
with LPS/IFNg  for 4, 12 and 30 hrs. LPS/IFNg stimulation for rest of the time points shows no 
difference in expression of IL-12b in KOs compared to WT BMDMs. BMDMs were also stimulated 
with 10ng/ml of both IL-4 and IL-13 but no IL-12b mRNA could be detected. Relative expression was 
taken as expression against b2m (a house keeping gene). Time points 2, 6, 12, 22, and 30 hrs (n=3 ; time 
point 4hrs (n=6). Student’s t-test was used to check for statistical significance: p-value of <0.05 is 
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Figure 3.6 Relative expression of IL-12β 
 
89 
Protein level analysis was performed using supernatants from WT or Raptor KO BMDMs stimulated with 
100ng/ml of LPS and 20ng/ml of IFNg, showing a significant increase in secretion of WTs at 4, and 12 hrs. 
LPS/IFNg stimulation at other time points shows no difference of protein secretion for WTs compared to 
KOs. BMDMs were also stimulated with 10ng/ml of both IL-4 and IL-13, which showed no secretion. All 
time points (n=3). Student’s t-test was used to check for statistical significance: p-value of <0.05 is 
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There was significantly higher expression of Il-6 in Raptor KO BMDMs at 12 and 30 hrs 
stimulation with LPS/IFNg as compared to WTs. The increase was evident at later time 
points as compared to other cytokines studied, which may be due to the fact that it takes 
Il-6 longer time to be transcribed. At the rest of the time points there was no difference in 
Il-6 expression in the Raptor KOs as compared to the WT controls (Figure 3.9). IL-6 
protein secretion was also significantly different after LPS/IFNg stimulation at 6 and 22 
hrs, but it increases for WTs as opposed to the KOs (Figure 3.10).   
qPCR analysis of mRNA levels from BMDMs of WT and Raptor KOs stimulated with 100ng/ml of LPS 
and 20ng/ml of IFNg, showing a significant increase in expression of KOs stimulated at 12 and 30 hrs. 
LPS/IFNg stimulation at other time points shows no difference in expression of KOs compared to WTs. 
BMDMs were also stimulated with 10ng/ml of both IL-4 and IL-13, which showed no expression. Relative 
expression was taken as expression against β2m (a housekeeping gene). Time point 2, 6, 12, 22, and 30 hrs 
(n=3) ;  time point 4 hrs (n=6). Student’s t-test was used to check for statistical significance p-value of 
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Protein level analysis was performed on supernatants from BMDMs of WT and Raptor KOs stimulated 
with 100ng/ml of LPS and 20ng/ml of IFNg, showing a significant increase in secretion of IL-6 in WTs 
stimulated at 6 and 22 hrs. LPS/IFNg stimulation at other time points shows no difference in secretion for 
WTs as compared to KOs. BMDMs were also stimulated with 10ng/ml of both IL-4 and IL-13, which 
showed no secretion. All time points (n=3). Student’s t-test was used to check for statistical significance p-
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There was no significant difference in the relative expression of Nos2 between WT and 
Raptor KO BMDMs (Figure 3.11). Protein analysis was also performed using FACS. 
BMDMs were stimulated with LPS/IFNg for 6 hrs, iNOS protein expression shows no 
difference in BMDMs stimulated with LPS/IFNg either from WTs or Kos. Unstimulated 
BMDMs show expression of iNOS at basal levels. Isotype was used as a negative control, 
confirming minimal expression in BMDMs of both WT and KO (Figure 3.12).  
 
qPCR analysis of mRNA levels from BMDMs of WT and Raptor KOs stimulated with 100ng/ml of LPS 
and 20ng/ml of IFNg, showing no significant difference in expression of WTs compared to KOs. BMDMs 
were also stimulated with 10ng/ml of both IL-4 and IL-13, which showed no expression. Relative 
expression was taken as expression against β2m (a house keeping gene). Time points 2, 6, 12, 22, and 30 
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Protein level analysis was performed using FACS on BMDMs of WT and Raptor KOs stimulated with 
100ng/ml of LPS and 20ng/ml of IFNg, showing no significant difference between WT and KO stimulated 
with LPS/IFNg. Non stimulated levels had basal expression of iNos without having statistical significance. 
Isotype was used as a negative control (n=3). Student’s t-test was used to check for statistical significance.  
3.6.5 IL-10 
There was a significantly higher expression shown for WT BMDMs at 4 hrs of 
stimulation with LPS/IFNg. IL-10 is known as an anti-inflammatory cytokine; its 
expression increases once stimulated with IL-4/IL-13. In view of the results observed it 
opposes what has been established in literature since it increases once stimulated with 
LPS/IFNg 89 87. Later time points show no Il-10 expression; this is comparable to the NS 
BMDMs (Figure 3.13). At the protein level IL-10 is produced and secreted at differing 
levels in WTs and KO BMDMs but showed no difference between BMDMs from WT or 




















































































Figure 3.11 Expression of iNOS	
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qPCR analysis of mRNA levels from BMDMs of WT and Raptor KOs stimulated with 100ng/ml of LPS 
and 20ng/ml of IFNg,showing a significant increase in expression of WTs stimulated at 4 hrs. BMDMs 
were also stimulated with 10ng/ml of both IL-4 and IL-13, which showed no expression. Relative 
expression was taken as expression against β2m (a housekeeping gene). Time point 2, 6, 12, 22, and 30 hrs 
(n=3) and time point 4 hrs (n=6). Student’s t-test was used to check for statistical significance: p-value of 
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Figure 3.12 Relative expression of Il-10 
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Protein level analysis was performed from supernatant of BMDMs of WT and Raptor KOs stimulated with 
100ng/ml of LPS and 20ng/ml of IFNg, showing no significant increases in secretion of either WTs or KOs 
stimulated with LPS/IFNg. BMDMs were also stimulated with 10ng/ml of both IL-4 and IL-13, which 
showed no significant cytokine secretion at differing time pointss. N=3 for all time points. Student’s t-test 
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There was no significant difference in relative expression of MRC1 in either WT or 
Raptor KO BMDMs at 4, 12, 22, and 30 hrs upon stimulation with IL-4/IL-13. At 2 and 6 
hrs the MRC1 levels were below detection. MRC1 mRNA expression was observed at 
basal levels in both WT and KO BMDMs at 4, 12, 22, and 30 hrs (Figure 3.15). Data for 
protein levels shows, there is a significant decrease in MRC1 levels of Raptor KOs in 
comparison to WT, during basal levels (Figure 3.16). 
 
qPCR analysis of mRNA levels from BMDMs of WT and Raptor KO stimulated with 100ng/ml of LPS and 
20ng/ml of IFNg, showing minimal expression levels. BMDMs stimulated with 10ng/ml of both IL-4 and 
IL-13 showed no difference in expression with WTs as compared to KOs at all time points. Non stimulated 
BMDMs also showed minimal expression at 4, 12, 22, and 30 hrs for both WT and KOs. Relative 
expression was taken as expression against β2m (a house keeping gene). Time point 2, 6, 12, 22, and 30 hrs 
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Figure 3.14 Relative expression of MRC1 
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Protein level analysis was performed using FACS on BMDMs of WT and Raptor KOs showed a significant 
decrease in secretion at basal levels of KO BMDMs as compared to WTs (n=3). Student’s t-test was used to 
check for statistical significance: p-value of <0.005 (**) is statistically significant. 
3.7 Summary of results from this chapter. 
In the Tables below I have summarized the significant differences between WT and 
Raptor KO BMDMs in terms of inflammatory mediator expression after LPS/IFNg or IL-
4/IL13 stimulation in vitro. 
RNA 2 hrs 4 hrs 6 hrs 12 hrs 22 hrs 30 hrs 
WT  Il-10     






Table 3.1 Summary of significant differences between WT and Raptor KO BMDMs 




Figure 3.15 Expression of MRC1 (CD206)	
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PROTEIN 2 hrs 4 hrs 6 hrs 12 hrs 22 hrs 30 hrs 
WT  IL-12β 
IL-6 
IL-12β IL-6  
MRC1 
KO      TNFα 
Table 3.2 Summary of significant differences between WT and Raptor KO BMDMs 
in terms of cytokine protein secretion after LPS/IFNγ stimulation (ELISA and 
FACS analysis) 
The Tables above show significant increases in either cytokine mRNA expressions or secretions 
which are comparisons obtained between the WT and KO BMDMs.   
3.8 Discussion 
The mTOR pathway is a major regulator of cell metabolism, growth, proliferation and 
survival. It also regulates critical processes such as cytoskeletal organization, ribosomal 
biogenesis, transcription, and protein synthesis 176 177 178. In this chapter I have 
investigated the influence that mTORC1 has on macrophage maturation, growth and 
differentiation using BMDMs in which Raptor, a major component of the mTORC1 
complex was deleted. The Raptor gene was removed using an inducible genetic mouse 
model. I found that deletion of Raptor did not have any significant effect in macrophage 
differentiation or maturation in vitro; the common myeloid progenitor populations of both 
WT and KOs had similar percentages on varying days of differentiation and growth. This 
also is evident for macrophage maturation in both WT and KOs as the frequency of F480 
positive cells on different maturational stages was comparable. It was shown in literature 
that when RHEB, a protein upstream of mTORC1 and a positive regulator, is removed, 
macrophage differentiation is impaired when a conditional deletion mouse model was 
used in which Rheb was deleted 179. The monocyte-macrophage differentiation was 
examined showing a decrease in the amount of differentiated cells in the KO as compared 
to WT controls. The reason for this discrepancy may be the fact that RHEB is a positive 
regulator of the mTORC1 pathway, which interacts with Raptor 180, therefore any 
impairment to this protein might have a more potent effect than deleting a component of 
the complex itself. 
In order to assess the role Raptor has on macrophage polarization, I studied inflammatory 
gene expression and cytokine secretion after in vitro stimulation. Results from TNFα are 
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in line with findings from literature 64, which showed an increase in TNFα expression and 
secretion once stimulated with LPS/IFNg. It also showed that removal of Raptor 
increased TNFα and was significantly higher in most time points that I investigated for 
both mRNA and at the longest time point for protein levels. It was reassuring to see that 
there was no change in expression from either NS or IL-4/IL-13 stimulated BMDMs 
whether they were KOs or controls. This is due to the fact that TNFα is a pro-
inflammatory cytokine and is known to increase upon addition of LPS/IFNg.  
Results for IL-12b show higher mRNA expression in KOs as compared to WTs that is in 
agreement with literature 89 181. Although IL-12(p40) secretion is inconsistent with 
literature as I have demonstrated that secretion is more in WT BMDMs in comparison to 
KOs, while literature showed that KOs secreted more IL-12(p40). This result may be due 
to Raptor absence affecting protein translation and therefore secretion of IL-12(p40).  
Levels of Nos2 mRNA expression along with protein expression showed no significant 
differences between WT and Raptor KOs. Literature shows that when rapamycin was 
used to inhibit the mTORC1 pathway in astrocytes it was found to decrease Nos2 mRNA 
levels and stability 182. 
My results for IL-6 showed a significantly higher expression at 12 and 30 hrs LPS/IFNg 
stimulation for KOs as compared to WTs on mRNA level, which is in line with literature 
89 Weichhart et al, have shown that inhibition of mTORC1 leads to an increase in IL-6 
production. 
Moreover, in literature it was shown that addition of rapamycin decreased expression of 
anti -inflammatory cytokines such as IL-10 183, which I was able to show in RNA levels 
at 4 hrs of stimulation. I also observed that stimulation with IL-4/IL-13 did not lead to IL-
10 mRNA expression of either WT or Raptor KO BMDMs which was unexpected, and it 
is not clear what is the cause, even though it is observed in secreted levels (the same 
BMDMs were used to assess mRNA and protein levels). It has been shown that inhibiting 
mTORC1 leads to a decrease in MRC1 expression in bone marrow derived dendritic 
cells. My results showed similar mRNA expression between WT and Raptor KO 
BMDMs, while there was a significant decrease in protein expression at basal levels of 
KO BMDMs in comparison to the WTs 184. 
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In regards to the results that I have observed, much of the data is in line with literature 
when other elements of the mTOR pathway have been inhibited in myeloid cells. Though 
there are a few contradictions, these contradictions should be considered unique to my 
model as it was interesting to see that inhibiting mTORC1 either pharmacologically or 
genetically may have different effects for example when Raptor was absent in 
comparison to RHEB absence, or usage of mTOR inhibitors such as rapamycin instead of 
inhibition through Raptor deletion. As it was mentioned earlier it may be due to the 
different impacts these inhibitions may have on particular components of this complex 
and thereby the activation of mTORC1. It was also interesting to see that for many of the 
cytokines there was an oscillating rhythm as to how they were expressed on mRNA levels 
as some peak at certain hours and lose expression in following hours and peak again at 
later timepoints. The differences observed between mRNA and protein levels were also 
unexpected, but again it may be because Raptor plays a major role in protein translation 
and in its absence, the cell may still have the transcription occurring but translation is 
impaired. Nevertheless, a more focused investigation on BMDM intracellular signalling 
in Raptor WT and Raptor KOs may be a useful addition to these studies. Signalling may 




4 Impact of Raptor Depletion on Intracellular Signalling 
Pathways  
4.1 Introduction 
As previously mentioned, the mTOR pathway is known to control cell size, proliferation 
and regulation of macrophages. Growth factors, nutrients, energy and mitogens are vital 
constituents needed for mTOR activation. They all stimulate mTOR activity by 
phosphorylating key kinases including S6K, Akt, and ERK. This means that numerous 
signalling pathways interconnect and contribute to mTOR activation 88. mTOR activation 
leads to S6K phosphorylation, prompting mRNA transcription and protein translation. 
Akt and ERK work upstream of mTORC1 as they both phosphorylate TSC1/TSC2, the 
negative regulators of RHEB, which is vital for mTOR activation. Therefore Akt and 
ERK may contribute to a feedback loop in the absence of mTORC1 activity 185 
Inflammatory cytokines released by macrophages are involved in cell development and 
differentiation and play critical roles in defending the host against foreign bodies 77 78. An 
excess of inflammation may progress with deleterious consequences such as development 
of autoimmune diseases or diabetes. Furthermore it may also support cancerous cells in 
evading immune responses, by co-opting mechanisms that assist in tissue repair and 
homeostasis 186. Deregulation of the mTORC1 pathway has been suggested to lead to 
increased pro-inflammatory cytokine production 89.  Although there are data proposing 
that regulation of the mTOR pathway by many of the kinases and pathways mentioned 
above is associated with enhancement of cellular growth and proliferation, whether 
inflammation plays a role in this regulation is yet to be established. It is also not clear 
whether an inhibition of mTORC1 by deletion of Raptor will affect these signalling 
pathways. Therefore, the main aim of this chapter was to assess the importance of Raptor 
on other signalling pathways in macrophages.  
4.2 The role of Raptor in intracellular signalling in BMDM 
After establishing that Raptor was successfully deleted in the Raptor f/f; Csf1r Cre-ERT 
mice (Figure 3.2), I wanted to investigate whether Raptor KO would have an effect on 
signalling downstream of mTORC1 in macrophages. In order to answer this question, I 
stimulated WT and Raptor KO BMDMs with LPS/IFNγ at different time points of 15, 30, 
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60, 120, and 180 min. WT and KO BMDMs that were left unstimulated were used to 
determine basal levels. Protein lysates were made and western blot analysis was 
performed. 
The target protein analysed was phosphorylated S6 (p-S6), a ribosomal protein which is a 
component of the 40S ribosomal subunit. S6 is directly phosphorylated by S6 kinase, 
which is a direct target of mTORC1. Phosphorylated S6 is routinely used as a read-out for 
mTORC1 activation, given its abundance and the availability of reliable reagents. The 
results show that there was a gradual increase of p-S6 (residue S23S/236) from the 30 
min time point peaking at 60 min and a slight decrease by 120 and 180 min for WT 
BMDMs. KO BMDMs show diminished p-S6 levels compared to WT throughout the 
time course. Hence this result confirmed that downstream signalling was disrupted as 
mTORC1 activation was inhibited in Raptor KO BMDMs. β-actin was used as a loading 
control (Figure 4.1). 
1x106 BMDMs from WT and Raptor KOs were plated and either left unstimulated (NS) or stimulated with 
100ng/ml of LPS and 20ng/ml of IFNγ for different time points of 15, 30, 60, 120, and 180 min. Cells 
were lysed and 20μg of protein was used targeting phosphorylated S6 (p-S6) (top blot) and for total S6 (T-
S6) (middle blot) using western blot analysis. β-actin was used as a loading control (bottom blot). This 
immunoblot in the figure is representative of 3 independent experiments (BMDM lysates from 3 different 
mice).     
 






Figure 4.1 BMDM downstream signalling in absence of Raptor 
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4.3 Akt levels in BMDMs in the absence of Raptor 
Once I established that there was an mTORC1 downstream signalling defect, I next 
wanted to investigate whether these Raptor KOs would also have different levels of 
phosphorylated Akt. Akt feeds into the mTORC1 signalling pathway by inhibiting the 
negative regulation of TSC1/2 on the RHEB protein, which is upstream of mTORC1. 
Inhibition of TSC1/2 regulation on RHEB leads to mTORC1 activation. Since Raptor is 
absent in the KOs, I hypothesised that there would be an effect on Akt which would lead 
to changes in Akt phosphorylation (p-Akt). As before, I stimulated WT and KO BMDMs 
with LPS/IFNγ at different time points of 15, 30, 60, 120, and 180 min. WT and KO 
BMDMs that were left unstimulated were used to determine basal levels. Protein lysates 
were made and western blot analysis was performed. 
Phosphorylation of Akt (residue S473) in KO BMDMs upon stimulation was overall 
lower compared to WT counterparts, with the exception of the 60 min time point where 
levels in KO were slightly higher. This result indicates that, there may be an effect on Akt 
as mTORC1 is impaired. β-actin was used as loading control (Figure 4.2). 
1x106 BMDMs from WT and Raptor KOs were plated and either left unstimulated (NS) or stimulated with 
100ng/ml of LPS and 20ng/ml of IFNγ for different time points of 15, 30, 60, 120, and 180 min. Cells 
were lysed and 20 μg of protein was used targeting phosphorylated Akt (p-Akt) (top blot) and for total Akt 
(T-Akt) (middle blot) using western blot analysis. β-actin was used as a loading control (bottom blot). This 




NS NS15 1530 3060 60120 120180 180LPS/IFNγ (+)
minutes
WT KO
Figure 4.2 Effects on Akt activation in the absence of Raptor 
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4.4 Are other signalling pathways affected in the absence of Raptor?  
To investigate whether absence of Raptor in BMDMs may affect other signalling 
pathways I chose to study ERK phosphorylation since activation of the ERK pathway 
leads to an inhibition of TSC1/2 and therefore instigates active mTORC1 by Rheb 
activation. In the absence of Raptor, it would be likely to see an induction of 
phosphorylated ERK (p-ERK) activating the ERK signalling pathway that would enhance 
mTORC1 activation. In order to address this question, I stimulated WT and Raptor KO 
BMDMs with LPS/IFNγ at the same time points described above. Protein lysates were 
made and western blot analysis was performed. 
The phosphorylation of ERK increased in the WT BMDMs starting from the 15 min time 
point and peaking at 30 min. Overall, I observed similar kinetics but weaker induction in 
p-ERK (residue T202/Y206) levels in KO compared to WT BMDMs. This result suggests 
that mTORC1 inhibition through Raptor KO results in a less efficient activation of the 
ERK pathway upon stimulation. β-actin was used as loading control (Figure 4.3). 
1x106 BMDMs from WT and Raptor KOs were plated and either left unstimulated (NS) or stimulated with 
100ng/ml of LPS and 20ng/ml for IFNγ for different time points of 15, 30, 60, 120, and 180 min. Cells 
were lysed and 20 μg of protein was used for assaying phosphorylated ERK (p-ERK) (top blot) and for 
total ERK (T-ERK) (middle blot) using western blot analysis. β-actin was used as a loading control 







NS NS15 1530 3060 60120 120180 180
WT KO
Figure 4.3 Effects on the ERK pathway in absence of Raptor 
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4.5 Is STAT3 phosphorylation affected by mTORC1 inhibition? 
As described in the literature, the mTOR pathway is activated during nutrient abundance, 
which has also been shown to increase STAT3 translocation to the nucleus mediating the 
expression of many genes that are needed for cell growth and survival 187. I was interested 
in evaluating the phosphorylation level of STAT3 (p-STAT3) and if it would be affected 
by loss of Raptor. I stimulated WT and Raptor KO BMDMs with LPS/IFNγ as described 
above. Protein lysates were made and western blot analysis was performed. 
Results show a general decrease in phosphorylation levels of STAT3 (residue Y705) in 
all time points from KO BMDMs as compared to WTs. As mTORC1 activation is 
inhibited the likelihood of finding a decrease in STAT3 phosphorylation should be 
evident. It is clear that mTORC1 has an effect on STAT3 expression levels. β-actin was 
used as loading control (Figure 4.4). 
1x106 BMDMs from WT and Raptor KOs were plated and either left unstimulated (NS) or stimulated with 
100ng/ml of LPS and 20ng/ml of IFNγ for different time points of 15, 30, 60, 120, and 180 min. Cells 
were lysed and 20 μg of protein was used targeting phosphorylated STAT3 (p-STAT3) (top blot) and for 
total STAT3 (T-STAT3) (middle blot) using western blot analysis. β-actin was used as a loading control 
(bottom blot). This is representative of 2 independent experiments (BMDM lysates from 2 different mice).   











4.6 What happens to the NFκB signalling pathway in absence of 
Raptor? 
There is evidence in the literature suggesting an increase of proinflammatory cytokines 
released by macrophages as mTORC1 is inhibited 89. From the data I have shown 
previously I was able to confirm an upregulation in proinflammatory cytokine at mRNA 
and to a lesser extent, protein level, within BMDM Raptor KOs (Chapter 3). Though 
there is a trend of increased inflammatory cytokines, I wanted to investigate further if this 
was due to an effect on the NFκB pathway, which is a transcription factor that 
translocates to the nucleus in the event of stress or infection, furthermore inducing the 
transcription of many inflammatory cytokines. Therefore, to determine whether BMDM 
Raptor KOs have enhanced NFκB activation, I decided to check phosphorylation levels of 
IκBα (p-IκBα). IκBα is a negative regulator of NFκB, as it sequesters it within the 
cytoplasm preventing it from translocating to the nucleus. I stimulated WT and KO 
BMDMs with LPS/IFNγ as described above. Protein lysates were made and western blot 
analysis was performed. 
Stimulation of WT BMDMs resulted in phosphorylation of IκBα (residue S32) which 
peaked at the 60 min time point, substantially dropped at 120 min and remained to similar 
levels at 180 min.  Stimulation of KO BMDMs resulted in phosphorylation of IκBα 
(residue S32) which peaked at the 60 min time point but to lower levels compared to WT. 
Interestingly, and in contrast to WT, at 120 min phosphorylation of IκBα was not reduced 
and was found to be at similar levels to the 60 min time point. p- IκBα levels dropped at 
180 min following stimulation to similar levels as the WT. Total IκBα (T-IκBα) was also 
determined; as the phosphorylation levels of IκBα increased there was a general decrease 
in the total protein which was more profound in the KOs. Notably, although 
phosphorylation of IκBα was prolonged in KOs at 120 min, the levels of total IκBα had 
been restored. Together these results indicate an increase in the activation and altered 
kinetics of the NFκB pathway when Raptor is depleted and thus illustrate a crosstalk 
between these two pathways. β-actin was used as loading control (Figure 4.5)  
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1x106 BMDMs from WT and Raptor KOs were plated and either left unstimulated (NS) or stimulated with 
100ng/ml of LPS and 20ng/ml of IFNγ for different time points of 15, 30, 60, 120, and 180 min. Cells 
were lysed and 20 μg of protein was used targeting phosphorylated IκBα (p-IκBα) (top blot) and for 
total IκBα (T-IκBα) (middle blot) using western blot analysis. β-actin was used as a loading control 
(bottom blot). This is representative of 3 independent experiments (BMDM lysates from 3 different mice).   
 
4.7 Discussion 
I was able to establish that disruption of Raptor in KO BMDMs, led to a disruption in the 
downstream signalling of mTORC1, as indicated by the diminished S6 phosphorylation 
in the KOs. Interestingly there was no major compensatory induction arising through 
other signalling pathways such as PI3K/Akt or ERK. These pathways have been shown to 
feed into the mTOR pathway as they phosphorylate the negative regulator of RHEB, 
TSC1/2, thereby activating mTORC1 88. In fact, I observed a weaker induction of pAkt 
and pErk in KOs. Carracedo et al, have shown that inhibition of mTORC1 may lead to a 
feedback activation of MEK/ERK signalling in a tumour setting, although I was not able 
to observe this with my stimulated Raptor KO BMDMs 188. In addition, I provided 
evidence of a decrease in p-STAT3 induction in Raptor KO BMDMs upon stimulation. 
STAT3 is phosphorylated in presence of cellular stimuli through growth factors and 
cytokines. My observations are in line with literature of reduced STAT3 phosphorylation 
when mTORC1 is inhibited 187 189 190. I also was able to confirm that there is an increase 
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Figure 4.5 Effects on NFκB signalling in absence of Raptor 
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protein levels of S6, ERK, and STAT3, I repeatedly observed a trend of an increase in 
WT vs KO BMDMs. This could reflect an effect of Raptor depletion on basal protein 
levels. A summary figure was made to incorporate the findings of chapter 4 (Figure 4.6 ).  
In the presence of Raptor, Akt and ERK inhibit the negative regulator of RHEB; the TSC1/2 complex 
leading to RHEB activation through a GDP to a GTP conversion, which in turn activates mTORC1. Once 
mTORC1 is activated it leads to downstream signalling through the phosphorylation of S6. Phosphorylation 
of S6 allows translocation of STAT3 from the cytoplasm into the nucleus where transcription of genes 
needed for growth and survival commence. To a lesser extent there is NFκB activation permitting its 
translocation into the nucleus mediating gene transcription of inflammatory cytokines (A). In the absence of 
Raptor, Akt and to a lesser extent ERK inhibit TSC1/2 activating RHEB, which activates mTORC1, but 
phosphorylation of S6 is inhibited due to the absence of Raptor thereby preventing downstream signalling 





















Figure 4.6 Summary of intracellular signalling pathways in presence and 
absence of Raptor. 
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I have demonstrated differences in macrophage polarization in the absence of Raptor with 
a more M1-like phenotype with an increase in transcription of inflammatory genes and to 
an extent their translation into cytokines. This was confirmed by the increase in the NFκB 
activation and aberrations in other signalling pathways. Caution must be taken when 
speaking of an increase in NFκB activation, since this pathway may be activated through 
canonical and non-canonical means. Further experiments should be performed to confirm 
that it is indeed activated and it is not just IκBα becoming phosphorylated and degraded 
without pathway activation 192. Unravelling the consequences of this macrophage 
inflammatory phenotype on their basic functionality would be quite interesting. 
Therefore, I decided that the next step to my experimental analysis would take me to 
focus on the functional aspect of BMDMs in the absence of Raptor. Hence finding 
functional differences would open up a window to look into macrophage behaviour in a 
tumour setting, and whether the absence of Raptor would affect tumour growth and the 





5 Effects of Raptor Protein on Macrophage Function 
5.1 Introduction 
Macrophages are fundamental to the immune system; they participate in innate immunity 
by detecting foreign bodies as a first line of defence, doing so through cell surface 
receptors 193. Foreign pathogens secrete chemotactic factors attracting macrophages to the 
area of infection. Once they have detected pathogens, macrophages are able to bind to 
them through these receptors, thereby initiating cytoskeletal rearrangements involving 
actin polymerisation and membrane trafficking 194. This allows macrophages to engulf 
these foreign bodies in a process known as phagocytosis 195 196. Phagocytosis is a form of 
endocytosis, and is specific for the type of pathogen engulfed, as they bind to specific cell 
receptors on the macrophages. As the pathogen is internalised in a phagosome certain 
changes occur that allow this phagosome to mature into a phagolysosome. Reactive 
oxygen and nitrogen species are secreted in the phagolysosome that digest and kill the 
pathogen. The digested bacterial peptides reach the major histocompatibility complex 
(MHC class II) through membrane trafficking and move to the cell surface where they 
interact with the T cell receptor (TCR) in a process known as antigen presentation that is 
a bridge between innate and adaptive immunity 197. This presentation subsequently 
orchestrates a host adaptive immune response. 
Phagocytosis is not only important in defence against foreign bodies but is also equally 
important in cellular homeostasis in removal of apoptotic cells. It is also required for 
embryonic development and tissue repair 198. Another form of endocytosis is pinocytosis, 
which involves uptake of fluids and small particles, it differs from phagocytosis as the 
uptake is not specific and doesn’t involve receptor binding.    
The exact nature of the phagocytic process depends on size of the foreign body being 
engulfed, the type of receptors that recognise the foreign body, and how this foreign body 
is internalised. Fc receptor (FcR) mediated phagocytosis begins by membrane protrusions 
that encapsulate the pathogen and is pro-inflammatory in nature, while complement 
receptor phagocytosis does not involve encapsulation of the foreign particle and is anti-
inflammatory 193 197. Foreign body internalisation involves many signalling pathways and 
these pathways organize actin rearrangements that are needed to encapsulate the pathogen 
and allow formation of the phagolysosome. As the pathogens are internalised a series of 
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gene transcription and protein secretions occur that eventually lead to microbicidal 
affects.  
PKC, a downstream target of mTORC2, plays a major role in particle internalization 199 . 
Upon activation, PKC is translocated to the membrane of macrophages where it promotes 
formation of actin filaments below the particle, participating in the early stages of the 
internalisation. Another pathway involved in internalisation and thereby phagocytosis is 
the PI3K pathway 200. PI3K is needed to recruit Akt to the cell membrane and further 
production of actin filaments. Removal of PI3K is not essential in early particle 
internalisation but is required for later stages. Another important aspect of macrophage 
function is their ability to migrate towards certain stimuli while assisting in immune host 
responses. The PI3K pathway is involved in migration as it regulates actin polymerisation 
in macrophages 201. Since PI3K is involved in signalling through the mTORC1 pathway, 
as Akt inhibits TSC1/2 (the negative regulator of RHEB) therefore activating mTORC1, 
it is important to look at macrophage function and how absence of Raptor may affect 
functional abilities. As macrophages are implicated in tumour progression and their 
involvement in the tumour microenvironment, any functional defects may also have an 
impact on the tumour microenvironment and tumour development 202 134 186 132. 
Therefore, the aim of the work described in this chapter was to investigate functional 
abilities of macrophages in the absence of Raptor and whether this absence may have an 
impact on tumour growth and progression within the tumour microenvironment.  
5.2 Does absence of Raptor impair BMDM phagocytic activity? 
In order to address this question BMDMs from Raptor WT/WT; Csf1r Cre-ERT (WT) and 
Raptor f/f; Csf1r Cre-ERT (KO) mice were tested for their phagocytic capabilities. I 
decided to investigate phagocytosis by using fluorescent beads that were 1.0 um in size 
203 204. BMDMs were stimulated with LPS overnight prior to incubation with the beads in 
order to ‘prime’ them with the aim of enhancing phagocytosis. Fluorescein beads were 
incubated with the BMDMs at 4 time points: 15, 30, 60, and 90 min. BMDMs without 
beads were used as controls. Once the beads were added to the BMDM cultures, the 
macrophages were able to engulf the beads in a timely manner. After the cells were 
scraped from the tissue culture well, fluorescence intensity was quantified using FACS 
analysis, the amount of fluorescence was taken to be equivalent to phagocytic activity. 
The results show a reduction in phagocytic activity in KO BMDMs in comparison to their 
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WT counterparts. This was found at all the time points, and results were statistically 
significant at 15, 30, and 60 min after addition of the beads. This observation suggests 
that in the absence of Raptor these BMDMs have impaired phagocytic abilities (Fig 5.1). 
 
 
WT and KO BMDMs were stimulated with 100ng/ml of LPS overnight prior to addition of fluorescent 
beads. As fluorescent beads were added at differing time points of 15, 30, 60 and 90 min, BMDMs were 
able to phagocytose these beads. A significant decrease in the phagocytic capacity was seen in KO BMDMs 
(black bars) as compared to WT BMDMs (white bars). This significant decrease was observed for the 
following time points (15, 30, and 60 min). Media control was prepared to demonstrate no phagocytosis. 
Percentage of phagocytosis was analysed as mean fluorescence intensity (n=3).  Student’s t-test was used to 





























Figure 5.1 Phagocytic capacity of BMDMs to engulf fluorescent beads 
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Many would argue that this result is not a consequence of impaired phagocytosis but 
pinocytosis due to the size of the fluorescent beads being engulfed, as they are not large 
enough to activate phagocytosis. Moreover, activation of phagocytosis involves Fc 
receptors, which is not occurring during the uptake of fluorescent beads. To ensure that 
absence of Raptor truly impairs phagocytic activity, I performed another experiment 
using gemcitabine treated cancer cells. For this, I treated a murine pancreatic cancer cell 
line, TB32048, with a cytotoxic dose of gemcitabine. Gemcitabine is a known 
chemotherapeutic agent used to treat pancreatic cancer patients. In vitro treatment of 
cancer cells with gemcitabine will initiate apoptosis within these cancer cells, thereby 
producing signals activating BMDMs, which in turn will begin phagocytosing these 
cancer cells 205. WT and KO BMDMs were stained separately using cell tracker 
fluorescein stains in order to differentiate between apoptotic cancer cells and 
macrophages. The BMDMs were stimulated with LPS overnight prior to the addition of 
gemcitabine treated murine pancreatic cancer cells. The apoptotic cancer cells were added 
on to the BMDMs the following day and were incubated together for 2, 4, 6, 8, and 16 
hrs. BMDMs without cancer cells (0 hrs) and 16 hrs ice were used as controls (maximum 
hours of BMDMs with cancer cells on ice were chosen as a control setting to make sure 
there is minimal phagocytosis occurring throughout the incubation periods). After the 
cells were scraped from the wells, fluorescence intensity was quantified using FACS 
analysis. Both apoptotic cancer cells and macrophages were labelled with different 
colours of cell trackers and therefore amount of fluorescence of both colours together 
were taken to be equivalent to phagocytic activity. The results obtained for 4, 6, 8, and 16 
hr time points showed a significant reduction in the phagocytic activity of KO BMDMs 
compared to the WT BMDMs. At the 2 hr time point there was no reduction in the 
phagocytic activity for KO BMDMs as compared to the WT BMDMs. This confirms that 
in the absence of Raptor protein, phagocytic activity is impaired (Figure 5.2). The reason 
for this reduction may be due to a defect in their cytoskeleton as actin polymerisation may 






WT and KO BMDMs were stimulated with 100ng/ml of LPS overnight prior addition of pancreatic 
cancer cells, TB32048 treated with 100uM of gemcitabine. A significant decrease in the phagocytic 
capacity was seen in KO BMDMs (black bars) as compared to WT BMDMs (white bars). This 
significant decrease was observed for the following time points (4, 6, 8, and 16 hrs). Media and ice 
control showed minimal phagocytosis. Percentage of phagocytosis was analysed as mean fluorescence 
intensity (n=3).  Student’s t-test was used to assess statistical significance: p-value of <0.05 is 
statistically significant (*) or <0.005 (**). 
5.3 Does absence of Raptor affect BMDM cytoskeleton? 
5.3.1 BMDM morphology 
To assess cytoskeletal impairment in absence of the RAPTOR protein BMDMs from both 
WT and KO mice were re-plated on coverslips and were either left unstimulated (NS) or 
stimulated by LPS/IFNg or IL-4/IL-13 for 4 hrs After stimulation, the cells were stained 
with phalloidin (F-actin stain) using a fluorescein dye to evaluate the concentration and 
localisation of F-actin in BMDMs of both WT and KOs. I was also interested in 
evaluating the size and shape of the BMDMs and whether absence of Raptor would affect 





























appeared to show that KO BMDMs are smaller in size in comparison to their WT 
counterparts. BMDMs in the absence of Raptor also had a more rounded appearance and 
did not show the typical elongated shape when compared to WT BMDMs. BMDMs 
stimulated with LPS/IFNγ appeared to show a less pronounced elongated shape in the 
KOs compared to WT BMDMs. There was however, no apparent difference in 
morphology between WT and KO BMDMs after stimulation with IL-4/IL-13 (Figure 
5.3). As this evaluation was only by observing the images, I needed to quantify cell size 
and fluorescein intensity in order to investigate whether absence of Raptor affects 
BMDM cytoskeleton, through F-actin fluorescence staining.  
Fluorescence staining was performed on WT and KO BMDMs. Phalloidin (F-actin) appears as red, and cell 
nucleus in blue. Images of non-stimulated (NS) KO BMDMs are smaller in size and more rounded 
compared to WTs (Left: top and bottom). BMDMs stimulated with 100ng/ml of LPS and 20ng/ml of IFNγ, 
show a less elongated morphology in KOs as compared to WTs (Middle: top and bottom). BMDMs 
stimulated with 10ng/ml of both IL-4 and IL-13 show no differences in BMDM morphology for either WT 







Figure 5.3 BMDM morphology in absence of Raptor protein 
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5.3.2 Quantification of cell size and fluorescence intensity 
I began quantification by using images of WT and KO BMDMs from 5 different fields 
for all of the 3 conditions (NS, LPS/IFNγ and IL-4/IL-13). Using ImageJ I was able to 
evaluate BMDM cell size. The results show no difference in cell size for KO BMDMs in 
comparison to their WT counterparts (Figure 5.4). I also evaluated the mean intensity of 
fluorescence of BMDMs from WT and KO in order to observe whether absence of Raptor 
may affect the amount of F-actin within the cells. The results show that non-stimulated 
KO BMDMs had comparable mean intensities of F-actin to WTs. After stimulation with 
LPS/IFNγ again there was no difference in mean intensity of KO BMDMs compared to 
WTs, as was also shown when they were stimulated with IL-4/IL-13 revealing no 
differences (Figure 5.5). I decided to check integrated density, which will evaluate the 
spread of F-actin within the BMDMs taking into consideration the cell size. The results 
show that there was no reduction in integrated density in KO BMDMs in comparison to 
the WTs in non-stimulated conditions. BMDMs stimulated with LPS/IFNγ show a 
significant decrease in KOs compared to WTs. IL-4/IL-13 stimulation show no 
differences in integrated density (Figure 5.6). These results suggest cytoskeletal 
impairment of BMDMs in the absence of Raptor since they appear to be smaller in size 




Fluorescence staining of phalloidin (F-actin) was performed on BMDMs from WT and Raptor KOs. 
Quantification was performed to assess cell size (mm2). Non stimulated (NS) KO BMDMs were no 
different to WT BMDMs. When WT and KO BMDMs were stimulated with 100ng/ml of LPS and 20ng/ml 
of IFNγ, there was no difference observed in KOs as compared to WTs. BMDMs were stimulated with 
10ng/ml of both IL-4 and IL-13 showing no difference in size between WT and Kos, (NS and LPS/IFNγ 
n=3; IL-4/IL-13 WT: n=2 KO: n=3). Student’s t-test was used to check for statistical significance. 
Fluorescence staining of phalloidin (F-actin) was performed on WT and Raptor KO BMDMs. 
Quantification was performed to assess F-actin intensity. Non stimulated (NS) KO BMDMs showed no 
difference in mean intensity as compared to WT BMDMs. BMDMs from WT and KOs were stimulated 
with 100ng/ml of LPS and 20ng/ml of IFNγ, showing no reduction in mean intensity was observed in KOs 
as compared to WTs. BMDMs were stimulated with 10ng/ml of both IL-4 and IL-13 showing no difference 
in mean intensity staining for both WTs and KOs (NS and LPS/IFNγ n=3; IL-4/IL-13 WT: n=2 KO: n=3). 
Student’s t-test was used to check for statistical significance. 
 









































































































































Fluorescence staining of phalloidin (F-actin) was performed on BMDMs from WT and Raptor KOs. 
Quantification was performed to assess F-actin intensity. Non stimulated (NS) BMDMs had no reduction in 
integrated density for KOs as compared to WTs. WT and KO BMDMs were stimulated with 100ng/ml of 
LPS and 20ng/ml of IFNγ, showing a significant reduction in integrated density in KOs as compared to 
their WT counterparts. BMDMs were stimulated with 10ng/ml of both IL-4 and IL-13 showing no 
difference in integrated density for both WTs and KOs (NS and LPS/IFNγ n=3; IL-4/IL-13 WT: n=2 KO: 





















































































5.4 Does absence of Raptor affect BMDM actin polymerisation? 
Since I had seen a significant reduction in the integrated density of KO BMDMs 
stimulated with LPS/IFNγ compared with WT BMDMs, I decided to investigate actin 
filament polymerisation and see whether this polymerisation is affected in the absence of 
Raptor. Actin polymerisation occurs when free monomers known as G-actin, polymerise 
into what is known as active F-actin. It was important for me to assess the amount of F-
actin polymerised, as this is the active state needed for essential cytoskeletal functions 
such as cell motility and phagocytosis in macrophages 206. BMDMs were stimulated with 
LPS overnight prior incubation with fluorescent beads (refer to section 5.2) Fluorescein 
beads were incubated with the BMDMs at 5, 20, 30, 60, and 90 min. BMDMs without 
beads were used to check basal levels. After the cells were scraped they were fixed, 
permeabilised, and stained for F-actin and G-actin. Results show no differences in the 
F/G actin ratio between BMDMs from WTs and KOs (Figure 5.7). These results suggest 
that in absence of Raptor F-actin polymerisation is not changed and may not be the reason 
for a cytoskeletal defect in KO BMDMs.   
 
 
WT and KO BMDMs were stimulated with 100ng/ml of LPS prior to their incubation with fluorescent 
beads at differing time points of 5, 20, 60, and 90 min. The BMDMs were stained for G-actin and F-actin 
and the ratios were evaluated. No significant differences were observed (n=3). Student’s t-test was used to 
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Figure 5.7 F/G actin ratios in absence of Raptor protein 
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5.5 Does an absence of Raptor affect Fc receptors? 
I wanted to investigate whether absence of Raptor would affect Fc receptors as I have 
shown above that there is a reduction in phagocytic capabilities of KOs compared to WTs 
(refer to section 5.2). Therefore, I stimulated both WT and KO BMDMs with LPS/IFNγ 
and stained the cells with different antibodies targeting different Fc receptors, CD16/32, 
and CD64. I also looked at other receptors that are needed for macrophage antigen 
presentation and phagocytosis, CD86, and CD206 respectively. BMDMs left without 
stimulation were used to check basal levels of receptor expressions. Results show that 
there is a significant reduction in basal levels of expression of CD16/32 in KO BMDMs 
compared to WT BMDMs but in stimulated conditions there were no differences in the 
amount of CD16/32 expression between the two (Figure 5.8 A). CD64 expression also 
shows a significant reduction in KO BMDM expression as compared to their WT 
counterparts at basal level, but this reduction is not seen in stimulated conditions (Figure 
5.8 B). There were no differences shown in CD86 expression between WT and KO 
BMDMs (Figure 5.8 C). In regards to CD206 expression there were significant reductions 
observed at both basal and stimulated conditions for KOs in comparison to WTs (Figure 
5.8 D). 
Results for the Fc receptors show that in the absence of Raptor, the expressions are 
affected mainly at basal levels, once stimulated with LPS/IFNγ level of expression are 
similar suggesting stimulation does not have an effect on either WT or KO BMDMs. 
Absence of Raptor does not have an effect on CD86 expression suggesting no difference 
in the way these BMDMs provide costimulatory signals for T cell activation (Figure 5.8 
C). On the other hand, the reduction in mannose receptor (CD206) expression seen at 
both basal and stimulated conditions in KO BMDMs in comparison to WTs suggests a 
defect in phagocytic function (Figure 5.8 D).   
 
121 
WT and KO BMDMs were stimulated with 100ng/ml of LPS and 20ng/ml of IFNγ. They were stained for 
different cell receptors and mean fluorescent intensity was evaluated. CD16/32 staining shows a significant 
reduction in expression in KO BMDMs in comparison to WTs at basal level, but no difference was 
observed in stimulated conditions (A). CD64 expression was reduced significantly in the KOs as compared 
to their WT counterparts at basal levels but no difference was shown in stimulated conditions (B). There 
were no changes observed in CD86 expression either in KOs or WTs at basal levels and stimulated 
conditions (C). Mannose receptor expression was significantly reduced in KO BMDMs in basal and 
stimulated conditions (D). NS : (n=3) ; LPS/ IFNγ : (n=6). Student’s t-test was used to check for statistical 

























































































































































Figure 5.8 Effects on cell surface receptor expression in absence of Raptor 
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5.6 Does absence of Raptor affect the migratory ability of BMDMs? 
5.6.1 BMDMs migration towards fibroblasts 
I also wanted to evaluate BMDM migration capabilities in the absence of Raptor. In order 
to address this, WT and KO BMDMs were either left un-stimulated (NS) or stimulated 
with LPS/IFNγ or IL-4/IL-13 for 4 hrs in transwells. After stimulation, transwells were 
incubated with mouse embryonic fibroblasts (MEFs) in a 24 well plate (1:1 ratio) and left 
overnight. MEFs were used in these experiments as they secrete insulin growth factor 
(IGF), hepatocyte growth factor (HGF) and cytokines such as IL-1 along with 
chemokines such as monocyte chemotactic protein 1 (MCP1/CCL2) needed to activate 
macrophages and stimulate their migratory properties 207. The following day these 
transwells were stained with crystal violet. After washing, the transwells were left to dry 
and then placed in acetic acid where any purple colour would diffuse into the acid. 
Migration was assessed by the intensity of the purple colour in acetic acid. The intensity 
of the colour was taken to be equivalent to the amount of BMDMs that have moved 
through the transwells towards the fibroblasts. Results show no significant difference in 
the migratory capability of KO BMDMs as compared to the WT BMDMs, in non 





WT and KO BMDMs were either unstimulated (NS) or stimulated with 100ng/ml of LPS and 20ng/ml of 
IFNγ or stimulated with 10ng/ml of both IL-4 and IL-13 for 4 hrs. There were no significant differences in 
BMDM migratory capabilities between WT and KOs left unstimulated or stimulated with either LPS/ IFNγ 
or IL-4/IL-13. NS and LPS/IFNγ: (n=8) ; IL-4/IL-13 : (n=5).  Student’s t-test was used to check for 
statistical significance.  
5.6.2 BMDM migration towards cancer cells 
I was also interested in evaluating BMDM migration capability towards cancer cells in 
absence of Raptor. I investigated this by performing the same experiment, as shown 
previously in section 5.6.1 but using a murine pancreatic cancer cell line, TB32047 (the 
use of this murine pancreatic cell line instead of the TB32048s was merely due to 
availability at the given time of the experiments), instead of MEFs. Pancreatic cancer 
cells were used since they secrete factors that may enhance BMDM migration towards 
them such as CCL2, CCL5, CCL7, CCL8, CXCL12, VEGF, and CSF-1 208 209. Results 
show that there was a significant reduction in migration of BMDMs towards the cancer 
cells from KO BMDMs as compared to the WT BMDMs stimulated with either 
LPS/IFNγ or IL-4/IL-13 (Figure 5.10). This result suggests that there is a defect in the 
migratory capability in absence of Raptor. This result is different than what has been 
shown in BMDM migration towards MEFs, which may be due to the fact that cancer cells 
release more potent chemoattractants used as homing signals for macrophages 
































































WT and KO BMDMs were either unstimulated (NS) or stimulated with 100ng/ml of LPS and 20ng/ml of 
IFNγ or stimulated with 10ng/ml of both IL-4 and IL-13 for 4 hrs. There were no significant differences in 
BMDM migratory capabilities between WT and KOs left unstimulated. There was a significant reduction in 
migration towards cancer cells observed in KO BMDMs compared to their WT counterparts once 
stimulated with either LPS/ IFNγ, or IL-4-IL-13 (n=3). Student’s t-test was used to check for statistical 
significance: p-value of <0.05 is statistically significant (*) or <0.005 (**).  
5.7 Does absence of Raptor affect the tumour microenvironment? 
5.7.1 Subcutaneous tumour experiment 
In the presence of murine pancreatic cancer cells I found a reduction in phagocytic and 
migratory functions of BMDMs in which Raptor had been deleted, I next wanted to 
evaluate whether there are differences within a tumour microenvironment when Raptor is 
absent in macrophages. I thereby performed an in vivo subcutaneous tumour experiment 
by injecting 4 mice each from Raptor WT/WT; Csf1r Cre-ERT (WT) and Raptor f/f; Csf1r 
Cre-ERT (KO) with the murine pancreatic cell line, TB32048, and assessed the cellular 
composition of the tumour microenvironment, along with lymphoid and myeloid cells in 
spleen and blood. This is to observe whether the presence of tumour will have an effect 
on leukocyte counts that are found in either the spleen or blood, which may lead to a 



























































Figure 5.10 Migration of BMDMs towards murine pancreatic cancer cells 
(TB32047) in absence of Raptor 
 
125 
purposes. Once tumours were 1.2 cm in diameter, mice were culled and tumour, spleen, 
and blood were collected. Tumour and spleen were weighed. FACS was used to assess B 
cells (CD19), T cells (CD3) cells, and their subsets CD4 and CD8. I also quantified 
expression of F480 for macrophages and the expression of MHCII. This subcutaneous 
tumour experiment gave me preliminary data since not all mice developed tumours. 
Moreover, the FACS data for the tumours were impossible to interpret due to the high 
percentage of cell death observed. Therefore, I was only able to analyse results for blood 
and spleen.  
There was no significant difference between tumour and spleen weights from WT and 
KO mice (Figure 5.11 A and B). In the blood there was no significant difference in B and 
T cells (Figure 5.12 A and B), but there was a significant reduction in the amount of CD4 
T cells in KO mice compared to their WT counterparts (Figure 5.12 C). There was no 
difference in CD8 T cells either for both WT and KOs (Figure 5.12 D).  
There were no differences in the B and T cell populations or the subset populations of T 
cells in spleens from WT and KO mice (Figure 5.13 A-D). However, spleens of KO mice 
show a significant reduction in macrophages as compared to the WT mice (Figure 5.13 
E). There was no significant difference in the MHCII population either in WT and KO 
mice (Figure 5.13 F).  
WT and KO mice were given I.P injections of tamoxifen once per day for 3 consecutive days a week prior 
the starting of the subcutaneous experiment Mice from WT and KOs were injected with 1x105 of murine 
pancreatic cancer cells (TB32048) subcutaneously. All mice were given tamoxifen once per week for 3 
consecutive days by oral gavage, until end of the experiment in order to sustain KO status in their myeloid 
cells. After tumours reached 1.2 cm, mice were culled and tumour and spleen were weighed. There was no 
significant difference in tumour or spleen weights from either WT or KO mice (A and B). Tumour (n=2); 





































Figure 5.11 Subcutneous tumour experiment: tumour and spleen weights 
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WT and KO mice were given I.P injections of tamoxifen once per day for 3 consecutive days a week prior 
the starting of the subcutaneous experiment. Mice were injected with 1x105 of murine pancreatic cancer 
cells (TB32048) subcutaneously. All mice were given tamoxifen once per week for 3 consecutive days by 
oral gavage, until end of the experiment in order to sustain KO status. After tumours reached 1.2 cm, mice 
were culled and blood was collected. FACS was performed and cells were quantified. There was no 
difference in the peripheral blood B cell (CD19) and T cell (CD3) populations (A and B), but there was a 
significant decrease in the CD4 population of KO mice in comparison to WT mice (C). CD8 showed no 
difference in the population between WT and KO (D). (n=4) Student’s t-test was used to check for 





















































WT and KO mice were given I.P injections of tamoxifen once per day for 3 consecutive days a week prior 
the starting of the subcutaneous experiment. Mice were injected with 1x105 of murine pancreatic cancer 
cells (TB32048) subcutaneously. All mice were given tamoxifen once per week for 3 consecutive days by 
oral gavage until end of the experiment in order to sustain KO status. After tumours reached 1.2 cm, mice 
were culled and spleen was collected. FACS was performed and cells were quantified. There was no 
difference in the B cell (CD19) and T cell (CD3) populations (A and B), or the T cell subsets CD4 and CD8 
(C and D), but there was a significant decrease in the F480 population of KO mice in comparison to WT 
mice (E). MHCII showed no difference in the population between WT and KO (F). (n=4) Student’s t-test 

































































5.7.2 Orthotopic tumour experiment 
Implanting tumour cells directly into the organ provides a more realistic organotypic 
interaction between the tumour cells and the microenvironment surrounding the organ. 
Therefore, I decided to perform an orthotopic experiment by injecting murine pancreatic 
tumour cells (TB32048) directly into the pancreas. In order to perform this experiment, 5 
mice from both WT and KO were recruited. Dr. Sarah Spear a post doc in the Centre for 
Cancer and Inflammation performed the surgery. Unfortunately, two WT mice and one 
KO mouse had to be culled before the experiment came to an end as mice were showing 
signs and symptoms of infection. Their behaviour showed characteristics of weakness, 
pain, and discomfort, as they were barely moving and were not consuming any of their 
food. They were culled for humane purposes. 
Once the tumours were palpable and had reached 1.2cm (approximately), all the mice 
were culled and tumour, spleen, and blood were collected. Tumours and spleen were 
weighed. Tumours, spleen, and blood were then stained for FACS analysis (refer to 
section 5.7.1) in order to compare cell populations and to evaluate whether absence of 
Raptor within myeloid cells would have an effect on these populations and the tumour 
microenvironment in general. The results show that there was no significant weight 
change in tumours or spleen from WT or KO mice (Figure 5.14 A and B). Infiltrating 
tumour leukocyte populations were quantified and there are no significant differences in 
B (CD19) and T (CD3) cell populations between WT and KO mice (Figure 5.15 A and 
B). There was a significant decrease in CD4 T cells in the tumours from KO mice in 
comparison to their WT counterparts (Figure 5.15 C) but CD8 T cells showed no 
differences between WT and KO mice (Figure 5.15 D). Also the macrophage population 
(F480) and MHCII populations showed no differences between WT and KO mice (Figure 
5.15 E and F).  
Spleen cell populations were also quantified showing a reduction in the B cell population 
of KO mice in comparison to the WT mice (Figure 5.16 A). All other populations (T 
cells, T cell subsets, macrophages, and MHCII) showed no significant differences 
between WT and KO mice (Figure 5.16 B-F). Results for blood cell populations show a 
reduction in B, T, and CD4 T cells, in KO mice in comparison to WT counterparts 
(Figure 5.17 A-C). There was no significant change in the CD8 T cell, macrophage, or 
MHCII populations (Figure 5.17 D-F). The findings in this experiment show that there 
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are differences between WT and KO mice and suggest that in the absence of Raptor the 
tumour microenvironment as well as spleen and blood are affected. Since these results are 
based on preliminary data it is difficult to properly address reasons for these reductions 
and this experiment must be repeated at least two more times to get clearer picture of 
whether or not these results will reproduce.  
WT and KO mice were given I.P injections of tamoxifen once per day for 3 consecutive days a week prior 
the starting of the orthotopic experiment. Mice were injected with 5x103 of murine pancreatic cancer cells 
(TB32048) orthotopically directly into the pancreas. All mice were given tamoxifen once per week for 3 
consecutive days by oral gavages, until end of the experiment in order to sustain KO status. After tumours 
reached 1.2 cm, mice were culled and tumour and spleen were weighed. There was no significant difference 
in tumour or spleen weights from either WT or KO mice (A and B). Student’s t-test was used to check for 






































Figure 5.14 Orthotopic tumour experiment: tumour and spleen weights 
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WT and KO mice were given I.P injections of tamoxifen once per day for 3 consecutive days a week prior 
the starting of the orthotopic experiment. Mice were injected with 5x103 of murine pancreatic cancer cells 
(TB32048) orthotopically directly into the pancreas. All mice were given tamoxifen once per week for 3 
consecutive days by oral gavages, until end of the experiment in order to sustain KO status. After tumours 
reached 1.2 cm, mice were culled and tumour was collected. FACS was performed and cells were 
quantified. There was no difference in the B cell (CD19) and T cell (CD3) populations (A and B), but there 
was a significant decrease in the CD4 population of KO mice in comparison to WT mice (C). CD8 showed 
no difference in the population between WT and KO (D). Macrophage (F480) population and MHCII 
showed no differences between WT and KO mice (E and F). WT: (n=3); KO: (n=4) Student’s t-test was 
































































 WT and KO mice were given I.P injections of tamoxifen once per day for 3 consecutive days a week prior 
the starting of the orthotopic experiment. Mice were injected with 5x103 of murine pancreatic cancer cells 
(TB32048) orthotopically directly into the pancreas. All mice were given tamoxifen once per week for 3 
consecutive days by oral gavages, until end of the experiment in order to sustain KO status. After tumours 
reached 1.2 cm, mice were culled and spleen was collected. FACS was performed and cells were 
quantified. There was a significant reduction in the B cell (CD19) from KO mice in comparison to the WT 
(A). There was no significant change in all the rest of the cell populations quantified (T cell (CD3) 
populations and T cell subset CD4 and CD8, macrophages (F480) and MHCII) between WT and KO mice 
(B-F). WT: (n=3); KO: (n=4). Student’s t-test was used to check for statistical significance: p-value of 



































































WT and KO mice were given I.P injections of tamoxifen once per day for 3 consecutive days a week prior 
the starting of the orthotopic experiment. Mice were injected with 5x103 of murine pancreatic cancer cells 
(TB32048) orthotopically directly into the pancreas. All mice were given tamoxifen once per week for 3 
consecutive days by oral gavages, until end of the experiment in order to sustain KO status. After tumours 
reached 1.2 cm, mice were culled and blood was collected. FACS was performed and cells were quantified. 
There was a significant reduction in the B cell (CD19) population from KO mice in comparison to the WT 
(A). There was significant reduction in the T cell population and its subset CD4 in KO mice compared to 
their WT counterparts (B and C). There was no significant change in all the rest of the cell populations 
quantified (CD8, macrophages (F480) and MHCII) between WT and KO mice (D-F). WT: (n=3); KO: 


































































5.7.3 Cell populations found in spleen and blood in absence of tumour 
Data from both the subcutaneous and orthotopic tumour models were compared to data I 
obtained from Raptor WT/WT; Csf1r Cre-ERT (WT) and Raptor f/f; Csf1r Cre-ERT (KO) 
given I.P injections of tamoxifen once for 3 consecutive days but without any tumour cell 
injections. These mice were culled on the 4th day and spleen and blood samples were 
collected in order to compare cell populations of WT and KO mice.  
Spleens from Raptor KO mice showed a significant decrease in B cell populations in 
comparison to their WT counterparts (Figure 5.18 A), this result has also been seen in 
spleen samples of the orthotopic tumour model (Figure 5.16 A). Mice from Raptor KO 
have also shown a significant increase in the CD8 T cell population in KO mice 
compared to the WTs (Figure 5.18 D). This result may be due to CD8 T cell sequestration 
in the spleen caused by the absence of Raptor. Other cell populations showed no 
significant differences between WT and KO mice (Figure 5.18 B, C, E, F). Blood samples 





WT and KO mice were given I.P injections of tamoxifen once per day for 3 consecutive days, Spleen was 
collected and FACS was performed and cells were quantified. There was a significant reduction in the B 
cell (CD19) population from KO mice in comparison to the WT (A). There was no significant reduction in 
the T cell population and its subset CD4 in KO mice compared to their WT counterparts (B and C). There 
was a significant increase in the CD8 T cell population observed in the KOs compared to the WTs (D). 
There were no significant changes in the macrophage population or in the MHCII populations (E and F). 
WT: (n=3); KO: (n=4). Student’s t-test was used to check for statistical significance: p-value of <0.05 is 




























































Figure 5.18 Effects on splenic cells in absence of Raptor 
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Figure 5.19 Effects on blood cells in absence of Raptor 
 
 
Mice from WT and KOs were given I.P injections of tamoxifen once per day for 3 consecutive days, Spleen 
was collected and FACS was performed and cells were quantified. There was no significant reduction in 
any of the cell populations analysed (A-F). WT: (n=3); KO: (n=4). Student’s t-test was used to check for 




























































5.7.4 Result summary of cell populations using different mouse models   
I have made a comparison between cell populations from different mouse models in the 
absence of Raptor either with or without injection of pancreatic tumour cells. It should 
also be mentioned that orthotopic tumour models are likely to be more clinically relevant 
since tumour cells are implanted directly into the organ of interest (in my case the 
pancreas). The orthotopic tumour model is said to have a more realistic 
microenvironment compared to the subcutaneous site, and may differ in tumour growth 











This chapter included experiments that were performed in order to evaluate how the 
absence of Raptor may affect macrophage functionality. To my knowledge, there is little 
information in the literature on the role of Raptor in macrophage phagocytosis. A post 
doctorate colleague, Dr. Maryam Jangani has been working on Rictor protein that is part 
of mTORC2 and has seen a reduction of phagocytic capabilities of BMDMs from 
macrophages in which RICTOR has been deleted (m.jangani personal communication). 
RICTOR is known to play a central role in cytoskeletal reorganisation, through activation 
of mTORC2 210, therefore I wanted to investigate whether Raptor may also have a role in 
macrophage phagocytic ability. I was able to show that in KO BMDMs there was a 
significant reduction in phagocytic capabilities as BMDMs were unable to engulf both 
fluorescent beads and apoptotic cancer cells at the same levels when compared to BMDM 
WT counterparts. This reduction in phagocytic activity may be due to several reasons, 
which may be attributed to cytoskeletal defects and/or defective cell surface receptors on 
the BMDMs. In order to address whether this reduction of phagocytic ability in absence 
of Raptor was due to a cytoskeletal defect, BMDMs were stained with phalloidin which 
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binds to F-actin and both WT and KO BMDMs were compared for cell size and F-actin 
intensity and distribution. There was a non-significant reduction of cell size in KO 
BMDMs in comparison to the WT BMDMs in non-stimulated and stimulated conditions. 
The mean intensity also showed no significant reduction in non-stimulated and LPS/IFNγ 
stimulated conditions for KO BMDMs compared to WT. Results for integrated density 
show a significant reduction in KO BMDMs in comparison with WT in LPS/IFNγ 
stimulated conditions. These results point to a probable cytoskeleton defect in KO 
BMDMs. I wanted to assess F/G actin ratios in order to evaluate F-actin polymerisation, 
since polymerisation is an important mechanism that allows macrophages to phagocytose 
and allows macrophage movement. The F/G actin ratio shows no difference in 
polymerisation occurring in general at basal levels and in LPS/IFNγ stimulated conditions 
within KO BMDMs compared to the WTs. I have interpreted the result this way since G-
actin is in the form of monomers, these monomers become filaments of F-actin as 
polymerisation occurs and F-actin is the active form that is needed for macrophage 
phagocytosis and motility. If F-actin is reduced, that means less polymerisation is 
happening and therefore there are more G-actin monomers. 
 I also wanted to look at receptors in these BMDMs and to investigate whether absence of 
Raptor may affect them. Results show that there were nonsignificant decreases at basal 
levels of KO BMDMs compared to WTs for CD64, CD16/32, and CD86, as for CD206 
there was a significant decrease at both basal and LPS/IFNγ stimulated conditions. These 
results show that in the absence of Raptor there are changes in the cytoskeleton and 
receptors. 
Another feature that is important for macrophage function is migration. I assessed 
migratory capability of WT and KO BMDMs towards fibroblasts and cancer cells. In 
regards to migration of BMDMs towards fibroblasts there were no significant differences 
in non-stimulated or stimulated conditions between WT and KOs. Results for BMDM 
migration towards cancer cells shows that as they are stimulated with either LPS/IFNγ or 
IL-4/IL-13 there is a reduction seen in KO BMDMs in comparison to WT. These results 
may only prove the fact that cancer cells secrete factors into the tumour 
microenvironment that lead to migration of different types of macrophages, some that 
lead to tumour progression which are of an M2 phenotype and those that are pro-
inflammatory which assume an M1 phenotype.  
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I have also performed preliminary in vivo transplantable tumour subcutaneous and 
orthotopic experiments in mice Raptor WT/WT; Csf1r Cre-ERT (WT) and Raptor f/f; 
Csf1r Cre-ERT (KO). I faced many complications with these in vivo experiments and 
therefore it must be noted that repetition of these experiments must be performed in order 
to increase n numbers and also to make sure that results would reproduce in the next 
experiments. The preliminary results show that in cases of both subcutaneous and 
orthotopic experiments there were no significant decreases in tumour or spleen weights. 
Pertaining to the subcutaneous tumour model, there were significant reductions in the 
CD4 T cell populations in the blood samples of Raptor KO mice compared to WT mice. 
Significant reductions were also observed in macrophage populations of the spleen from 
Raptor KO mice. In regards to the orthotopic tumour model there were significant 
reductions in all of the B, total T and CD4 T cell populations in the blood samples of 
Raptor KO mice compared to WT counterparts. These findings could suggest that in the 
absence of Raptor the tumour microenvironment releases more inflammatory cytokines, 
therefore there may may be an increase in T regulatory cells present to reduce this 
inflammation by increasing immunomodulatory cytokine secretions. These 
immunomodulatory cytokines would lead decreases in CD4 T cell populations. These 
results also show that macrophages are decreased in the spleen along with B cells, which 
may be due to mTORC1 regulating macrophages, and an impairment of this regulation 
would result in the inability of macrophages to secrete proper cytokines used by B cells 
for their differentiation. In order to have a clear understanding of what is happening to 
tumours and the microenvironment a repetition of these experiments must be performed.   
 There is no well-defined understanding of mTOR and its complexes in macrophage 
migration and functionality and therefore it was important to attempt these experiments to 
shed light on how mTOR may regulate these aspects in macrophages. What I have 
observed was that in the absence of Raptor macrophage function was compromised as 
shown in the reduction of macrophage phagocytic abilities and in the reduction of their 
migratory capabilities. These functional defects may be due to cytoskeletal impairments 
and/or reductions in their overall receptors. This was also shown to affect the tumour 
microenvironment and surrounding cells, which will have an impact on how tumours 
grow and proliferate. I think that Raptor plays an important role in macrophage function 
and tumour progression and more experiments should be performed to confirm 
preliminary findings.  
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6 Discussion and Plans for Future Work 
6.1 Raptor and myeloid cells 
mTOR, known as the master growth regulator, senses environmental and nutritional cues 
such as growth factors, amino acids, energy levels and stress signals from the cells’ 
surroundings integrating them in order to promote growth 211. This is achieved by 
phosphorylating key substrates that lead to anabolic processes such as mRNA translation, 
protein and lipid synthesis 212. Over the past few years there have been many reports 
suggesting a central role for the mTOR pathway in diseases such as diabetes, cancer, and 
neurodegeneration 213 214 215. Deregulation of the mTOR pathway in pancreatic cancer has 
been implicated in progression to the most invasive form 157. Present knowledge of 
pancreatic cancer and its tumour microenvironment has placed great emphasis on TAMs 
as critical cells in providing the appropriate milieu needed for tumour advancement 216 
217. Targeting TAMs has been shown to influence the tumour microenvironment, by 
reducing the immunosuppressive setting provided by TAMs while facilitating a more pro-
inflammatory background leading to tumour regression 218 219. Despite the current 
evidence of the mTOR pathway and TAMs being important in pancreatic cancer 
development, there have not been many studies investigating the link between mTOR and 
macrophages and evaluation of the extent to which mTOR regulates macrophages, which 
potentially may have an effect on the tumour microenvironment and thereby tumour 
progression. This thesis describes in vitro and in vivo experiments using myeloid cells 
that lack Raptor (Raptor f/f; Csf1r Cre-ERT), which is a key protein in mTORC1 needed 
for cell survival and development 220. These experiments were performed to:   
1. Characterise the role of Raptor of the mTORC1 complex in myeloid cell 
maturation, differentiation, and function. 
2. Explore the effect of Raptor KO on macrophage polarisation.  
3. Explore the effect of Raptor KO on macrophage signalling. 
4. Explore the role that myeloid cells lacking Raptor have on the pancreatic tumour 
microenvironment. 
This chapter will discuss the degree to which this thesis has addressed the above aims, the 
future work that is needed to clarify some of the experimental findings and will outline 
any additional experiments that could be conducted in regards to the conclusions. 
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6.1.1 Effects of Raptor on BMDM differentiation and maturation 
In vitro experiments were performed using murine bone marrow cells and cultured 
BMDMs to investigate whether Raptor plays a role in their maturation and differentiation. 
Mice from Raptor WT/WT; Csf1r Cre-ERT (WT) and Raptor f/f; Csf1r Cre-ERT (KO) 
were used to investigate differences in the common myeloid progenitors on chosen 
differentiation days. By evaluating expression of specific lineage markers, I found that 
there were no significant differences in the common myeloid progenitors between WT 
and KO BMDMs. I also investigated whether there would be differences in how these 
myeloid cells were maturing into macrophages by assessing F4/80 expression. Again 
there were no significant differences between WT and KO BMDMs. Therefore, I 
concluded that Raptor does not have a role in macrophage differentiation and maturation. 
This conclusion is very interesting given the fact that Wang et al have published that with 
a RHEB deletion in macrophages they were able to observe decreased numbers of 
macrophages from the KOs as compared to WTs 179. They have also observed decreased 
differentiation from monocyte to macrophages in their KOs 179, making me speculate that 
RHEB is a more potent protein within mTORC1 as it is the positive regulator of the 
complex which lies upstream and furthermore any disruption to RHEB may generate 
more significant effects on the complex, hence the regulation of monocyte differentiation 
and maturation.  
6.1.2 Effects of Raptor on BMDM polarisation 
Further to the in vitro studies mentioned in section 6.1.1 with BMDMs, I decided to 
evaluate the impact Raptor may have on BMDM polarisation. Mice from Raptor WT/WT; 
Csf1r Cre-ERT (WT) and Raptor f/f; Csf1r Cre-ERT (KO) were used, and qPCRs were 
performed on these BMDMs. mRNA levels of different M1(TNFα, IL-12β, IL-6, iNOS) 
and M2 (IL-10 and MRC1) genes were investigated, showing Raptor KOs in general had 
significantly higher levels of M1 genes (TNFα, IL-12β, IL-6) in comparison to their WT 
counterparts both of which were stimulated with LPS/IFNγ or IL-4/IL-13. These results 
emphasise that once Raptor is lost within BMDMs, inflammatory cytokine mRNA levels 
increase thereby suggesting a polarisation of these LPS/IFNγ stimulated BMDMs into an 
M1 phenotype. It has been shown previously by Byles et al, Weichhart et al and Zhu et al 
that disrupting mTORC1 either genetically or pharmacologically leads to an increase in 
inflammatory cytokine production in myeloid cells 87 89 88. However, when I assessed M1 
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and M2 cytokine secretion from the same BMDMs stimulated with LPS/IFNγ or IL-4/IL-
13 translation and secretion of inflammatory cytokines was not observed to the same 
extent. Most of the M1 cytokines (IL12(p40) and IL-6) were significantly increased in 
WT BMDMs stimulated with LPS/IFNγ, in comparison to Raptor KOs, apart from TNFα 
secretion, which was significantly increased at the latest time point for KO BMDMs. The 
only argument that I would be able to provide for these results is that Raptor KO BMDMs 
have defective translational abilities; thereby cytokine production is not sustained 
properly as observed in cytokine production of the WT counterparts, all with the 
exception of TNFα. 
In parallel to the work I have described in this thesis, Dr Maryam Jangani, a postdoc in 
the lab, has been investigating the role of Rictor on myeloid cells using the same genetic 
approach. Dr. Jangani used the C57Bl/6 mouse strain to obtain an inducible model that 
deleted Rictor part of mTORC2 within myeloid compartments, these mice were either 
Rictor WT/WT; Csf1r Cre-ERT (WT) or Rictor f/f; Csf1r Cre-ERT (KO). Rictor plays a 
main role in actin cytoskeletal organisation 45. Dr. Jangani used BMDMs to assess the 
role Rictor plays on myeloid cell regulation and function. I compared Raptor KO protein 
secretion results to those obtained with Rictor KO BMDMs. The Rictor KO BMDMs 
secreted significantly higher amounts of TNFα, IL12(p70), IL-6 and NOS2 compared to 
their WT counterparts after LPS/IFNγ stimulation (m.jangani personal communication). 
This was reassuring since mTORC2 does not have a role in protein translation and 
therefore my results are specific to Raptor that is known to play a major role in protein 
translation 10 221. Moreover, I would assume if inflammatory cytokine secretions from 
Raptor KO BMDMs were higher than their WT counterparts, this would provide a basis 
in order to manipulate the tumour microenvironment to become more inflammatory. As 
macrophages would polarise into an M1 phenotype secreting inflammatory cytokines that 
would reduce the likelihood of tumour progression, instead of cytokines secreted by 
macrophages found within the tumour environment that are of the M2 phenotype. It is 
well established that these M2 macrophages release immunomodulatory cytokines, that 
drive tumour growth 222 223. 
6.1.3 Effects of Raptor absence on BMDM signalling pathways 
I decided to explore further the mechanistic aspects of BMDM signalling stimulated with 
LPS/IFNγ in the absence of Raptor. I evaluated intracellular signalling downstream 
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mTORC1 in the absence of Raptor by observing phosphorylation of S6 (S23S/236). 
Phosphorylation of S6 was weak, almost negligible in the absence of Raptor compared to 
WT BMDMs, which is what I was expecting since Raptor is an important constituent of 
the mTORC1 complex and disruption will influence downstream signalling abilities. This 
result confirms the KO status of my BMDMs, highlighting that Raptor absence impacts 
downstream signalling in BMDMs. 
I also wanted to investigate whether there would be differences in signalling through the 
PI3K/Akt axis, since Breuleux et al showed that when mTORC1 is inhibited by RAD001 
(an mTORC1 inhibitor) more phosphorylation of Akt (S473) occurs 224. My findings 
contradicted their results, as I found similarities in Akt phosphorylation between both 
BMDMs of WT and KOs with only slight reductions of phosphorylation in KO BMDMs. 
I would assume that for Akt to have approximately similar phosphorylation levels within 
BMDMs from both WT and Raptor KOs this could be due to Raptor not having such a 
potent influence on PI3K/Akt signalling as RAD001 had and therefore increase in 
phosphorylation was not observed indicating Raptor does not affect upstream mTORC1 
signalling as much as mTORC1 inhibitors. Furthermore, Breuleux et al used tumour cell 
lines not primary myeloid cells and this may also play a major role in how signalling 
pathways are activated in comparison to what may be occurring in BMDMs absence of a 
tumour microenvironment. 
I next assessed the ERK signalling pathway as it also feeds into the mTOR pathway by 
phosphorylating TSC1/2 allowing RHEB to activate mTORC1. I evaluated 
phosphorylation of ERK (T202/Y206) and found that phosphorylation decreases in KO 
BMDMs as compared to WT BMDMs.  This result is in disagreement to previous 
findings of Carracedo et al where it was observed that by inhibiting mTORC1 through 
rapamycin or RAD001 in either epithelial cells (breast) or cancer cells (breast) leads to a 
feedback activation of MEK/ERK signalling 188. This increased signalling was said to be 
dependent on the S6K/PI3K/Ras pathway. Despite their findings that were contradictory 
to my own, I would speculate that Raptor absence has the opposite effect on ERK 
signalling, as it does not impact upstream signalling thereby generating insignificant 
inhibitory signs that would usually trigger feedback activation of the ERK pathway thus 
the reductions I observe on ERK phosphorylation. It may also be due to the difference in 
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cells used for either experiments as Carracedo et al used epithelial cells while I was 
working on primary myeloid cells.   
STAT3 becomes phosphorylated during increased fluxes of growth factors and cytokines, 
mainly through activation of mTORC1. I have investigated phosphorylation levels of 
STAT3 (Y705) in absence of Raptor and observed as mTORC1 activation was inhibited, 
STAT3 phosphorylation was reduced in comparison to WT BMDMs. This result is 
supported by Li et al where their findings showed as mTORC1 was inhibited STAT3 
phosphorylation was reduced 190. 
As I found that BMDMs in the absence of Raptor to show increased amounts of 
inflammatory cytokine production at the level of transcription, which might lead them to 
adopt a more M1 phenotype, I was interested in examining the NFκB signalling pathway 
to detect whether there would be increased activation through the phosphorylation of the 
negative regulator of the pathway. Increased IκBα phosphorylation (S32) of KO BMDMs 
was observed in comparison to WT counterparts, which corresponds to an increase in 
NFκB signalling activation, this result also has been observed by Weichhart et al 89. Dr. 
Jangani has also examined phosphorylation levels of S6 on Rictor KOs and found 
decreased phosphorylation levels in comparison with WT counterparts. Despite this 
decrease in S6 phosphorylation levels, it remains much higher than phosphorylation 
levels found with Raptor KOs. Observing her findings pertaining to Akt phosphorylation 
there was a decrease in phosphorylated Akt from both Rictor WT and KO BMDMs (a 
slight more reduction in the Rictor KOs). It was not surprising to observe these 
differences between Akt phosphorylation from Raptor KO and Rictor KO, as mTORC2 
targets Akt by downstream signalling, leading to activation of Akt, while mTORC1 does 
not target Akt. This Rictor KO reduction in phosphorylated Akt levels is an important 
confirmation of the Rictor KO status (m.jangani personal communication). 
Taken together these results show that Raptor plays a major role in mTORC1 downstream 
signalling. It also shows that there is an increase in NFκB signalling which suggests that 
these BMDMs are polarised to an M1-like phenotype making them more inflammatory as 
has been also interpreted by Weichhart et al.  
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6.1.4  Effects of Raptor absence on BMDM function 
A series of experiments were then performed to evaluate BMDM function in the absence 
of Raptor. Investigating phagocytic activity of BMDMs using either fluorescence beads 
or apoptotic cancer cells showed that in absence of Raptor there was a significant 
reduction in phagocytosis in comparison to WT BMDM counterparts. My findings are in 
line with what have been shown in literature using rapamycin as an mTORC1 inhibitor 
instead of genetic inhibition of the complex as I have done 5 225. I was interested in 
elucidating on what could be the cause of such a reduced phagocytic ability in the 
absence of Raptor, pursuing two options of cytoskeletal abnormalities or Fc receptor 
impairment. I checked for cytoskeletal abnormalities by observing whether there were 
changes occurring in F-actin between BMDMs of KOs in comparison with their WT 
counterparts. I showed that as these BMDMs were stimulated with LPS/IFNγ there were 
significant reductions within the integrated density of Raptor KO BMDMs as compared 
to WTs. This finding in itself is interesting since it shows that F-actin distribution is 
affected between WT and KOs, suggesting impairment to cytoskeletal rearrangements in 
the KO BMDMs. I was also interested in looking at F-actin polymerisation in Raptor KO 
BMDMs. I assessed F-actin polymerisation by acquiring results from an F/G ratio, which 
demonstrates the capacity of G-actin monomers to polymerise into the active form known 
as F-actin. My findings show that there were no reductions in the amount of F-actin 
polymerisation. According to data obtained by integrated density these data are 
suggestive of cytoskeleton impairment, which was thought provoking, since it is an 
established fact that mTORC2 is the complex that plays a major role in cytoskeleton 
rearrangements 210 226. Therefore, to observe that mTORC1 also plays a part in this 
regulation as seen with Raptor absence was interesting. Comparing my data to Dr. 
Jangani’s data (Rictor KO in BMDMs) they were similar to each other, as she has also 
observed significant reductions in phagocytic abilities within Rictor KO BMDMs in 
comparison to WTs. Although her F-actin polymerisation data was preliminary (n=1) it 
showed F-actin polymerisation was reduced in her Rictor BMDM KOs compared to WT 
counterparts (m.jangani personal communication) but more experiments must be 
performed to increase n numbers in order to prove reductions were truly found.  
I subsequently performed experiments to observe whether Raptor may have an effect on 
the Fc receptors, as phagocytosis is Fc receptor mediated. Looking at non-stimulated 
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BMDMs there were significant reductions in Fc gamma receptors (FcγRs) CD16/32 and 
CD64 on BMDMs from Raptor KOs as compared to WTs. This significant reduction was 
lost as BMDMs were stimulated with LPS/IFNγ. I found this result quite unexpected 
since I would suspect as these BMDMs become simulated, larger differences in FcγRs 
would be observed between KOs and WTs. Moreover, I assessed other BMDM receptors, 
finding significant reductions in mannose receptors of KO compared to WT BMDMs in 
both non stimulated and LPS/IFNγ stimulated conditions. These findings suggest that in 
the absence of Raptor these receptors are affected, which may be caused by reduced 
transcription or increased amounts of receptor internalisation and proteasomal 
degradation. I compared Raptor KO to Rictor KO BMDM FcγR data, Rictor absence 
showed reduced expressions of CD64 and CD86 in comparison to the WT counterparts. 
Dr. Jangani also showed that in the absence of Rictor there were similar expressions of 
CD16/32 and CD206 between Rictor WTs and KOs (m.jangani personal 
communication), suggesting that Raptor and Rictor influence BMDM receptors in 
different ways.  
Furthermore, I examined the role of Raptor on BMDM migration; while there were no 
significant differences in migratory capabilities of WT or KO BMDMs towards 
fibroblasts, I did observe significant reductions in migration of KOs towards cancer cells, 
while stimulated with LPS/IFNγ as well as IL-4/IL-13. This suggests that cancer cells are 
producing chemokines that are used to attract BMDMs but in the absence of Raptor, 
BMDMs are incapable of responding to the chemotactic stimulus appropriately despite 
stimulation with either LPS/IFNγ or IL-4/IL-13. Dr. Jangani also assessed BMDM 
migratory capability in absence of Rictor, in which she found reductions in migration of 
Rictor KO BMDMs towards both fibroblasts and tumour cells. This result was quite 
interesting as previously stated mTORC2 plays a major role in cell cytoskeletal 
rearrangements, therefore if Rictor (a major component of the complex) is absent cell 
motility should be affected. This result also shows that Rictor absence impacts motility 
more than absence of Raptor on BMDMs (m.jangani personal communication). 
6.1.5 Role of macrophages in the absence of Raptor in a pancreatic tumour 
microenvironment 
Following previous in vitro experiments evaluating impact of Raptor on BMDMs I 
wanted to assess effects of Raptor absence within macrophages in a pancreatic tumour 
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microenvironment. Therefore, I performed preliminary in vivo experiments using 
subcutaneous and orthotopic murine tumour models. I would have liked to obtain well-
defined results from these experiments but due to lack of time and mice availability, I was 
unable to perform more than one experiment of each condition. These first in vivo 
experiments showed that tumours containing Raptor KO myeloid cells were no different 
from WT controls at least in terms of tumour weight. Observing the subcutaneous tumour 
model, there were significant reductions in the CD4 T cell populations in the blood 
samples of Raptor KO mice. There were also significant reductions in the macrophage 
populations observed in the spleen samples of Raptor KO mice. In regards to the 
orthotopic tumour model there were significant reductions in the B cell populations, total 
T cell populations and also the CD4 T cell populations in the blood samples of Raptor 
KO mice. There was a significant reduction in the B cell population found in spleen 
samples of Raptor KO mice. These findings suggest that within the tumour 
microenvironment of Raptor KO mice, there is an increase in inflammatory cytokines, 
therefore I speculate that there may be an increase in T regulatory cells present in the 
niche to reduce this inflammation by increasing immunomodulatory cytokine secretions, 
leading to decreases in the CD4 T cell populations. These results also propose that 
macrophages are decreased in the spleen along with B cells which may be due to the fact 
that mTORC1 is needed for macrophage regulation and once macrophage regulation is 
impaired it is unable to secrete proper cytokines used by B cells for their differentiation. 
Hence this demonstrates the importance of Raptor in macrophages and the impact it holds 
on the pancreatic tumour microenvironment as shown from the set of results from these 
two models. Dr. Jangani performed two subcutaneous tumour experiments with the same 
cancer cells. Her results show that there were significant increases in blood monocytes in 
Rictor KO mice. There were also significant decreases in the B cell population in blood 
samples of Rictor KO mice. After tumour digestion it was shown that there was 
significant increases in the macrophage population of Rictor KO mice, suggesting an 
increase in macrophage infiltration within the tumour microenvironment (m.jangani 




6.1.6 Summary of results obtained from mice with either Raptor or Rictor 
KO  
In this chapter I have compared my results to those obtained in mice in which Rictor was 
deleted in the myeloid cell compartment. The table below summarises the similarities and 






Cytokine	Secretion	 éTNFα éiNOS,	IL-12(p70),	IL-6 
Downstream	Signalling	 êS6	êSTAT3	éNFκΒ êS6êAkt	êFOXO	 
Phagocytosis	




F/G	actin	Ratio	 NS ê(n=1) 
Fc	 Receptors	 and	 other	








êCD19,	 CD3,	 CD4	 (blood)	
êCD19	(spleen) N/A	
Table 6.1 Summary of results comparing mice with either Raptor or Rictor KO in 
myeloid cells (NS: non significant ; N/A: not available) 
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As would be expected Table 6.1, shows some similarities and some differences between 
Raptor and Rictor KO myeloid cells. In both cases there is an increase in inflammatory 
cytokine mRNA after LPS/IFNγ stimulation, but differences in protein secretion were 
evident although increases seen are in pro-inflammatory cytokines. Downstream 
intracellular signalling shows a decrease in S6 phosphorylation, but downstream targets 
of mTORC1 and mTORC2 are affected in different ways. Both phagocytosis and 
migration are impaired which may be due to cytoskeletal and Fc receptor changes.   
In summary my findings have shown that Raptor impacts macrophage polarisation and 
functionality. Furthermore, it affects downstream signalling pathways by inhibiting 
activation of mTORC1. However, Raptor does not influence macrophage differentiation 
and maturation status, which suggests Raptor effects are imposed after maturation of 
macrophages. Nevertheless, more experiments are needed to substantiate these findings 
as will be described in the next section. 
6.2 Plans for Future Work   
In this section I would like to describe particular areas that I would want to pursue to 
further understand the role of Raptor and the mTORC1 pathway in macrophages.   
6.2.1 Effects of Raptor absence on BMDM metabolism 
These experiments would be undertaken using the Seahorse XF Analyzer on in vitro 
BMDMs. 
I would like to investigate whether Raptor has an impact on BMDM metabolism as it is 
well established that mTORC1 activation is related to cell growth and survival 213 185. I 
WT and KO BMDMs are either left unstimulated, or stimulated with either LPS/IFNγ or 
IL-4/IL-13. This would provide results pertaining to the glycolytic pathway together with 
oxygen consumption rates. 
6.2.2 Antigen presentation capabilities of BMDMs in absence of Raptor  
These experiments would be undertaken using in vitro BMDMs co-cultured with T cells 
(obtained from cell sorting from WT mice). 
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I would like to assess if Raptor impacts antigen presentation in BMDMs. I would use WT 
and KO BMDMs either left unstimulated, or stimulated with LPS/IFNγ and culture them 
with T cells. T cell activation markers would be evaluated by FACS analysis.  
6.2.3 In vivo LPS-induced inflammation experiment 
These experiments would be undertaken using mice from WT and Raptor Ko in myeloid 
cells. I would inject a non-lethal dose of LPS into the mice, before end point I would cull 
the mice and inflammatory cytokines would be assessed using a cytokine array kit. These 
cytokine array kits would provide a more diverse cytokine range, and I would personalise 
the kit for specific inflammatory cytokines and chemokines, in order to compare 
differences between WT and Raptor KO mice. 
6.2.4 Orthotopic tumour model 
I would repeat the orthotopic tumour model two more times with a larger cohort of mice 
in order to ensure that the results I have obtained in the preliminary experiments are 
reproducible. It would be important to do detailed studies on the tumour 
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